Author's posts

ICARE Featured Video December 2024

Coping with Hereditary Cancer

Below is a featured video from the December 2024 case conference, during which Lora Thompson, PhD from Moffitt Cancer Center discusses coping with hereditary cancer. Dr. Thompson was joined in commentary by BRCA carriers, Marleah Dean Kruzel, PhD (University of South Florida) and Kathy Baker (My Faulty Gene), as well as panelists Deborah Cragun, PhD, MS, CGC …

Continue reading

Permanent link to this article: https://inheritedcancer.net/video121224/

ICARE Social Media Post December 2024

ACMG Clinical Practice Resource on ATM

Check out the recently released ACMG Clinical Practice Resource on ATM, developed through a group of worldwide experts! 🌍👇 https://authors.elsevier.com/c/1kD7w3vlFV4Eph

Permanent link to this article: https://inheritedcancer.net/post120524/

ICARE Social Media Post December 2024

Alu-Mediated Breakpoints in VHL Pathogenic Variants

A study on mutations in Von-Hippel-Lindau (VHL) syndrome families revealed that: What does this mean?• In families that meet clinical criteria for VHL without a detectable VHL pathogenic variant whole genome sequencing may be considered for further analysis To learn more, read the full article at:https://pubmed.ncbi.nlm.nih.gov/33675279/ Reference: Vocke CD, et al. Hum Mutat. 2021; 42(5):520-529. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post120424/

ICARE Social Media Post December 2024

VHL Syndrome Characteristics

A recent study in carriers with Von-Hippel-Lindau Syndrome, an inherited condition that causes tumors and cysts to grow in certain areas of the body, found:▪️ Nearly 100% of carriers show some signs of this condition by age 65▪️ Demonstrates that this condition is highly penetrant Read the full article to learn more at:https://pubmed.ncbi.nlm.nih.gov/34916234/ Reference: Zhang …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-social-media-post-december-2024-vhl-syndrome-characteristics/

ICARE Social Media Post November 2024

BRCA1/2 Carriers with Advanced Breast Cancer

As highlighted in our latest ICARE newsletter, a new study in BRCA1/2 carriers with advanced breast cancer found: Read the full article to learn more at: https://pubmed.ncbi.nlm.nih.gov/37437366/Reference: Valenza, et al. Eur J Cancer. 2023;190:112944. PMID: 37437366. We also encourage you to read the full ICARE newsletter for other clinical and research updates at https://inheritedcancer.net/newsletters/

Permanent link to this article: https://inheritedcancer.net/icare-social-media-post-november-2024-brca1-2-carriers-with-advanced-breast-cancer/

ICARE Social Media Post November 2024

Breast Cancer After Ovarian Cancer in BRCA Carriers

As highlighted in the latest ICARE newsletter, a recent study evaluated breast cancer risks after ovarian cancer in BRCA1 & BRCA2 carriers. 🔍 After chemotherapy for ovarian cancer: 📊 Incidence rates were: 📈 What does this mean? Learn more at: https://tinyurl.com/yc8de3py Reference: Evans, et al. Genet Med. 2024;26(9):101172. PMID: 38847192. We also encourage you to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111924/

ICARE Social Media Post November 2024

Germline Mutations in Renal Cell Cancer Patients

A new study among patients with renal cell carcinoma reported a higher chance of finding a mutation in an inherited cancer-related gene in those with: Read the full article to learn more at:https://pubmed.ncbi.nlm.nih.gov/38127826/ Reference: Nguyen, et al. JCO Precis Oncol. 2023;7: e2300168. PMID: 38127826.

Permanent link to this article: https://inheritedcancer.net/post111424/

ICARE Social Media Post November 2024

BRCA Carriers with Breast Cancer: Trial to Compare PARP Inhibitors to Chemotherapy

As highlighted in the latest ICARE newsletter, a recent trial among BRCA1/2 carriers with breast cancer comparing PARP inhibitors to standard chemotherapy (Treatment of Physician’s Choice – TPC) found that after 25.7 months of follow up: Overall survival in each group was: The % alive at 3 years was: Patients who received Olaparib for first …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111224/

ICARE Social Media Post November 2024

Reduced Penetrance BRCA1/2 Pathogenic Variants

Check out our recently published study that brings attention to “reduced penetrance” BRCA1 and BRCA2 (BRCA) pathogenic variants, which impart LOWER breast cancer risks than ‘typical’ BRCA mutations. Specifically, lifetime breast cancer risks for these reduced penetrance BRCA variants are 20-30% which is similar to that seen in moderate penetrance breast cancer genes (e.g., CHEK2 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111124/

ICARE Social Media Post November 2024

NCCN Breast, Ovarian, Pancreatic, and Prostate Cancer Guidelines Update

The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Cancer guidelines on November 7th, 2024 (Version 2.2025) You read that right – they have now added “prostate” to the name as well as the relevant content! Prostate cancer specific testing and risk management information is now centralized …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110824/

ICARE Social Media Post November 2024

NCCN Guideline Updates: CDKN2A

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024 (Version 1.2025), which included the following CDKN2A updates ⤸ The CDKN2A gene produces two isoforms, both of which are tumor suppressors:➡️ p16INK4A and p14ARF For individuals with both of these isoforms, recommend:➡️ Skin exams …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110724/

ICARE Social Media Post November 2024

NCCN BOP Guideline Update #10: BRCA2 Update

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updates, NCCN added consideration of pancreatic cancer screening for BRCA2 carriers as outlined in PANC-A 1 of 2 (Page 52). To read more, you can check out the full guidelines by creating …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110224/

ICARE Social Media Post November 2024

May 2025 BRCA Symposium

Calling all healthcare providers and researchers! 🧬 Join us at BRCA 2025 – the 10th International Symposium on Hereditary Breast and Ovarian Cancer, taking place from May 6th-9th, 2025 in Montréal, Québec, Canada. We’re celebrating 30 years since the discovery of the BRCA genes and 20 years of bringing the world’s top minds together to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110124/

ICARE Social Media Post October 2024

Personalized Screening Recommendations for CHEK2 Carriers

A recent editorial highlights the value of personalized screening recommendations for CHEK2 carriers▪️ Notably, three common low-risk mutations (p.I157T, p.S428F, and p.T476M) impart a breast cancer risk of less than 1.4 fold▪️ This level of risk does not warrant high-risk breast screening or other heightened care Read the full article to learn more at: https://www.oncotarget.com/article/28604/pdf/ …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post103124/

ICARE Featured Video October 2024

Inherited Breast Cancers in Men

Below is a featured video from the October 2024 patient forum, during which patients had the opportunity to ask questions and discuss inherited breast cancers in men with our expert panelists

Permanent link to this article: https://inheritedcancer.net/video102924/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #9: Pancreatic Cancer Screening Update

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. An important update includes consideration of pancreatic cancer screening for ATM and BRCA2 carriers even in the absence of family history as outlined in PANC-A 1 of 2 (PAGE 52). To read more, you …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102824_1/

ICARE Social Media Post October 2024

Men’s Stories About Hereditary Cancer

In recognition of Breast Cancer Awareness Month, we are excited to share the newly released “Men’s Stories About Hereditary Cancer”. Read the full piece to hear how BRCA gene mutations affect men and steps you can take to learn about and manage your cancer risks ⤸https://tinyurl.com/mensstorieshereditarycancer

Permanent link to this article: https://inheritedcancer.net/post102824/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #8: CHEK2 Bi-allelic Mutations

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updates, NCCN outlines emerging data regarding breast cancer risks for bi-allelic CHEK2 mutations (i.e., mutations in both copies of the gene) as outlined in GENE-A (Page 38) ⤸ To read more, you …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102424/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #7: CHEK2: Ile157Thr and Ser428Phe

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updates, NCCN outlines the following for the CHEK2 Ile157Thr and Ser428Phe variants as outlined in GENE-A (Page 38) ⤸ To read more, you can check out the full guidelines by creating a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102324_1/

ICARE Social Media Post October 2024

Lack of Genetic Counseling and Testing Among Female Cancer Survivors

A recent study among women with early-stage breast cancer revealed that many female cancer survivors who meet guidelines for genetic counseling and testing for inherited cancer do not receive it. These findings underscore the need for better access to genetic counseling and testing to support patients and their families. Learn more at: https://bit.ly/3MkeM2o Reference: Katz, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102324/

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update V2.2024 – #2 EPCAM Updates

The National Comprehensive Cancer Network (NCCN) released updated Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on October 3rd, 2024. In these updated guidelines, NCCN revised information about EPCAM gene (which has usually been lumped together with MSH2) as follows ⤸ You can check out the full guidelines by creating a FREE account …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102224/

ICARE Social Media Post October 2024

Inherited Breast Cancers in Men

In honor of Breast Cancer Awareness month, we wanted to spread awareness about inherited breast cancer risks among men. Did you know that men with a BRCA2 mutation have about a 7% lifetime risk of breast cancer and those with a BRCA1 or PALB2 mutation have about a 1% lifetime risk of breast cancer? Thus, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102124/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #6: BRCA1 R1699Q

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. Some BRCA1 updates as outlined in GENE-A (Page 36) include ⤸ To read more, you can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post101924/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #5: ATM Update

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these new guidelines, there were several updates for ATM carriers, including adding colorectal cancer risk as outlined in GENE-A (Page 35) and consideration of pancreatic cancer screening as outlined in PANC-A 1 of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101724_1/

ICARE Social Media Post October 2024

November 2024 BRCA Hybrid Event Post – Patients & Public (Nov 5th) First post

Are you or someone you love affected by a BRCA gene mutation 🧬 ? This event is for you! On November 5th, Women’s College Hospital will be hosting a hybrid event entitled, BRCA: 30 Years, Discovery to Impact, to celebrate 30 years since the groundbreaking discovery of the BRCA1 and BRCA2 genes. Learn from leading …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101724/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #4: Ovarian Cancer Risks and Management Updates

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. Some updates include revisions to ovarian cancer risks and management including ⤸ To read more, you can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post101224/

Oct 15

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update V2.2024 = #1 Testing Considerations

The National Comprehensive Cancer Network (NCCN) released updated Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on October 3rd, 2024. In these updated guidelines, NCCN added the following to testing being considered ⤸Personal history of colorectal or endometrial cancer at or older than age 50, and: You can check out the full guidelines …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101524/

ICARE Social Media Post October 2024

Pancreatic Cancer Screening in High-Risk Patients

A recent study among high-risk patients found that pancreatic cancer screening through endoscopic ultrasound and/or MRI-based tests led to detection of smaller and earlier-stage cancers and overall, seemed to result in longer survival. Patients with an inherited gene mutation that predisposes to pancreatic cancer and/or a family history of pancreatic cancer were considered to be …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101024/

ICARE Featured Video October 2024

BRCA1/2 Genotype/Phenotype Associations: Implications to Care

Below is a featured video from the October 2024 case conference, during which Tuya Pal, MD, FACMG discusses BRCA1/2 genotype/phenotype associations and implications to care.

Permanent link to this article: https://inheritedcancer.net/video101024/

ICARE Social Media Post October 2024

Double Mastectomy Not Linked To Survival Advantage

A recent study found that in women with breast cancer, double mastectomy did NOT lead to longer survival. This is very important information for women to know as they make decisions about breast cancer surgery. Read the full article to learn more at: https://bit.ly/47a5O1b Reference: Giannakeas, et al. JAMA Oncol. 2024:e242212. PMID: 39052262.

Permanent link to this article: https://inheritedcancer.net/post100924_1/

Oct 09

ICARE Social Media Post October 2024

NCCN CDH1 Guideline Update

CDH1 gastric cancer risk management options are included in the recently released National Comprehensive Cancer Network (NCCN) Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines. Gastric (stomach) cancer risk management options include ⤸ In certain circumstances, gastrectomy is recommended based on findings at biopsy or endoscopy or other persistent unexplained symptoms. Regardless, a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100924/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #3: Genetic Testing in Breast Cancer Patients Age 65 and Below

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updated guidelines, NCCN indicates testing criteria for high-penetrance breast cancer susceptibility genes should be considered for those with a personal history of breast cancer ≤ age 65 (used to be < age …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100824_1/

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update V2.2024

The National Comprehensive Cancer Network (NCCN) released updated Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on October 3rd, 2024. Updates include ⤸ Added the following to testing being considered: Personal history of colorectal or endometrial cancer at or older than age 50, and: Revised information about EPCAM gene (which has usually been …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100824/

ICARE Social Media Post October 2024

BRCA2: Male Breast Cancer Risks

Did you know that men can get breast cancer too? In fact, Beyonce’s father, Matthew Knowles, was diagnosed with breast cancer in October 2019 and was found to have a BRCA2 mutation. Matthew’s children have a 50/50 chance of inheriting his BRCA2 mutation. Men with an inherited BRCA2 mutation are at an increased risk for …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100724/

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 5

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. An important update includes the revision of CHEK2 estimated absolute colon cancer risk to “NO INCREASED RISK”; thus, general population screening is appropriate for these individuals. You can check out the full guidelines …

Continue reading

Permanent link to this article: https://inheritedcancer.net/100624-2/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #2: Testing Unaffected Family Members

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updates, NCCN clarified that it is appropriate to test unaffected (not best testable) family members when they meet testing criteria. To read more, you can check out the full guidelines by creating …

Continue reading

Permanent link to this article: https://inheritedcancer.net/100424_1/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #1: Point-of-Care Testing

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updated guidelines, the minimal components that should be discussed during point-of-care testing are outlined (found in EVAL-A 10 of 11; Page 17). To read more, you can check out the full guidelines …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100324/

ICARE Newsletter Fall 2024

Community Spotlight: The Patient and the Researcher Shares Her Uncertain Future and Lessons She’s Learned

By Marleah Dean Kruzel, PhD, BRCA2 Previvor When I was eight years old, my mother found a lump in her breast – barely noticeable. For a few years, I watched her undergo chemotherapy, radiation, and a prophylactic mastectomy and reconstruction. Since then, my maternal aunt and grandmother also fought breast cancer, and we learned my …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-community-spotlight-the-patient-and-the-researcher-shares-her-uncertain-future-and-lessons-shes-learned/

ICARE Newsletter Fall 2024

Double Mastectomy Not Linked to Survival Advantage

A recent study found that in females with unilateral breast cancer (meaning breast cancer on one side) who decided to have a double mastectomy had similar mortality rates to those treated with lumpectomy or unilateral mastectomy (meaning double mastectomy did NOT lead to longer survival). Findings showed that while bilateral mastectomy greatly lowered the risk …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-double-mastectomy-not-linked-to-survival-advantage/

ICARE Newsletter Fall 2024

New Study to Evaluate Pancreatic Cancer Screening

A recent study among high-risk patients found that pancreatic cancer screening through endoscopic ultrasound and/or MRI-based tests led to detection of smaller and earlier-stage cancers, and overall, seemed to result in longer survival. Patients with an inherited gene mutation that predisposes to pancreatic cancer and/or a family history of pancreatic cancer were considered to be …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-new-study-to-evaluate-pancreatic-cancer-screening/

ICARE Newsletter Fall 2024

BRCA1/2 Carriers: Treatment Advances

Among BRCA1/2 carriers with advanced breast cancer, PARP inhibitors showed some activity even in patients with platinum resistant/unresponsive disease. However, the optimal delivery of platinum agents and PARP inhibitors was not clear.1 In another study of BRCA1/2 carriers with breast cancer (OlympiAD Trial), PARP inhibitors were compared to chemotherapy Treatment of Physician’s Choice (TPC), with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-brca1-2-carriers-treatment-advances/

ICARE Newsletter Fall 2024

American Society of Clinical Oncology (ASCO) Guideline Update: Selecting Genetic Tests in Patients with Various Cancers

What elements are most important in the collection of family history? When and how to use multigene panel testing when indicated? Which genes should be tested based on cancer type? Among patients with tumor testing, who should be offered germline testing? For a full list of recommendations in this guideline, the article is available at: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-american-society-of-clinical-oncology-asco-guideline-update-selecting-genetic-tests-in-patients-with-various-cancers/

ICARE Newsletter Fall 2024

Breast Cancer After Ovarian Cancer in BRCA1/2 Carriers

A recently published study reported that among females with ovarian cancer who received chemotherapy, their risk for breast cancer was lower for the next 5 years. Specifically, incidence rates were lower at 2 years (1.18%) and between 2 to 5 years (1.13%); however, incidence rates rose thereafter for BRCA1 carriers (>4% annually post 10 years). This study …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-breast-cancer-after-ovarian-cancer-in-brca1-2-carriers/

ICARE Newsletter Fall 2024

BRCA1/2 Carriers and Pregnancy-Related Risk

A recent study reported that pregnancy after breast cancer was safe for both mother and baby.1 Specifically, the researchers found that pregnancy after breast cancer was not associated with adverse maternal prognosis or fetal outcomes. Another study reported that breast cancer after pregnancy could be associated with poorer outcomes. Specifically, breast cancer diagnosed within 10 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-brca1-2-carriers-and-pregnancy-related-ris/

ICARE Newsletter Fall 2024

BRCA1/2 Carriers: Risk of Peritoneal Cancer After Bilateral Oophorectomy

A recent study among BRCA1 and BRCA2 carriers, which included ICARE participants, found that the risk for peritoneal cancer following a preventive bilateral oophorectomy was higher among BRCA1 carriers than BRCA2 carriers. Specifically, among 6310 females, the annual risk of peritoneal cancer was 0.14% for BRCA1 carriers and 0.06% for BRCA2 carriers, and the 20-year …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-brca1-2-carriers-risk-of-peritoneal-cancer-after-bilateral-oophorectomy/

ICARE Newsletter Fall 2024

Risk of Melanoma in BRCA1/2 Carriers

Over the last few years, there has been mixed information about the risk of melanoma in BRCA1/2 carriers – while earlier studies had suggested an association,1,2 other studies showed no association.3,4 Thus, based on current evidence, it is unclear if BRCA1 and/or BRCA2 pathogenic variants increase melanoma risk based on the current evidence.5,6 However, more recently, a study, which …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-risk-of-melanoma-in-brca1-2-carriers/

ICARE Newsletter Fall 2024

BRCA2-Associated Prostate Cancer

A new study found that males with a BRCA2 mutation and metastatic hormone-sensitive prostate cancer face poorer outcomes. BRCA2 carriers were also found to have a higher risk of progression to castration-resistant prostate cancer. These findings highlight the importance of evaluating germline mutations among prostate cancer patients. Custodio-Cabello, et al. Urol Oncol. 2024;42(10):331.e13-331.e24. PMID: 38926076. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-brca2-associated-prostate-cancer/

ICARE Newsletter Fall 2024

Risks of Cancer in Individuals with TWO CHEK2 Mutations (called “Bi-Allelic” Mutations)

A new study found that risks may be higher for multiple types of cancer, including breast cancer, in both females and males who have two CHEK2 mutations: Additionally, findings showed that the type of mutation may be important to guide level of risk (e.g., truncating 1100delC homozygotes being at a higher risk than compound heterozygotes …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-risks-of-cancer-in-individuals-with-two-chek2-mutations-called-bi-allelic-mutations/

ICARE Newsletter Fall 2024

National Comprehensive Cancer Network (NCCN) Guideline Updates

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer – Released September 11th, 2024 (V1.2025) Check out the full guidelines by creating a FREE account at www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Testing Updates: Gene Updates: Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric Cancer – Released August 8th, 2024 (V1.2024) Check out the full guidelines by creating a FREE account at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-national-comprehensive-cancer-network-nccn-guideline-updates/

ICARE Social Media Post September 2024

BRCA2-Associated Prostate Cancer

A new study found that men with a BRCA2 mutation and metastatic hormone-sensitive prostate cancer face poorer outcomes. BRCA2 carriers were also found to have a higher risk of progression to castration-resistant prostate cancer. These findings highlight the importance of evaluating germline mutations among prostate cancer patients. Learn more by reading the full article at: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post93024/

ICARE Social Media Post September 2024

NCCN CEG Guideline Update #3: Use of HRT following premature surgical menopause

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include use of hormone replacement treatment following premature surgical menopause from risk-reducing oophorectomy. You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf

Permanent link to this article: https://inheritedcancer.net/poat92524/

ICARE Social Media Post September 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 3

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include gynecologic risk and preventive surgery considerations for MLH1, MSH6, MSH2, and PMS2 carriers. You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf

Permanent link to this article: https://inheritedcancer.net/post91824/

ICARE Social Media Post September 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 2

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include ⤸ You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf

Permanent link to this article: https://inheritedcancer.net/post91424/

ICARE Featured Video September 2024

Genetic Predisposition to Prostate Cancer & Relevance to Targeted Screening

Below is a featured video from the September 2024 case conference, during which Ros Eeles, PhD, FRCP, FRCR, FMedSci discusses the genetic predisposition to prostate cancer and its relevance to targeted screening.

Permanent link to this article: https://inheritedcancer.net/video091224/

ICARE Featured Video September 2024

NCCN Genetic/Familial Guideline Updates: Breast, Ovarian, Pancreatic (V1.2025)

Below is a featured video from the September 2024 case conference, during which Tuya Pal, MD, FACMG from Vanderbilt University Medical Center presents on recent updated to the National Comprehensive Cancer Network (NCCN) Genetic/Familial Breast, Ovarian, and Pancreatic cancer guidelines.

Permanent link to this article: https://inheritedcancer.net/video0912242/

ICARE Social Media Post September 2024

NCCN Breast, Ovarian, and Pancreatic Cancer Guidelines Update

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. Some updates include ⤸ To read more, you can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post91224/

ICARE Social Media Post September 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update

The National Comprehensive Cancer Network (NCCN) released the new Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include ⤸• Endometrial cancer recommendations included throughout• Hereditary Diffuse Gastric Cancer section added (HGAST-1)• Gynecologic risk and preventive surgery considerations for those with Lynch Syndrome• Use of hormone replacement treatment following …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post90324/

ICARE Social Media Post August 2024

ICARE Overview Video

Learn more about the Inherited Cancer Registry (ICARE) by watching an exciting presentation by student researcher, Reagan Sellers, who provides information about the history of ICARE, what being an ICARE participant entails, our various education and engagement efforts, and the focused research studies being conducted through ICARE. Check out the full video on our YouTube …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82824/

ICARE Social Media Post August 2024

BRCA1/2 carriers: Melanoma Risk?

A new study in which ICARE participants were included reported that compared to 1.5% in the general population, the risk of melanoma may be slightly elevated: in BRCA1/2 carriers:○ BRCA1: 2.5%○ BRCA2: 2.3% Read the full article to learn more at: https://tinyurl.com/ye2xxfru Reference: Narod et al. Hered Cancer Clin Pract. 2024;22(1):7. PMID: 38741145.

Permanent link to this article: https://inheritedcancer.net/post82624/

ICARE Social Media Post August 2024

Peritoneal Cancer After Oophorectomy in BRCA1/2 Carriers

A recent study among BRCA1 and BRCA2 carriers, which included ICARE participants, found that the risk for peritoneal cancer following a preventive bilateral oophorectomy was higher among BRCA1 carriers than BRCA2 carriers. Specifically, among 6310 women, the annual risk of peritoneal cancer was 0.14% for BRCA1 carriers and 0.06% for BRCA2 carriers, and the 20-year …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82524/

ICARE Social Media Post August 2024

How to Access NCCN Guidelines

Unlock valuable resources for your health journey! 🌟 The National Comprehensive Cancer Network (NCCN) guides clinical practice by providing free access to their guidelines that are available to both patients and healthcare providers. To access the most recent version of cancer-related guidelines that are updated at least annually, create a free username and password at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82024/

ICARE Featured Video August 2024

EGFR and the INHERIT Study

Below is a featured video from the August 2024 case conference, during which Diane Koeller, MPH, MS, CGC presents on EGFR and the INHERIT study.

Permanent link to this article: https://inheritedcancer.net/video80824/

ICARE Social Media Post August 2024

FDA Approved a Blood Test for Colorectal Cancer Screening

Breaking News: The FDA recently approved a blood test for colorectal cancer screening! 🔍 What does this mean? ⭐ Bottom Line: Learn more at: https://www.nejm.org/doi/full/10.1056/NEJMoa2304714 Reference: Chung, et al. N Engl J Med. 2024;390(11):973-983: PMID: 38477985.

Permanent link to this article: https://inheritedcancer.net/post80824/

ICARE Social Media Post August 2024

Comparing Cancer Risk Management between Females with Truncating CHEK2 1100delC versus Missense CHEK2 I157T Variants

In a recent study based on ICARE participants, we compared cancer risk management between those with CHEK2 1100delC (which leads to moderate breast cancer risk, generally more than 20% lifetime risk) versus I157T (which is a low penetrance mutation, with breast cancer risks of less than 20%) 👩‍🔬 Of the 150 CHEK2 carriers, there were …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post80524/

ICARE Social Media Post July 2024

Genetics Role in Identifying Lower Breast Cancer Risk

A new study of 25,591 women found: Based on genetic risk, identifying individuals at: This study challenges a one-size-fits all mammogram screening approach. This approach could possibly reduce rising healthcare costs by reallocating resources and lower unnecessary anxiety that comes with frequent screenings, and even prevent unnecessary procedures. Read the full article to learn more …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72924/

ICARE Social Media Post July 2024

New Study in POT1 Carriers

In recognition of Sarcoma Awareness Month, a new study found that POT1 mutations are associated with an increased risk for melanoma and a wider variety of different sarcomas than previously described. Specifically, the study showed significant raised risks of around 7-fold for both sarcoma and melanoma. This included many different types of sarcomas, including: Learn …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72824/

ICARE Social Media Post July 2024

New Genes Raise Breast Cancer Risks Identified in Study of African Women

A new study, which included ICARE-related efforts through including BEST study participants:▪️ Identified 12 breast cancer genes that may help to predict breast cancer risk▪️ Included more than 40,000 women of African ancestry, almost half of which had breast cancer Why is studying individuals from diverse ancestral backgrounds important?▪️ Refine risks across diverse populations▪️ A …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72524/

ICARE Featured Video July 2024

Li-Fraumeni Syndrome

Below is a featured video from the July 2024 case conference, during which Megan Frone, MS, CGC presents on Li-Fraumeni Syndrome.

Permanent link to this article: https://inheritedcancer.net/video71224/

ICARE Social Media Post June 2024

ICARE Post #3 – PALB2 Genomics Study Post

If you have a history of breast cancer and a mutation in the PALB2 gene, you may be eligible to contribute to tumor genomics studies to help better understand inherited breast cancer in PALB2 carriers. Through the Inherited Cancer Registry (ICARE), we are studying: With your help, we hope that one day our research may …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post71124/

ICARE Featured Video July 2024

Coping with Hereditary Cancer: Managing Emotional Distress and Communicating with Family

Below is a featured video from the July 2024 patient forum, during which patients had the opportunity to ask questions and discuss how to manage emotional distress and communicate with family about inherited cancer predisposition with our expert panelists.

Permanent link to this article: https://inheritedcancer.net/video70924/

ICARE Social Media Post June 2024

ICARE Post #3 – CHEK2 Genomics Study Post

If you have a history of breast cancer and a mutation in the CHEK2 gene, you may be eligible to contribute to tumor genomics studies to help better understand inherited breast cancer in CHEK2 carriers. Through the Inherited Cancer Registry (ICARE), we are studying: With your help, we hope that one day our research may …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post7052024/

ICARE Social Media Post June 2024

ICARE Post #3 – ATM Genomics Study Post

If you have a history of breast cancer and a mutation in the ATM gene, you may be eligible to contribute to tumor genomics studies to help better understand inherited breast cancer in ATM carriers. Through the Inherited Cancer Registry (ICARE), we are studying: With your help, we hope that one day our research may …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post62324/

ICARE Social Media Post June 2024

Breast Cancer Patients with BRCA Variants Diagnosed Within 10 Years Postpartum at Higher Mortality Risk

A new study reported that among BRCA carriers, breast cancer diagnosed within 10 years of having a child was associated with a higher risk of mortality, especially in BRCA1 carriers. This information could be important for genetic counseling, prevention, and treatment strategies in BRCA carriers. Learn more by reading the full article at: https://bit.ly/3wHyAIz Reference: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60624/

ICARE Social Media Post June 2024

Pregnancy after Breast Cancer: BRCA carriers

A new study reported that pregnancy after breast cancer was not associated with adverse maternal prognosis or fetal outcomes. These findings suggest that pregnancy after breast cancer is safe for both mother and baby. Read the full article at: https://bit.ly/3wcoa3xReference: Newman, et al. JAMA Surg. 2024. Online ahead of print. PMID: 38536201. Follow us to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60324/

ICARE Social Media Post May 2024

New ASCO Guideline: Selection of Germline Testing Panels in Patients With Cancer

The American Society of Clinical Oncology (ASCO) just released new guidelines for the selection of germline genetic testing panels in patients with cancer. Items addressed include ⤸ What elements are most important in the collection of family history?🧬 Details of cancers in first- and second-degree relatives and the patient’s ethnicity. When and how to use …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post52124/

ICARE Social Media Post May 2024

AACR Cancer Disparities Progress Report 2024

The American Association for Cancer Research (AACR) just released a Cancer Disparities Progress Report on May 15th, which includes highlights on inherited cancers! On Page 163, this report discusses policies to address disparities in screening and surveillance for hereditary cancer syndromes. It also highlights an electronic support tool, called MyLynch, that can be used to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post5172024/

ICARE Featured Video May 2024

SDHA Germline Genetic Testing and Surveillance

Below is a featured video from the May 2024 case conference, during which Helen Hanson, MD and Ruth Casey, MD present on SDHA. Please visit our YouTube channel to watch the full May conference, including valuable discussion from genetics professionals!

Permanent link to this article: https://inheritedcancer.net/video50924/

ICARE Social Media Post May 2024

CHEK2: Bi-Allelic Mutations

Do you know the cancer risks for individuals with CHEK2 bi-allelic mutations (i.e., those with TWO CHEK2 mutations)? A new study found that risks may be higher for multiple types of cancer, including breast cancer, in both females and males ⤸▪️ Females more frequently developed 2 or more cancers at younger ages▪️ Males more frequently …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post50324/

ICARE Social Media Post April 2024

YouTube Channel

 

Curious about inherited cancer and the latest breakthroughs? Look no further than the ICARE YouTube channel! 🎥 Join genetics experts as they dive into discussions on important topics like updates to NCCN cancer risk management guidelines and insights into specific inherited cancer genes. 💡 Don’t miss out on some of our top-viewed videos covering management …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42824/

ICARE Featured Video April 2024

Hereditary Kidney Cancer

Below is a featured video from the April 2024 case conference, during which Ramaprasad Srinivasan, MD, PhD from the National Cancer Institute presents on hereditary kidney cancer.

Permanent link to this article: https://inheritedcancer.net/video41124/

ICARE Newsletter Spring 2024

Inherited Risk in Patients with Pancreatic Acinar Cell Carcinoma

In a study of a rare type of pancreatic cancer, called pancreatic acinar cell cancer (PACC), over one third (36.7%) of a total of 49 patients with PACC had a mutation in an inherited cancer gene. The most commonly mutated gene was BRCA2 (12), and other genes included BRCA1 (1), PALB2 (2), ATM (2), and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-inherited-risk-in-patients-with-pancreatic-acinar-cell-carcinoma/

ICARE Newsletter Spring 2024

BRCA-Associated Prostate Cancer Treatment Updates

New studies to guide treatment strategies in men with prostate cancer and a BRCA mutation were recently published. Specifically, a recent study suggested that platinum-based chemotherapy may be as effective as PARP inhibitors for individuals with BRCA-positive metastatic castration-resistant prostate cancer.1 The study sheds light on treatment options for advanced prostate cancer patients. More recently, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-brca-associated-prostate-cancer-treatment-updates/

ICARE Newsletter Spring 2024

Ask the Expert

This question was addressed by Ronald D. Alvarez, MD, MBA, Professor and Chairman of the Department of Obstetrics and Gynecology at the Vanderbilt University Medical Center in Nashville, Tennessee. He is also the current vice chair of the National Comprehensive Cancer Network (NCCN) Ovarian Cancer Treatment Guidelines and has served in multiple leadership roles in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-ask-the-expert/

ICARE Newsletter Spring 2024

How Well Do Cancer Risk Management strategies Work Among BRCA Carriers

Several important studies were published recently on the effectiveness of risk management strategies in BRCA carriers. Specifically, a recently published study in which ICARE participants were included suggested that preventive bilateral mastectomy for BRCA carriers greatly reduced the risk of developing breast cancer by 80%.1 Additionally, study findings showed that after preventive mastectomy, the chance …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-how-well-do-cancer-risk-management-strategies-work-among-brca-carriers/

ICARE Newsletter Spring 2024

Aerobic Exercise May Reduce Risk of Colorectal Cancer in Patients with Lynch Syndrome

A new research study among individuals with Lynch Syndrome reported that regular and intense aerobic exercise may lower the risk of colorectal cancer by improving the immune system’s ability to detect and remove potentially harmful cells. Specifically, the researchers enrolled 21 patients with Lynch Syndrome either to an 1) exercise group (45 minute cycling classes …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-aerobic-exercise-may-reduce-risk-of-colorectal-cancer-in-patients-with-lynch-syndrome/

Apr 09

ICARE Newsletter Spring 2024

New Guidelines Released Through ASCO-Society of Oncology; Germline Testing in Patients with Breast Center

In January 2024, the American Society of Clinical Oncology (ASCO) in conjunction with the Society of Surgical Oncology released new guidelines for germline testing in patients with breast cancer, which include the following:  For a full list of recommendations in this guideline, the article is available at: https://ascopubs.org/doi/10.1200/JCO.23.02225 Bedrosian, et al. J Clin Oncol. 2024;42(5):584-604. PMID:38175972. Social …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-new-guidelines-released-through-asco-society-of-oncology-germline-testing-in-patients-with-breast-center/

ICARE Newsletter Spring 2024

National Comprehensive Cancer Network (NCCN) Guideline Updates

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer – Released February 12th, 2024 (V3.2024) Check out the full guidelines by creating a FREE account at www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Contralateral breast cancer risks in these updated guidelines: Expanded guidance about gynecologic cancers in BRCA1/2 carriers: Some highlights related to HRT include: Genetic/Familial High-Risk Assessment: Colorectal Cancer – Released …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-national-comprehensive-cancer-network-nccn-guideline-updates/

ICARE Featured Video March 2024

NCCN Genetic/Familial Guideline Updates: Breast, Ovarian, Pancreatic (V3.2024)

Below is a featured video from the March 2024 case conference, during which Tuya Pal, MD, FACMG from Vanderbilt University Medical Center presents on recent updated to the National Comprehensive Cancer Network (NCCN) Genetic/Familial Breast, Ovarian, and Pancreatic cancer guidelines.

Permanent link to this article: https://inheritedcancer.net/video30724_2/

ICARE Featured Video March 2024

Liquid Biopsies to Guide Breast Cancer Therapies

Below is a featured video from the March 2024 case conference, during which Ben Ho Park, MD, PhD discusses liquid biopsies.

Permanent link to this article: https://inheritedcancer.net/video30724/

ICARE Social Media Post March 2024

 Risk Management Strategies for Women with BRCA1/2

  

Two new research studies that 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝗱 𝗜𝗖𝗔𝗥𝗘 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀 showed that risk of death is lowered among BRCA1/2 carriers with 1) MRI screening for breast cancer and 2) removal of both ovaries and fallopian tubes. 💡 In the first study, MRI screening greatly lowered the risk of death from breast cancer (hazard ratio of 0.23) with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post3524/

ICARE Social Media Post February 2024

Risk-reducing mastectomy and breast cancer mortality in women with BRCA1/BRCA2

 

🔬 Exciting news! A recent study, which included ICARE participants, suggests the life-saving potential of preventive mastectomy for BRCA1 and BRCA2 carriers. 💪 This procedure significantly reduces the risk of developing breast cancer and may even decrease the risk of breast cancer-related mortality. The study found that after preventive mastectomy, the chance of dying from …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post22724/

PARP Inhibitor (Olaparib) in men with BRCA mutations and prostate cancer

A recent study found that Olaparib (Lynparza) improved survival outcomes among men with BRCA1/2 mutations and metastatic castration-resistant prostate cancer, regardless of whether the mutation was germline or somatic. This underscores the potential of targeted therapies in improving outcomes for those with inherited cancer gene mutations. Learn more at: https://ascopubs.org/doi/10.1200/JCO.23.00339 Reference: Mateo, et al. J …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post22024/

ICARE Social Media Post February 2024  Updates to NCCN Guidelines: Genetic/Familial Breast, Ovarian, and Pancreatic Post #2 

The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on February 12th, 2024! Updates include expanded guidance about gynecologic cancers in BRCA1 and BRCA2, including:✓ Reproductive considerations✓ Non-surgical and surgical risk reduction✓ Salpingectomy✓ Hysterectomy considerations✓ HRT after risk-reducing removal of the ovaries You can check out the full …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21324_2/

ICARE Social Media Post February 2024

 Updates to NCCN Guidelines: Genetic/Familial Breast, Ovarian, and Pancreatic Post #1 

 

The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on February 12th, 2024! Updates include adding contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and other genes to the GENE-A (Cancer Risk Management) table 🧬 You can check out the full guidelines by creating a FREE account …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21324/

ICARE Social Media Post February 2024

 Germline EGFR Mutations and Familial Lung Cancer 

   

As featured in our Fall 2023 newsletter, inherited T790M EGFR mutations lead to a higher risk of lung cancer and are more common in the Southeast United States due to a ‘founder effect’. A study, in which our fellow Vanderbilt colleagues contributed, among individuals with this inherited cancer gene mutation found that more than half …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21224/

ICARE Featured Video February 2024

The Long Telomere Syndromes: POT1 Mutations in Cancer

Below is a featured video from the February 2024 case conference, during which Mary Armanios, MD discusses POT1 mutations.

Permanent link to this article: https://inheritedcancer.net/video20824/

ICARE Social Media Post January 2024

Hereditary Cancer Genetic Testing Educational Video

 

Want to learn more about genetic testing for inherited cancer? We use patient stories to give information about testing, its possible value to individuals and their family, and ways to access resources to learn more about getting tested. Check out the video here: http://tinyurl.com/genetictestingvideo To get free personalized information about hereditary cancer risk and testing, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11724/

ICARE Featured Video January 2024

Transplant Eligibility and Inherited Cancer Results

Below is a featured video from the January 2024 case conference, during which Katie Lang, MS, CGC discusses transplant eligibility in the context of inherited cancer genetic test results.

Permanent link to this article: https://inheritedcancer.net/video11224/

ICARE Social Media Post January 2023

Colon Adenomas in Lynch Syndrome

New research reveals that individuals under the age of 50 with Lynch Syndrome often develop small, flat adenomas, particularly in the right (proximal) colon. This finding emphasizes the importance of rigorous screening, with a special focus on the proximal colon, among these young Lynch Syndrome patients 🩺🔍 Learn more at: https://www.dldjournalonline.com/article/S1590-8658(23)00946-5/fulltext Reference: Alric, et al. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11024/

ICARE Social Media Post January 2023

New ASCO Germline Testing in Patients With Breast Cancer Guidelines

The American Society of Clinical Oncology (ASCO) just released new guidelines for germline testing in patients with breast cancer, which include the following:🧬 BRCA1/2 testing should be offered to ALL patients diagnosed with breast cancer at or below age 65🧬 Testing for other hereditary cancer genes should also be offered based on personal and family …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post10524/

ICARE Social Media Post January 2023

BRCA/Prostate Cancer/Treatment

A recent study suggests that Platinum Chemotherapy is as effective as PARP inhibitors for individuals with BRCA-positive metastatic castration-resistant prostate cancer. The study sheds light on treatment options for advanced prostate cancer patients 🩺✨ Learn more at: http://tinyurl.com/3vs2mk8f Reference: Fazekas, et al. Eur Urol Oncol. 2023: S2588-9311(23)00174-8. PMID: 37722977.

Permanent link to this article: https://inheritedcancer.net/post10324/

ICARE Social Media Post December 2023

BRCA1/2 carriers with Risk Reducing Salpingo-oophorectomy

A study among BRCA1/2 carriers who underwent a risk-reducing salpingo-oophorectomy (i.e., removal of both ovaries and fallopian tubes) found that the risk of peritoneal cancer increases if serous tubal intraepithelial carcinoma (STIC) is present – specifically, peritoneal cancer risk was 10.5% with STIC versus 0.3% without STIC at 5 years and 27.5% with STIC versus …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post121923/

ICARE Featured Video December 2023

Care for Gender Diverse Individuals with or at Risk for Inherited Cancer Predisposition

Below is a featured video from the December 2023 case conference, during which Kim Zayhowski, MS, CGC, Sarah Roth, ScM, and Sasha Weiss, MA discuss care for gender diverse individuals with or at risk for inherited cancer predisposition. Please visit our YouTube channel to watch the full December conference, including valuable discussion from genetics professionals!

Permanent link to this article: https://inheritedcancer.net/video121423/

ICARE Social Media Post December 2023

BRCA1/2: removing both ovaries and tubes to lower risks

A recent study among nearly 500 BRCA1/2 carriers who underwent breast cancer surgery found that survival was higher in those who chose preventive removal of their ovaries and fallopian tubes (in order to reduce cancer risks) compared to those who did not, particularly in BRCA1 carriers. Learn more at: https://tinyurl.com/5hdx6ytv Reference: Martelli, et al. JAMA …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post121323/

ICARE Social Media Post December 2023

Tamoxifen and Breast Cancer Risk in BRCA Mutations

In a recent study among female BRCA1/2 carriers, including ICARE participants, researchers explored the impact of using tamoxifen and/or raloxifene on breast cancer risk. 👩‍🔬 After almost 7 years of follow-up, only 10.9% of those in the tamoxifen/raloxifene group were diagnosed with breast cancer, compared to 14.3% of those in the non-user group. These findings …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post120523/

ICARE Social Media Post November 2023

Aerobic Exercise May Be Effective At Reducing Risk Of Colorectal Cancer In Patients With Lynch Syndrome

New research suggests regular, intense aerobic exercise may lower colorectal cancer risk in Lynch Syndrome patients 🏃‍♂️🧬 Learn more at: https://tinyurl.com/2s44828h Reference: Deng, et al. Clin Cancer Res. 2023; 29(21): 4361-4372. PMID: 37724990.

Permanent link to this article: https://inheritedcancer.net/post111523/

ICARE Social Media Post November 2023

Inherited Genes Associated With Aggressive Types Of Prostate Cancer

A new study found that inherited BRCA2, ATM, and NBN genes were most strongly associated with aggressive or metastatic prostate cancer. Learn more at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2809874 Reference: Darst, et al. JAMA Oncol. 2023. PMID: 37733366.

Permanent link to this article: https://inheritedcancer.net/post110923/

ICARE Featured Video November 2023

Pancreatic Cancer Screening

Below is a featured video from the November 2023 case conference, during which Bryson Katona, MD, PhD from Penn Medicine presents on pancreatic cancer screening. Please visit our YouTube channel to watch the full November conference, including valuable discussion from genetics professionals!

Permanent link to this article: https://inheritedcancer.net/video110923/

Nov 01

ICARE Social Media Post November 2023

Piloting a Spanish-Language Web-Based Tool for Hereditary Cancer Genetic Testing

Las barreras del idioma nunca deberían impedir que las personas accedan a información esencial en el campo de la atención de salud. Para llenar el vacío causado por la falta de asesores genéticos que hablan español, nuestro equipo desarrolló una herramienta de educación genética basada en la web. Un estudio entre 41 hispanohablantes encontró que …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110123_1/

Nov 01

ICARE Social Media Post November 2023

Piloting a Spanish-Language Web-Based Tool for Hereditary Cancer Genetic Testing

Language barriers should never prevent people from accessing essential information in the field of healthcare. To fill the gap caused by the lack of Spanish-speaking genetic counselors, our team developed a web-based genetic education tool 🧬 A study among 41 Spanish-speaking found that viewing the tool significantly increased knowledge and feeling informed and empowered to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110123/

ICARE Social Media Post October 2023

Pancreatic Acinar Cell Carcinoma

Permanent link to this article: https://inheritedcancer.net/post102923/

ICARE Social Media Post October 2023

Triple-negative breast cancers across populations

Triple-negative breast cancers, which do not have estrogen, progesterone, or HER2 receptors, can be more serious and difficult to treat. Inherited breast cancer gene mutations, like BRCA1/2, are more common among this type of breast cancer – which is why it is important for those with triple-negative breast cancer to consider getting genetic testing that …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102223/

ICARE Social Media Post October 2023

BRCA1/2 Carriers with Risk-Reducing Salpingo-Oophorectomy: Cancer Worry?

A study found that the majority of BRCA1/2 carriers who underwent risk-reducing salpingo-oophorectomy have declining cancer worry. However, a subset had concerns – these individuals are important to identify and try to offer additional support to. Use the following link to learn more: https://bit.ly/3qflyig Reference: van Bommel, et al. Support Care Cancer. 2022;30(4):3409-3418. PMID: 34997316.

Permanent link to this article: https://inheritedcancer.net/post102023/

ICARE Featured Video October 2023

Management of Individuals with CHEK2 Mutations

Below is a featured video from the October 2023 case conference, during which Helen Hanson, MD from the Royal Devon University Healthcare NHS Foundation Trust and Douglas Stewart, MD from the National Cancer Institute present on the management of individuals with CHEK2 germline pathogenic variants. Please visit our YouTube channel to watch the full October …

Continue reading

Permanent link to this article: https://inheritedcancer.net/video101223/

ICARE Social Media Post October 2023

Navigating BRCA1/2 Choices

A recent randomized controlled trial among 107 BRCA1/2 carriers, which included ICARE participants, evaluated the effectiveness of a behavioral phone intervention delivered by genetic counselors on the uptake of risk-reducing salpingo-oophorectomy. Women who received the intervention had significantly lower decisional conflict and higher knowledge after one year, and at the two year mark, nearly 54% …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101223/

ICARE Social Media Post October 2023

BRCA2 & Melanoma Risk

Are BRCA2 carriers at higher risk for developing melanoma? As featured in our Fall 2023 newsletter, at present, we are not sure because results from different studies have been inconsistent. For instance, one study among 173 families with a BRCA2 mutation found a 2.6-fold risk of developing melanoma; however, another study of 139 Dutch families …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100623/

ICARE Newsletter Fall 2023

Community Spotlight

My paternal grandparents were my heroes. Wise beyond their time, they relished teaching our familythat knowledge is power, health is everything, and love is unconditional. Back then, Prevention healthmagazine and vitamin supplements filled their mailbox and 1960’s exercise guru Jack LaLane, and health foodadvocate Euell Gibbons, beckoned new followers from a talking picture box in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-community-spotlight/

ICARE Newsletter Fall 2023

Ask the Expert

This question was addressed by Kelly Taylor, MS, LCGC, a licensed and certified genetic counselor with expertise inresearch genetics and hereditary cancers at the Vanderbilt Hereditary Cancer Clinic. If you have a question you wouldlike addressed, please email the ICARE team at ICARE@vumc.org for consideration in future newsletters. Q: I have Lynch Syndrome and an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-ask-the-expert/

ICARE Newsletter Fall 2023

BRCA-associated Prostate Cancers

On April 28th, 2023, the FDA approved olaparib plus abiraterone acetate for first line treatment for metastatic castration-resistant prostate cancer, but only in patients whose tumors have BRCA mutations. Although a broad indication for the combination therapy was desired, concerns about the trial design were raised, and the phase III results did not explicitly show …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-brca-associated-prostate-cancers/

Oct 05

ICARE Newsletter Fall 2023

Healthcare Delivery

A recent study, based on ICARE participants, found that getting care according to guidelines depends on what the healthcare provider recommends, as well as how much trust the patient has in their care. This study shows us how important it is to find ways to improve knowledge among healthcare providers and trust in care among …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-healthcare-delivery/

ICARE Newsletter Fall 2023

Germline EGFR Mutations and Familial Lung Cancer

A study, in which our Vanderbilt colleagues Georgia Wiesner, MD, MS (geneticist) and Kelly Taylor, MS, LCGC (genetic counselor) participated, was recently published about the inherited T790M EGFR mutation. Mutations in this gene lead to a higher risk or lung cancer and were found to be more common in the Southeast United States where there …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-germline-egfr-mutations-and-familial-lung-cancer/

ICARE Newsletter Fall 2023

Genes Associated with Aggressive Prostate Cancer

A new study of almost 18,000 men with prostate cancer showed that inherited mutations in the BRCA2, ATM, and NBN genes were strongly associated with aggressive prostate cancer. Less strong associations were seen for inherited mutations in the MSH2, XRCC2, and MRE11A genes. The findings of this study suggest that knowing about inherited genes that …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-genes-associated-with-aggressive-prostate-cancer/

ICARE Newsletter Fall 2023

Are BRCA2 Carriers at Higher Risk for Melanoma?

At present, we are not sure because results from different studies have been inconsistent (1). For instance, one study among 173 families with a BRCA2 mutation found a 2.6-fold risk of developing melanoma (2); however, another study of 139 Dutch families with a BRCA2 mutation revealed a lower than general population risk for melanoma (3). …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-are-brca2-carriers-at-higher-risk-for-melanoma/

ICARE Newsletter Fall 2023

Fertility Treatment in BRCA Carriers: Breast Cancer Risk

A recent study among female BRCA carriers showed risk of breast cancer was not significantly raised through fertility treatment, which is reassuring. There remains a need to further study this question in more detail, for associations with breast cancers across different breast cancer subtypes, including breast cancers that are hormone-related and breast cancers that are …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-fertility-treatment-in-brca-carriers-breast-cancer-risk/

ICARE Newsletter Fall 2023

Newly released ACMG Clinical Practice Resource on CHEK2 Developed Through a Group of Worldwide Experts!

A person with a pathogenic variant in the CHEK2 gene may be at an increased risk for developing breast and other cancers. This ACMG Clinical Practice Resource, published in ACMG’s flagship journal, Genetics in Medicine, provides valuable information for healthcare providers caring for individuals with pathogenic variants in the CHEK2gene. This new ACMG Practice Resource …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-newly-released-acmg-clinical-practice-resource-on-chek2-developed-through-a-group-of-worldwide-experts/

ICARE Newsletter Fall 2023

Tamoxifen and Breast Cancer Risk in Women with a BRCA1 or BRCA2 Mutation

In a study of female BRCA carriers, including ICARE participants, those that used tamoxifen and/or raloxifenewere compared to those that did not. After an average follow-up time of almost 7 years, 10.9% of those in the tamoxifen/raloxifene group were diagnosed with breast cancer, compared to 14.3% in the group that did not use thesedrugs. This …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-tamoxifen-and-breast-cancer-risk-in-women-with-a-brca1-or-brca2-mutation/

ICARE Newsletter Fall 2023

BRCA1 and BRCA2 Carriers: Cancer Risks with Oral Contraceptive Use (UK)

Among female BRCA1 and BRCA2 carriers, a recent study found that oral contraceptive use is associated with:› Raised risk of breast cancer, but only in those using for over 5 years (relative risk: 1.25)› Lower risk of ovarian cancer (nearly cut in half) Park, et al. Carcinogenesis. 2022;43(3):231-242. PMID:

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-brca1-and-brca2-carriers-cancer-risks-with-oral-contraceptive-use-uk/

ICARE Newsletter Fall 2023

Recommendations for Inherited Ovarian Cancer Genes: United Kingdom (UK)

Through consensus, management recommendations were developed in the UK for females with pathogenic variants inthe following inherited ovarian cancer genes: RAD51C, RAD51D, BRIP1, and PALB2. Hanson, et al. J Med Genet. 2023;60(5):417-429. PMID: 36411032. Social media post September 26th, 2023.Available at https://tinyurl.com/post9262023.

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-recommendations-for-inherited-ovarian-cancer-genes-united-kingdom-uk/

ICARE Newsletter Fall 2023

Mammograms: New U.S. Preventive Services Task Force (USPSTF) Recommendations

On May 9th, 2023, the USPSTF published a new draft recommendation for all cisgender women and those assigned female sex at birth to do mammograms from ages 40 to 74, every two years, for those at average (population) risk forbreast cancer. This change in recommendation is due to recent troubling trends, including an increase in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-mammograms-new-u-s-preventive-services-task-force-uspstf-recommendations/

ICARE Newsletter Fall 2023

National Comprehensive Cancer Network (NCCN) Guidelines Updates

Check out the full NCCN guidelines by creating a FREE account at www.nccn.org Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic CancerReleased August 28th, 2023 (V1.2024) › Transgender, Non-Binary, and Gender Diverse Individuals: NEW section on care (Page 63-66, TNBGD-1 to 4)› Li-Fraumeni Syndrome: Significant updates to content (risks and care) (Pages 57-60, LIFR-A): Table added …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-national-comprehensive-cancer-network-nccn-guidelines-updates/

ICARE Social Media Post October 2023

What Are Established Cancer Genes?

There are many different inherited breast cancer genes, and different genes lead to different levels of breast cancer risk:

Permanent link to this article: https://inheritedcancer.net/post100423/

ICARE Featured Video September 2023

NCCN Genetic/Familial Guideline Updates: Breast, Ovarian, Pancreatic (V1.2024)

Below is a featured video from the September 2023 case conference, during which Tuya Pal, MD, FACMG from Vanderbilt University Medical Center presents on recent updated to the National Comprehensive Cancer Network (NCCN) Genetic/Familial Breast, Ovarian, and Pancreatic cancer guidelines. Please visit our YouTube channel to watch the full September conference, including valuable discussion about …

Continue reading

Permanent link to this article: https://inheritedcancer.net/video91423/

ICARE Social Media Post August 2023

  BRCA1/2 Outcomes: Metastatic Breast Cancer  

According to a recent study, germline BRCA1/2 status did not affect prognosis. However, outcomes differed by immunohistochemistry (IHC) subtype as follows: Use the link in bio to learn more! Reference: Mailliez, et al. Int J Cancer. 2023;152(5):921-931. PMID: 36161271.

Permanent link to this article: https://inheritedcancer.net/post83032/

ICARE Social Media Post August 2023

 Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

 

The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on August 28th, 2023, which included: You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post82923/

ICARE Social Media Post August 2023

 FDA Approval Post – Approves Niraparib 

 

A critical step forward in cancer care! The FDA has approved the use of niraparib and abiraterone acetate with prednisone in treating patients with BRCA-mutated castration-resistant prostate cancer. The green light comes backed by the robust efficacy data from the MAGNITUDE trial. Read more about the FDA approval at ⁠https://tinyurl.com/dzdvtm9m Learn more about the MAGNITUDE …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82423/

ICARE Social Media Post August 2023

Cancer Risks: Inherited CDH1 Mutations  

A recent study found that inherited CDH1 mutations: These findings support expansion of lobular breast cancer-centered criteria. Use this link to learn more: http://bit.ly/3DJa7Cs Reference: Garcia-Pelaez, et al. Lancet Oncol. 2023 Jan;24(1):91-106. PMID: 36436516.

Permanent link to this article: https://inheritedcancer.net/post82223/

ICARE Social Media Post August 2023

UK Recommendations for: Inherited Ovarian Cancer Genes

Through consensus, management recommendations were developed in the UK for females with pathogenic variants in the following inherited ovarian cancer genes: Learn more at the link in bio! Reference: Hanson H, et al. J Med Genet. 2023;60(5):417-429. PMID: 36411032.

Permanent link to this article: https://inheritedcancer.net/post81823/

ICARE Featured Video August 2023

SELECT: Using a Gene Expression-driven Algorithm to Prioritize Competing Treatment Options for BRCA Carriers with Breast Cancer

Below is a featured video from the August 2023 case conference, during which Sheila Rajagopal, MD, MPH, MSc from the National Cancer Institute presents on using a gene expression-driven algorithm to prioritize competing treatment options for BRCA carriers with breast cancer.

Permanent link to this article: https://inheritedcancer.net/video81023/

ICARE Social Media Post August 2023

Fertility Treatment in BRCA Carriers: Breast Cancer Risk

A study found that fertility treatment did not significantly raise the risk of breast cancer, which is reassuring. However, further research is required with regard to: Use the link in bio to learn more! Reference: Liu et al. Front Endocrinol (Lausanne). 2022;13:986477. PMID: 36176466.

Permanent link to this article: https://inheritedcancer.net/post81123/

ICARE Social Media Post August 2023

New Article – Cancer Risk Management

A recent study, which 𝗶𝗻𝗰𝗹𝘂𝗱𝗲𝗱 𝗜𝗖𝗔𝗥𝗘 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀, found that getting care according to guidelines depends on: Therefore, we need ways to improve knowledge among healthcare providers and trust in care among patients! Use this link to learn more: https://tinyurl.com/n26m4zys Reference: Dean, et al. Genet Med. 2023;100945. PMID: 37515473.

Permanent link to this article: https://inheritedcancer.net/post80723/

ICARE Social Media Post July 2023

ACMG Clinical Practice Resource on CHEK2

Check out the newly released ACMG Clinical Practice Resource on CHEK2 developed through a group of worldwide experts! 👇https://tinyurl.com/bp8esxsf Read the ACMG press release at 👇https://tinyurl.com/yvammhzt

Permanent link to this article: https://inheritedcancer.net/post72623/

ICARE Social Media Post July 2023

Inherited Cancer Genes in Children: BRCA1/2, PALB2, ATM, CHEK2 , Lynch Genes

Recent study findings suggest that BRCA1/2, PALB2, ATM, CHEK2, and the Lynch Syndrome genes might confer reduced penetrance cancer risk among children. However, there are no adjustments to management or testing recommendations based on the level of risk (i.e., normally do not test children for conditions that primarily increase the risk of cancer in adulthood). …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72123/

ICARE Social Media Post July 2023

BRCA1/2 carriers: Risks with Oral Contraceptives Use

Among female BRCA1 and BRCA2 carriers, a recent study found that oral contraceptive use is associated with an increased risk of breast cancer, but only among users who have been using them for more than five years, while ovarian cancer risk was nearly cut in half. Use the link in bio to learn more! Reference: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post70623/

ICARE Social Media Post July 2023

CDKN2A Mutations: Pancreatic Cancer Screening over 20 years of follow up

A study among CDKN2A carriers assessing the yield and outcomes of 20 years of pancreatic cancer screening found: These results highlight the potential importance of pancreatic cancer screening among CDKN2A carriers. Currently, NCCN guidelines recommend annual pancreatic cancer screening starting at age 40, regardless of family history. Use the link in bio to learn more! …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post70223/

ICARE Social Media Post June 2023

Breast Cancer Risk Model: Predicting Risk over 10-year period

A new study found that mammographic features (density, microcalcifications, masses, and left-right breast asymmetries) predicted risks better than traditional lifestyle/familial risk-based risk models over a 10-year period. ⁠Use this link to learn more: https://bit.ly/443GDLd Reference: Eriksson et al. J Clin Oncol. 2023;JCO2201564. PMID: 36930854.

Permanent link to this article: https://inheritedcancer.net/post62823/

ICARE Social Media Post June 2023

Li-Fraumeni Syndrome/TP53 mutations

A recent study found that, regardless of a prior cancer diagnosis, there was no increased cancer worry after 1 year of full-body MRI surveillance in TP53 carriers. Further research is needed to evaluate these issues further. Use the link in bio to read the full article! Reference: Omran, et al. Cancer. 2023;129(6):946-955. PMID: 36601958.

Permanent link to this article: https://inheritedcancer.net/post62123/

ICARE Social Media Post June 2023

Should Black women be screened earlier?

A recent study found that Black women had the highest rate of breast cancer deaths in their 40s, compared to White women and women of other races and ethnicities. ⁠Use this link to learn more: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803948?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=041923 Reference: Chen T, et al. JAMA Netw Open. 2023;6(4):e238893. PMID: 37074714.

Permanent link to this article: https://inheritedcancer.net/post62023/

ICARE Social Media Post June 2023

FDA Advisory Committee Recommendation: Olaparib for Prostate Cancer Treatment

Olaparib plus abiraterone acetate is recommended as the first line treatment for metastatic castration-resistant prostate cancer, but only in patients whose tumors have BRCA mutations. Although a broad indication for the combination therapy was desired, concerns about the trial design were raised, and the phase III results did not explicitly show that patients without a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post61623/

ICARE Social Media Post June 2023

Lynch Syndrome: Screening for Sebaceous Carcinomas

Permanent link to this article: https://inheritedcancer.net/post62223/

ICARE Featured Video June 2023

CHIP/Variant Interpretation in Li-Fraumeni Syndrome

Below you may watch a featured video from the June 2023 Genetics Case Conference, which focused on CHIP and variant interpretation in Li-Fraumeni Syndrome with guest expert Bita Nehoray, MS, CGC from the City of Hope.

Permanent link to this article: https://inheritedcancer.net/video60823/

ICARE Social Media Post June 2023

Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Colorectal Version 1.2023

The National Comprehensive Cancer Network (NCCN) just released updated colorectal cancer guidelines which includes: You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf

Permanent link to this article: https://inheritedcancer.net/post60823/

ICARE Social Media Post June 2023

Inherited Gene Mutation in Those with Multiple Primary Cancers

Among patients with multiple primary cancers, the proportion with inherited cancer gene mutations increased with the number of primary cancers:• 2 cancers: 13.1%• 3 cancers: 15.9%• 4+ cancers: 18.0% Many of the double primaries, such as those of the breast, ovary, colorectum, and endometrium, occurred in women who would already be eligible for genetic testing. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60723/

ICARE Social Media Post June 2023

June 4th: National Cancer Survivor’s Day

Today is National Cancer Survivors Day! Learn how you can support cancer survivors by visiting the American Association for Cancer Research (AACR) website 👇https://www.aacr.org/patients-caregivers/awareness-months/national-cancer-survivor-month/

Permanent link to this article: https://inheritedcancer.net/post60523-2/

ICARE Social Media Post June 2023

VUS Results: Rates of Reclassification in Inherited Cancer Genes

In a multicenter study evaluating reclassifications of variant of uncertain significance (VUS) results in breast, ovarian, and colorectal cancer susceptibility genes, it was discovered that of 3261 VUS results, 8.1% were reclassified. Of all the reclassified VUS results, 11.3% resulted in clinically actionable findings, and 4.6% led to changes in clinical management. The reclassification rates …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60523/

ICARE Social Media Post May 2023

Cancer Care: Transgender and Gender-Diverse Persons

Did you know that transgender and gender-diverse persons face unique challenges that can influence cancer risk and outcomes? For instance, these individuals face barriers to healthcare access and inequities in treatment, with healthcare providers lacking knowledge about the health needs of this population. Solutions are needed to offer the best care for these individuals. Use …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post52223/

ICARE Social Media Post May 2023

Women’s Health Week

In honor of National Women’s Health Week from May 14th to May 20th, we would like to encourage you to speak with your healthcare provider to make sure you are up-to-date on your cancer screenings, such as mammograms and colonoscopies, to help prevent cancer or find it early when it is easier to treat. Spread …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51523/

ICARE Social Media Post May 2023

ATM breast cancer risks: High Risk c.7271T>G mutation

According to a recent study, while there was a reported 2-fold risk for breast cancer overall among ATM carriers, those with the c.7271T>G mutation had the highest risk. Use the link to learn more: https://bit.ly/40bKovj Reference: Hall et al. Cancer Prev Res (Phila). 2021;14(4):433-440. PMID: 33509806.

Permanent link to this article: https://inheritedcancer.net/post51123/

ICARE Featured Video May 2023

Benign Tumor Predisposition/DGCR8 and Other Related Syndromes

Below you may watch a featured video from the May 2023 Genetics Case Conference, which focused on benign tumor predisposition/DGCR8 and other related syndromes with guest expert Barbara Rivera Polo, PhD from Bellvitge Biomedical Research Institute.

Permanent link to this article: https://inheritedcancer.net/video51123/

ICARE Social Media Post May 2023

USPSTF New Recommendation: Mammograms Start at Age 40

Yesterday the United States Preventive Services Task Force (USPSTF) published a new draft recommendation for all cisgender women and those assigned female sex at birth to do mammograms from ages 40 to 74, every two years. This change in recommendation is due to recent troubling trends, including an increase in the number of cancers diagnosed …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51023/

ICARE Social Media Post May 2023

Lynch Syndrome: Skin Neoplasms

According to a recent study among individuals with Lynch Syndrome: Use the link in bio to learn more! Reference: Zhong et al. J Am Acad Dermatol. 2023;S0190-9622(23)00173-1. PMID: 36773823.

Permanent link to this article: https://inheritedcancer.net/post50623/

ICARE Social Media Post May 2023

PARP Inhibitors for Metastatic Prostate Cancer: Talazoparib

A study that compared a PARP inhibitor (talazoparib) to the standard of care (an androgen receptor inhibitor) in metastatic castration-resistant prostate cancer found that it improved progression-free survival regardless of BRCA mutation status. However, the benefit was greatest in males with a BRCA or other DNA repair gene mutation. Read the full article at this …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post50823/

ICARE Social Media Post April 2023

Cancer Risks in Older Females with a BRCA Mutation

A recent study among over 2200 females (aged 50-75) with BRCA mutations, including ICARE participants, found 379 diagnosed cancers with breast and ovarian cancer being the most common cancers observed. Overall cancer risks were 49% in BRCA1 carriers and 43% in BRCA2 carriers, and cancer risks dropped to 9% among those who had preventative removal …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42823/


ICARE Social Media Post April 2023

Prostate Cancer in Black Men: New Genetic Variants to Explain Higher Risks

Researchers identified 9 new genetic variants that may increase the risk of developing prostate cancer. This study highlights the importance of studying diverse populations. Read the full article at this link: https://www.sciencedirect.com/science/article/abs/pii/S0302283823025617 ⁠Reference:Chen et al. Eur Urol. 2023;S0302-2838(23)02561-7. PMID: 36872133.

Permanent link to this article: https://inheritedcancer.net/post42223/


ICARE Social Media Post April 2023

New study for BRCA1, BRCA2 , or PALB2 carriers with stage 1-3 breast cancer

An open study for BRCA1, BRCA2, or PALB2 carriers with stage 1-3 breast cancer is currently recruiting! Learn more about the study by visiting https://vanderbilt.trialstoday.org/trial/NCT04584255

Permanent link to this article: https://inheritedcancer.net/post42123/


ICARE Social Media Post April 2023

PARP Inhibitors for Metastatic Prostate Cancer: Niraparib

A study that evaluated a PARP inhibitor (niraparib) in males with metastatic prostate cancer found that those with a BRCA1 or BRCA2 mutation lived longer on average than those who did not have a BRCA mutation. Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35131040/⁠Reference:Smith et al. Lancet Oncol. 2022;23(3):362-373. PMID: 35131040.

Permanent link to this article: https://inheritedcancer.net/post42023/

ICARE Featured Video April 2023

Tumor Testing & Germline Significance

Below you may watch a featured video from the April 2023 Genetics Case Conference, which focused on tumor testing and germline significance with guest expert Ben Ho Park, MD, PhD from Vanderbilt University Medical Center.

Permanent link to this article: https://inheritedcancer.net/video41323/

ICARE Social Media Post April 2023

Applying the Framework for Interventions to Increase Family Communication

A new study 𝗯𝘆 𝗼𝘂𝗿 𝘁𝗲𝗮𝗺 used the Framework for Developing and Evaluating Complex Interventions (FDECI) to evaluate an intervention to improve family communication of positive genetic test results for inherited cancer. The first FDECI phases were beneficial for improving the intervention and planning for continual effectiveness and future implementation phases. Use the link in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post41023/

ICARE Newsletter Spring 2023

Community Spotlight

In 1997 when I was a junior in college, my mom called to let me know that my father had been diagnosed with prostate cancer. Luckily for him, Prostate Specific Antigen (PSA) testing had recently started which resulted in early detection and subsequent prostatectomy. Due to his diagnosis and knowing prostate cancer is an inherited …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023span-stylecolor-56b0e4community-spotlight/

ICARE Newsletter Spring 2023

Ask the Expert

The below question was addressed by Ben Ho Park, MD, PhD, who is the Director of the Vanderbilt-Ingram Cancer Center and a Professor of Medicine in the Division of Hematology and Oncology. If you have a question you would like addressed, please email the ICARE team at ICARE@vumc.org for consideration in future newsletters. Q: As …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023ask-the-expert/

ICARE Newsletter Spring 2023

Prostate Cancer Treatment Updates

A study to test niraparib (a PARP inhibitor) in males with metastatic prostate cancer showed that those with an inherited BRCA1 or BRCA2 (BRCA) mutation lived longer on average compared to those without a BRCA mutation. Side effects from niraparib were similar to those previously reported with PARP inhibitors.1 Another PARP inhibitor trial tested an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023prostate-cancer-treatment-updates/

ICARE Newsletter Spring 2023
Breast Cancer Treatment Updates

Findings from a Phase II study to evaluate the use of talazoparib (a PARP inhibitor) in individuals with advanced PALB2-mutation breast cancer showed that it appeared effective in certain patients and appeared safe (with similar adverse events as those previously reported with this drug).1 There are several Phase II trials to evaluate PARP inhibitors in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-breast-cancer-treatment-updates/

ICARE Newsletter Spring 2023
Breast Cancer Screening in Male BRCA1/2 Carriers

Generally, males with breast cancer present with advanced stage disease, thought to be due to a lack of screening. While data to determine performance of breast screening through mammograms for males at inherited risk is limited, recent studies suggest that the detection rate is similar or better than for females at general population risk.1,2,3 In …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-breast-cancer-screening-in-male-brca1-2-carriers/

ICARE Newsletter Spring 2023
Lynch Syndrome: Colorectal Cancer Risks Revisited

While there are higher cancer risks in BRCA mutation carriers starting in the mid-20s, a recent study focused on studying cancer risks in older females aged 50-75. Of the over 2000 females in the study, which included ICARE participants, 379 cancers were found between age 50 to 75 with risks of 49% in BRCA1 carriers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-lynch-syndrome-colorectal-cancer-risks-revisited/

ICARE Newsletter Spring 2023

Lynch Syndrome: Colorectal Cancer Risks Revisited

A study of 381 individuals with Lynch Syndrome in New Zealand (98 with Lynch Syndrome-associated variants in MLH1, 159 in MSH2, 103 in MSH6, and 21 in PMS2) found that risks for colorectal cancer were lower in MSH6 and PMS2 carriers, suggesting that it might be possible to spread out colonoscopy intervals for these individuals.1 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023/

ICARE Newsletter Spring 2023

Inherited Breast Cancer: Contralateral Breast Cancer Risks

While higher risks for contralateral breast cancer (CBC) have been known for BRCA1 and BRCA2, a newly published study demonstrated that the risk of CBC is also higher for female PALB2 and CHEK2 carriers; however, no elevated risks were found for ATM carriers (Table 1).1 This information is important to study, as it may be …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-inherited-breast-cancer-contralateral-breast-cancer-risks/

ICARE Newsletter Spring 2023

Melanoma Risk in Li-Fraumeni Syndrome

A recently published cohort study of 483 individuals with Li-Fraumeni Syndrome (LFS) identified 113 skin cancers. The cumulative incidence of a diagnosis of any skin cancer was 36.3% by the age of 70. Specifically for melanoma, the median age at diagnosis was 42 with a 7-fold increased incidence (SIR 7.28, 95% CI 4.50-11.13) compared with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-melanoma-risk-in-li-fraumeni-syndrome/

ICARE Newsletter Spring 2023

National Comprehensive Cancer Network (NCCN) Guidelines Updates

Check out the full NCCN guidelines by creating a FREE account at www.nccn.org Genetic/Familial High-Risk Assessment: Breast, Ovarian, PancreaticJanuary 10th, 2023 (Version 2.2023) focused on male BRCA carriers:› Consider annual mammograms (particularly in BRCA2 carriers) starting at age 50 or 10 years before the earliest male breast cancer in the family (whichever comes first)February 13th, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-national-comprehensive-cancer-network-nccn-guidelines-updates/

Other Cancer Genetics Webinar April 2023

Communicating about Inherited Cancer Risk, Uncertainty, and Decision Making

Below you may watch an exciting presentation about communicating about inherited cancer risk, uncertainty, and decision making by Marleah Dean Kruzel, PhD from the University of South Florida.

Permanent link to this article: https://inheritedcancer.net/video40423/

ICARE Social Media Post March 2023

Treatment for PALB2-associated breast cancer with Talazoparib

According to a recent Phase II study, Talazoparib may benefit patients with PALB2-associated breast cancer. Findings showed that Talazoparib appeared effective and safe in certain patients with advanced disease. Read the full article at this link: https://www.nature.com/articles/s43018-022-00439-1 Reference: Gruber et al. Nat Cancer. 2022;3(10):1181-1191. PMID: 36253484.

Permanent link to this article: https://inheritedcancer.net/post32723/

ICARE Social Media Post March 2023

New Model: To identify those at high risk for Endometrial (Uterine) Cancer

Did you know endometrial cancer is the 4th most common cancer among females? Currently, clinical practice guidelines do not recommend endometrial cancer screening in the general population. A new risk prediction model was recently developed to identify those at high risk for endometrial (uterine) cancer to determine who could benefit from cancer screenings and risk-reducing …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32623/

ICARE Social Media Post March 2023

Inherited Cancer Testing: Pheochromocytoma & Paraganglioma

Because of the high frequency of mutations found in individuals with pheochromocytoma and paraganglioma, these individuals are advised to consider genetic testing for inherited cancer.Use this link to learn more: ⁠https://pubmed.ncbi.nlm.nih.gov/35976622/ Reference: Yip, et al. JAMA Surg. 2022;157 (10):870-877. PMID: 35976622

Permanent link to this article: https://inheritedcancer.net/post32223/

ICARE Social Media Post March 2023

Metachronous Colorectal Cancer in Lynch Syndrome

Findings from a recent study: Risk factors for metachronous colorectal cancer included a history of colorectal polyps and having an MLH1 or MSH2 mutation, while protective factors included female sex and extended surgical resection. This highlights the importance of genetic testing and counseling for Lynch syndrome prior to surgery, which can influence surgical strategy and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31923/

ICARE Social Media Post March 2023

Colorectal Cancer Risks: Lynch Syndrome

A study on colorectal cancer risks in Lynch Syndrome patients found that:• Colorectal cancer risks were lower in MSH6 and PMS2 carriers• Colonoscopy intervals for these individuals could be longer• Incomplete polyp removal may be responsible for 1/3 of surveillance-detected colorectal cancers Read the full article with the link in bio! Reference: Lamba, et al. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31323/

ICARE Social Media Post March 2023

New gene alert: MBD4

A new study shows germline MBD4 mutations cause an autosomal recessive tumor predisposing syndrome associated with: This highlights the importance of including MBD4 in genetic testing for polyposis and multi-tumor phenotypes to improve disease management. Use the link in bio to learn more! Reference: Palles, et al. Am J Hum Genet. 2022;109(5):953-960. PMID: 35460607.

Permanent link to this article: https://inheritedcancer.net/post31223/

ICARE Featured Video March 2023

IMPULSS: A Service Delivery Model for Lynch Carriers

Below you may watch a featured video from the March 2023 Genetics Case Conference, which focused on IMPULSS, a service delivery model for Lynch Syndrome carriers, with guest expert Deborah Cragun, PhD, MS, CGC from the University of South Florida.

Permanent link to this article: https://inheritedcancer.net/video30923/

ICARE Social Media Post March 2023

BGREAT December 2022 Newsletter

Check out the latest edition of our B-GREAT newsletter for updates about inherited cancers in the context of racial inequalities in healthcare. You can read the newsletter by visiting 👇https://bgreatinitiative.inheritedcancer.net/wp-content/uploads/BGREAT-December-2022-Newsletter.pdf Please feel free to share with family members, friends, and/or your healthcare providers.

Permanent link to this article: https://inheritedcancer.net/post30623/

ICARE Social Media Post March 2023

Melanoma in TP53 /Li-Fraumeni Syndrome

A new study found a 7-fold increased incidence of melanoma in individuals with TP53/Li-Fraumeni Syndrome compared with the general population:• Average age was 42• Risk to age 40 was 2.8%• Risk to age 60 was 7.8%• Risk to age 70 was 14.9% Learn more at the link below!https://pubmed.ncbi.nlm.nih.gov/35183552/ Reference: Hatton, et al. J Invest Dermatol. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post30723/

ICARE Social Media Post February 2023

Why is learning about inherited cancer important to guide care?

Why have genetic testing? Genetic testing for inherited cancer can help guide care, including:• Cancer treatment plans, such as chemotherapy, drugs, surgery, and radiation• Cancer screening and prevention Sharing genetic test results can also help family members understand their cancer risks.⁠

Permanent link to this article: https://inheritedcancer.net/post22423/

ICARE Featured Video February 2023

CanRisk: Personalizing Cancer Risk Prediction

Below you may watch a featured video from the February 2023 Genetics Case Conference, which focused on CanRisk, a tool to estimate future breast and ovarian cancer risks, with guest expert Antonis Antoniou, PhD from the University of Cambridge.

Permanent link to this article: https://inheritedcancer.net/video21023/

ICARE Social Media Post February 2023

ATM Gene and Breast Cancer Risk for: c.7570G>C Mutation

While ATM mutations are generally associated with a 25-30% lifetime risk for breast cancer, emerging information suggests that the risk in those with a c.7570G>C mutation may be higher. Once confirmed, this information may be important to guide cancer screening and risk-reducing surgery decisions. Use this link to learn more: https://onlinelibrary.wiley.com/doi/10.1002/ijc.34305

Permanent link to this article: https://inheritedcancer.net/post40623/

ICARE Newsletter Spring 2022 

 Reducing Hereditary Cancer Act of 2021 

On February 16th, 2022, the Reducing Hereditary Cancer Act (S.3656) was introduced to the U.S. Senate with the goal of ensuring Medicare beneficiaries have coverage for potentially life-saving inherited cancer genetic counseling and testing as well as recommended screening and risk-reducing procedures, when medically necessary and appropriate. Currently, Medicare only covers genetic testing for beneficiaries …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-reducing-hereditary-cancer-act-of-2021/

ICARE Newsletter Spring 2022 

 Community Spotlight 

Genetic testing sounded like a futuristic concept when it originally came to our attention. It sounded something to the likes of cloning. We didn’t really understand what it was and why it was important, but rather thought it sounded like something out of science fiction. Thankfully, our medical providers and genetic counselors stuck with us …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-community-spotlight/

ICARE Newsletter Spring 2022 

 Ask the Expert 

The below question was addressed by ICARE Founder, Dr. Tuya Pal, and her oncology colleague, Dr. Sonya Reid. Dr. Pal is a Professor of Genetic Medicine, Ingram Professor of Cancer Research, and the Associate Director for Cancer Health Disparities at VanderbiltIngram Cancer Center. Dr. Reid is an Assistant Professor of Hematology/Oncology at Vanderbilt University Medical …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-ask-the-expert/

ICARE Newsletter Spring 2022 

 Inherited Cancer Treatment Updates

Lynch Syndrome Carriers with Advanced Uterine Cancer: Treatment with PembrolizumabWomen with Lynch Syndrome are at high risk for uterine cancer. The type of uterine cancer they develop has the tumorcharacteristic of being ‘MSI-H’. A new study indicated treatment with pembrolizumab (Keytruda) resulted in benefit inpatients with MSI-H advanced uterine cancer. Von Hippel-Lindau Patients: Treatment of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-inherited-cancer-treatment-updates/

ICARE Newsletter Spring 2022 

  BRCA1/2 Oral Contraceptives and Breast Cancer

A new study found that among BRCA1/2 carriers, oral contraceptive use strongly lowered cancer risk over one’s lifetime, even though at first, they raise risks of breast, ovarian, and endometrial cancer.Schrijver et al. J Natl Cancer Inst. 2022 Jan. PMID: 35048954. Social media post February 15th, 2022. Available at:https://tinyurl.com/post21522.

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-brca1-2-oral-contraceptives-and-breast-cancer/

ICARE Newsletter Spring 2022 

  BRCA1/2 and Male Cancer Risks 

A recent international study found that male BRCA1 and BRCA2 carriers have a higher risk for breast, pancreatic, and stomach cancer. Additionally, male BRCA2 carriers were found to have higher risks for prostate cancer. See the below table for the specific risk levels: Li et al. J Clin Oncol. 2022 Jan. PMID: 35077220. Social media …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-brca1-2-and-male-cancer-risks/

ICARE Newsletter Spring 2022 

 Lynch Syndrome and Prostate Cancer  

A new study suggests men with certain MSH2 and MSH6 mutations have higher risks of prostate cancer and may be candidates for PSA screening. Bancroft et al. Lancet Oncol. 2021 Nov. PMID: 34678156. Social media postDecember 17th, 2021. Available at: https://tinyurl.com/post121721

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-lynch-syndrome-and-prostate-cancer/

ICARE Newsletter Spring 2022 

 Polygenic Risk Scores and Inherited Breast Cancer Genes: BRCA1/2, PALB2, CHEK2, and ATM  

Breast MRIs are advised in women with >20% lifetime risk of breast cancer. A new study showed that breast cancer risks in BRCA1, BRCA2 and PALB2 carriers remained higher than 20%, regardless of whether polygenic risk scores (PRS) were done, suggesting this is of limited help in refining screening. In contrast, PRS downgraded breast cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-polygenic-risk-scores-and-inherited-breast-cancer-genes-brca1-2-palb2-chek2-and-atm/

ICARE Newsletter Spring 2022 

 Li-Fraumeni Syndrome and Cancer Risks 

A new study reported on differences in the TP53 mutations between patients who met vs those who did not meet Li-Fraumeni Syndrome (LFS) testing criteria. Several variants were identified multiple times in those who did and did not meet LFS clinical criteria: p.R175, p.G245, p.R248, p.R273, and p.R282. Other variants were exclusively found in those …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-li-fraumeni-syndrome-and-cancer-risks/

ICARE Newsletter Spring 2022 

 CDH1 and Stomach Cancer 

A recent study of women with hereditary lobular breast cancer due to CDH1 mutations found high rates ofundetected stomach cancer (with signet ring features). The findings suggested that among CDH1 carriers, there werevery high risks for stomach cancer, even when family history of stomach cancer was absent.Gamble et al. JAMA Surg. 2021 Oct. PMID: 34643667. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-cdh1-and-stomach-cancer/

ICARE Newsletter Spring 2022 

  ATM and Pancreatic Cancer

A new article reported that pancreatic cancer risks are morethan 6-fold higher in individuals with an ATM mutation.Pancreatic cancer risks by age were:› 1.1% by age 50› 6.3% by age 70› 9.5% by age 80Hsu, et al. JAMA Oncol. 2021 Sep. PMID: 34529012. Social media post October 1st, 2021. Available at: https://tinyurl.com/post100121.

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-atm-and-pancreatic-cancer/

ICARE Newsletter Fall 2022 

 Community Spotlight 

When I was just 8 years old my mother was diagnosed with a very aggressive breast cancer. I didn’t reallyunderstand the concept of cancer at that age, but I knew what was happening was terrible. After manysurgeries and treatments, she passed away 2 years later at the age of 35. There was no hereditary cancertesting …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-community-spotlight/

ICARE Newsletter Fall 2022 

 Ask the Expert 

The below question was addressed by Dr. Kamran Idrees, Chief of the Division of Surgical Oncology & Endocrine Surgery, Associate Professor of Surgery, Ingram Associate Professor of Cancer Research, and Director of Pancreatic and Gastro Intestinal Surgical Oncology at Vanderbilt-Ingram Cancer Center. Dr. Idrees’ research has focused on colorectal cancer, liver metastases, and pancreatic cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-ask-the-expert/

ICARE Newsletter Fall 2022 

 ATM -associated Cancer Risks 

Female ATM carriers have approximately a 2-fold risk, on average, for developing breast cancer, which was confirmed through two large studies that reported risks (odds ratio) as 2.10 (95% CI, 1.71–2.57)1 and 1.82 (95% CI, 1.46–2.27). Both studies reported an association with ER+ tumors. Another recent study estimated breast cancer risks to be 13% by …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-atm-associated-cancer-risks/

ICARE Newsletter Fall 2022 

 Screening & Treatment Updates: New Modeling Analysis About Breast Cancer Screening in ATM and CHEK2 Carriers 

Using information from twelve prior population-based studies, a modeling analysis was done to look at when to start mammography and breast MRI in females with inherited mutations in genes including ATM and CHEK2. Overall, findings showed that starting annual MRI screening between age 30 to 35 and mammography at age 40 may lower death from …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-screening-treatment-updates-new-modeling-analysis-about-breast-cancer-screening-in-atm-and-chek2-carriers/

ICARE Newsletter Fall 2022 

 Screening & Treatment Updates: Pancreatic Cancer 

A recent small study suggests that immunotherapy may benefit patients with refractory pancreatic or biliary cancer who have inherited a mutation in the homologous recombination deficiency (HRD) genes, BRCA1, BRCA2, and RAD51C.Another new study reported that in BRCA1/2 carriers with pancreatic cancer, maintenance treatment with Olaparib may be of benefit. Findings showed that with Olaparib, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-screening-treatment-updates-pancreatic-cancer/

ICARE Newsletter Fall 2022 

 Which Genes Are Confirmed as ‘Inherited Breast Cancer Genes’? 

There were two large studies published early last year that evaluated which genes raise risks for breast cancer, including breast cancer patients from many centers worldwide, representing the largest available datasets to look at this question. These efforts were led by the worldwide Breast Cancer Association Consortium (BCAC)1 and the United States-based CARRIERS consortium. The …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-which-genes-are-confirmed-as-inherited-breast-cancer-genes/

ICARE Newsletter Fall 2022 

 Inherited Cancer Genes: New Associations 

A new study led by colleagues at Vanderbilt University Medical Center, including our clinical geneticist colleague, Dr. Georgia Wiesner, evaluated 23 hereditary cancer genes and found 19 new gene associations including 7 new associations with cancer and 12 new associations with noncancer diseases. The associations with cancer versus other conditions is included in the table. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-inherited-cancer-genes-new-associations/

ICARE Newsletter Fall 2022 

  BRCA1/2 Cancer Risk Updates

During preventive surgery to remove the ovaries and fallopian tubes (called a risk-reducing salpingo-oophorectomy orRRSO), a new study found that the detection of tubal intraepithelial carcinoma predicts the risk of later peritonealcancer.1 These findings show the importance of timely RRSO and the need to do a careful pathology exam of the ovaries and fallopian tubes …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-brca1-2-cancer-risk-updates/

ICARE Newsletter Fall 2022 

National Comprehensive Cancer Network (NCCN) Guidelines Updates 

Check out the full NCCN guidelines by creating a FREE account at www.nccn.org Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic – Released September 7th, 2022› Testing eligibility based on personal history of any type of breast cancer in females was updated from age ≤45 to ≤50 making more females with breast cancer eligible for testing …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-national-comprehensive-cancer-network-nccn-guidelines-updates/

ICARE Newsletter Fall 2021 

Resource Spotlight: National Cancer Institute’s Cancer Genetics PDQ 

 

Looking for a place to get the latest curated information about inherited cancers? Look no further… Provide evidence-basedsummaries about inheritedcancer genetics for healthprofessionals and patients Summaries updated basedon monthly review ofpublished literature Written and maintained by amultidisciplinary Editorial Board ofexperts in medical genetics, oncology,and related specialties Visit https://tinyurl.com/NCIPDQ and https://www.cancer.gov/publications/pdq/editorial-boards/genetics for more information

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-resource-spotlight-national-cancer-institutes-cancer-genetics-pdq/

ICARE Newsletter Fall 2021 

Direct-to-Consumer Tests: Not Reliable to Detect BRCA1/2 Mutations 

Researchers reported that single nucleotide polymorphism (SNP) tests, which are used by DTC tests such as 23andMe, are not reliable in identifying the majority of BRCA1/2 mutations or other inherited cancer gene mutations. The SNP test used by many DTC ancestry and DNA companies is designed to detect common traits many people share. However, when …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-direct-to-consumer-tests-not-reliable-to-detect-brca1-2-mutations/

ICARE Newsletter Fall 2021 

Reducing Hereditary Cancer Act of 2021  

Under current Medicare guidelines, only those with “signs, symptoms, complaints, or personal histories of disease” meet the criteria for medical services coverage. Thus, genetic testing is only covered for those already diagnosed with cancer, regardless of family history. If someone without cancer has an inherited mutation that increases cancer risk (e.g., BRCA1/2), Medicare may not …

Continue reading

Permanent link to this article: https://inheritedcancer.net/div-classboxedspan-stylecolor-whiteh6icare-newsletter-fall-2021-h6-span-divbrcenterh4span-stylecolor-56b0e4-reducing-heredit/

ICARE Newsletter Fall 2021 

Community Spotlight

At the age of 51, my first and only colonoscopy revealed 100 polyps in my colon, rectum, and anuseven though I had no symptoms or family history. I was immediately referred to a Certified GeneticCounselor at Tripler Army Medical Center in Hawai’i. Germline DNA testing revealed I had attenuatedfamilial adenomatous polyposis (AFAP), due to an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-community-spotlight/

ICARE Newsletter Fall 2021 

Ask the Expert 

 

In each newsletter, we give participants the opportunity to have their questions addressed by experts in thefield. This question was addressed by Kerry Schaffer, MD, medical oncologist at Vanderbilt University MedicalCenter with a focus on urological cancers. Q. Is there enough information to consider using PARP inhibitors to treat inherited forms ofprostate cancer? A. Over …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-ask-the-expert/

ICARE Newsletter Fall 2021 
>

Polygenic Risk Scores and Breast Cancer Risks: BRCA1/2, PALB2, CHEK2, ATM , and beyond!

A recent study found use of a polygenic risk score (PRS) modified the estimated riskof breast cancer among both carriers and non-carriers of inherited breast cancerpredisposition genes. Taking PRS into account, more than 95% of BRCA1, BRCA2,and PALB2 carriers had greater than 20% lifetime risks of breast cancer. In contrast,among ATM and CHEK2 carriers without …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-polygenic-risk-scores-and-breast-cancer-risks-brca1-2-palb2-chek2-atm-and-beyond/

ICARE Social Media Post February 2023

Risk for second breast cancer in premenopausal female BRCA1, BRCA2, PALB2 and CHEK2 carriers

Did you know female BRCA1, BRCA2, CHEK2, or PALB2 carriers have much higher risks for contralateral breast cancer?This information is important to guide cancer screening and risk reduction strategies. Use the link in bio to learn more!

Permanent link to this article: https://inheritedcancer.net/post40123/

Newsletter Fall 2021

Inherited Cancer Treatment Updates

Early-stage, high-risk breast cancer in BRCA carriers: Results of the highly awaited phase 3 OlympiA trial showed promising results for EARLY STAGE (i.e., localized Stage 2-3) high-risk breast cancer patients with a BRCA mutation who were treated with a PARP inhibitor (olaparib) in the adjuvant setting (i.e., AFTER surgery).1 Early-stage breast cancer in this trial …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-inherited-cancer-treatment-updates/

Newsletter Fall 2021

Modifying Risks in BRCA Carriers

Breast cancer risks: A risk-reducing salpingo-oophorectomy (i.e., removal of both ovaries and fallopian tubes) in BRCA carriers was associated with a reduced risk of breast cancer within five years after surgery, with evidence of longer-term risk reduction among those with BRCA1 variants.1 Ovarian cancer risks: A new study reported that the use of oral contraceptives …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-modifying-risks-in-brca-carriers/

Newsletter Fall 2021

Breast Cancer Risks Remain High in PALB2 & BRCA

A new study found that lifetime breast cancer risk is 15% or more in female BRCA1, BRCA2, and PALB2 carriers over age 65. This level of risk warrants consideration for continuing breast MRI.1 These results are similar to those of a study that included ICARE participants,2 which reported the risk of developing breast cancer remains …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-breast-cancer-risks-remain-high-in-palb2-brca/

Newsletter Fall 2021

Prostate Cancer and PALB2

A new Polish study based on two specific founder mutations in PALB2 reported that mutations in this gene may predispose to an aggressive, lethal form of prostate cancer.1 The investigators studied PALB2 prostate cancer risks, characteristics, and outcomes in almost 5,500 men with prostate cancer and compared them to over 8,000 cancer-free adults from Poland. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-prostate-cancer-and-palb2/

Newsletter Fall 2021

PALB2 : Increasingly Recognized as the Third Most Important Inherited Breast Cancer Gene

In May 2021, a clinical practice resource was released by the American College of Medical Genetics and Genomics (ACMG) from a global team of cancer genetics specialists (see figure) to help guide the care of PALB2 carriers.1 PALB2 is considered the third most important breast cancer risk gene, after BRCA1 and BRCA2, with PALB2 carriers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/div-classboxedspan-stylecolor-whiteh6newsletter-fall-2021-h6-span-divbrcenterh4span-stylecolor-56b0e4-ipalb2-i-increas/

Newsletter Fall 2021

Updates to NCCN Genetic/Familial High-Risk Assessment

Breast, Ovarian, and Pancreatic Guidelines V.1.2022: Released August 11th, 2021 Colorectal Cancer Guidelines V.1.2021: Released May 11th, 2021 Check out the full NCCN guidelines by creating a FREE account at www.nccn.org

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-updates-to-nccn-genetic-familial-high-risk-assessment/

ICARE Social Media Post January 2023

Inherited Breast Cancers Across Populations

Did you know that BRCA1/2 are amongst the most well-studied genes, yet most BRCA1/2 studies have been done in White populations? This means our knowledge about genes and risks comes primarily from White populations. • Some research suggests that BRCA1/2 gene mutations may be more common in young Black women with breast cancer. • Even …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12423-2/

ICARE Social Media Post January 2023

Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

The National Comprehensive Cancer Network (NCCN) just released updated breast, ovarian, and pancreatic cancer guidelines which included updated breast cancer screening recommendations for male BRCA carriers (particularly male BRCA2 carriers). It is now recommended that male BRCA carriers consider annual mammograms starting at age 50 or 10 years before the earliest male breast cancer in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12423/

ICARE Social Media Post January 2023

New Contralateral Breast Cancer Risk Prediction Model for BRCA1/2 Carriers

A new risk prediction model was developed to assess the risk of contralateral breast cancer in BRCA1/2 carriers. Risks are higher with:• Younger age at first breast cancer• Close family member with breast and/or ovarian cancer• Mutation located near the 3′ region of the gene Risks are lower with:• Endocrine therapy Use this link in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11423/

ICARE Social Media Post January 2023

Why is diversity in genomics studies important?

Did you know that about 80% of genomics data comes from European populations, yet they only make up about 16% of the world population? This bias means Europeans stand to benefit the most, while important associations for other ancestry groups may be missed. Not including diverse populations in genomics research can further WIDEN disparities!

Permanent link to this article: https://inheritedcancer.net/post10823/

ICARE Social Media Post December 2022

Negative or Uninformative Test Results

A new study demonstrates the importance of retesting patients with previously uninformative cancer genetics evaluations, especially in high risk individuals. Read the full article at this link for more info: https://pubmed.ncbi.nlm.nih.gov/34545504/ 🔗⁠ Reference: Dettwyler et al. Fam Cancer. 2022; DOI: 10.1007/s10689-021-00276-8. PMID: 34545504

Permanent link to this article: https://inheritedcancer.net/post121322/

ICARE Social Media Post December 2022

Bilateral Mastectomy in BRCA1/2, PALB2, ATM, & CHEK2 Carriers

A recent study including data from ICARE participants found similar rates of bilateral mastectomy across high (BRCA1, BRCA2, PALB2) and moderate (ATM, CHEK2) penetrance genes. The high rates of bilateral mastectomies seen in those with moderate penetrance genes is concerning for overtreatment. Use the link to learn more: https://jamanetwork.com/journals/jamaoncology/fullarticle/2797978?guestAccessKey=fe9a3a20-8623-4feb-a0c5-315ad43a8fcb&utm_source=jps&utm_medium=email&utm_campaign=author_alert-jamanetwork&utm_content=author-author_engagement&utm_term=1m Reference: Reid et al. Receipt of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post120822/

ICARE Social Media Post December 2022

Cancer Screen Week

This week is Cancer Screen Week! This week we would like to highlight the importance of screening for inherited cancer to help prevent cancer and find it early. Talk to your healthcare provider today about what screenings are best for you.

Permanent link to this article: https://inheritedcancer.net/post120622/

ICARE Social Media Post November 2022

Cancer Risks: CHEK2

A newly published study reports that the type of CHEK2 mutation leads to different cancer risks. Read the full article at this link: https://jamanetwork.com/journals/jamaoncology/fullarticle/2796767 Reference: Bychkovsky BL, et al. JAMA Oncol. 2022 Sep 22;e224071. PMID: 36136322.

Permanent link to this article: https://inheritedcancer.net/post112122-2/

ICARE Social Media Post November 2022

Fall 2022 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Kamran Idrees, Chief of the Division of Surgical Oncology & Endocrine Surgery, Associate Professor of Surgery, Ingram Associate Professor of Cancer Research, and Director of Pancreatic and Gastro-Intestinal Surgical …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111122/

ICARE Featured Video November 2022

RAD51C Variants of Uncertain Significance

Below you may watch a featured video from the November 2022 Genetics Case Conference, which focused on RAD51C variants of uncertain significance with guest experts David Adams, PhD from the Wellcome Sanger Institute.

Permanent link to this article: https://inheritedcancer.net/video111022/

ICARE Social Media Post November 2022

Guidelines for Hereditary Breast Cancer Treatment

The Expert Panel Consensus, chaired by the Society of Surgical Oncology with the American Society of Clinical Oncology and the American Society of Radiation Oncology, published new recommendations for hereditary breast cancer treatment. Learn more at https://pubmed.ncbi.nlm.nih.gov/32898012/ Reference: Corso & Magnoni. Eur J Cancer Prev. 2021;30(4):311-314. PMID: 32898012.

Permanent link to this article: https://inheritedcancer.net/post110822/

ICARE Social Media Post November 2022

ICARE Fall 2022 Newsletter

The ICARE Fall 2022 Newsletter is now available! Check out this latest edition for recent research and clinical updates, a Q&A with Dr. Kamran Idrees from Vanderbilt-Ingram Cancer Center, and an inspiring community spotlight piece. You can read and download a copy of the newsletter at: https://inheritedcancer.net/newsletters/ Please feel free to share with family members, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110422/

ICARE Social Media Post October 2022

Tool for Inherited Cancer Predisposition Counseling and Testing Study (TIPS)

Have you already had genetic testing for inherited cancer and want to get more education and information about what your results mean for you? We provide free education about inherited cancer risk through our Tool for Inherited Cancer Predisposition Counseling and Testing Study (TIPS). Visit https://redcap.link/TIPS and complete our survey. Once completed, we provide:• an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102422/

ICARE Social Media Post October 2022

October 21 – National Mammography Day

National Mammography Day is observed annually on the third Friday of every October. Today acts as reminder to everyone that early detection is the best defense against breast cancer!

Permanent link to this article: https://inheritedcancer.net/post102122/

ICARE Social Media Post October 2022

October 13 Metastatic Breast Cancer Awareness Day

October 13th is Metastatic Breast Cancer Awareness Day. Today is a day to raise awareness about the importance of furthering cancer research.

Permanent link to this article: https://inheritedcancer.net/post101322/

ICARE Social Media Post October 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines single post 3

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In these new guidelines, genetic testing eligibility based on age at breast cancer diagnosis in females was updated from ≤ 45 to ≤ 50 making more females with breast cancer eligible for testing regardless of family history …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101022/

ICARE Social Media Post October 2022

CanRisk Tool

Have you heard of the CanRisk Tool?The CanRisk Tool provides health care professionals a user-friendly resource to carry out breast and ovarian cancer risk predictions. It is the first freely accessible cancer risk prediction program!Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/33335023/ Reference: Carver et al. Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):469-473. PMID: 33335023.

Permanent link to this article: https://inheritedcancer.net/post100722-2/

ICARE Featured Video October 2022

CanVar-UK Variant Interpretation Platform Updates

Below you may watch a featured video from the October 2022 Genetics Case Conference in which Clare Turnbull, MD, PhD discusses recent updates to the CanVar-UK Variant Interpretation Platform.

Permanent link to this article: https://inheritedcancer.net/video100622_2/

ICARE Featured Video October 2022

NCCN Genetic/Familial Guideline Updates (V1.2023 & V.1.2022)

Below you may watch a featured video from the October 2022 Genetics Case Conference in which ICARE Principal Investigator, Tuya Pal, MD, discusses recent updates to the National Comprehensive Cancer Network (NCCN) guidelines.

Permanent link to this article: https://inheritedcancer.net/video100622/

ICARE Social Media Post October 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 2

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In these new guidelines, the age to start breast MRI screening in female ATM and CHEK2 carriers was updated from age 40 to 30-35 making more females eligible for screening at an earlier age.Check out the new …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100222/

ICARE Social Media Post October 2022

Ovarian Cancer Risks: Weight Gain in BRCA1/2 Carriers

A study found that adult weight gain is a risk factor for ovarian cancer. This highlights the importance for BRCA1/2 carriers to maintain a healthy weight throughout adulthood.⁠Read the full article to learn more! ⁠https://pubmed.ncbi.nlm.nih.gov/34426412/⁠Reference: Kim et al. Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2038-2043. PMID: 34426412.

Permanent link to this article: https://inheritedcancer.net/post100122/

ICARE Social Media Post September 2022

Breast cancer risks: BRCA1/2 carriers with risk reducing salpingo-oophorectomy (RRSO)

Three recent studies found varying results when evaluating breast cancer risk in BRCA1/2 carriers with risk-reducing salpingo-oophorectomy (RRSO). Use these links to learn more: https://pubmed.ncbi.nlm.nih.gov/31948486/ https://pubmed.ncbi.nlm.nih.gov/33630024/ https://pubmed.ncbi.nlm.nih.gov/35216860/

Permanent link to this article: https://inheritedcancer.net/post92722/

ICARE Social Media Post September 2022

Hormonal Replacement Therapy (HRT) in BRCA1 and BRCA2 carriers

A recent study showed hormone replacement therapy (HRT) is reasonable to offer to BRCA1 and BRCA2 carriers who underwent risk-reducing salpingo-oophorectomy (RSSO). Read the full article at this link: https://pubmed.ncbi.nlm.nih.gov/32143914/Reference: Mills, et al. Gynecol Oncol; 2020 Jun;157(3):706-710. PMID: 32143914.

Permanent link to this article: https://inheritedcancer.net/post2922/

ICARE Social Media Post September 2022

Bilateral Oophorectomy: Breast Cancer Risks in BRCA1 Carriers

A recent study, including ICARE participants, found preventive removal of the ovaries does not reduce breast cancer risk in BRCA1 carriers. These findings highlight that study bias can influence results.Read the full article at this link: https://pubmed.ncbi.nlm.nih.gov/35477169/⁠Reference: Kotsopoulos et al. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1351-1358. PMID: 35477169.

Permanent link to this article: https://inheritedcancer.net/icare-social-media-post-september-2022-bilateral-oophorectomy-breast-cancer-risks-in-brca1-carriers/

ICARE Social Media Post September 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 1

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In this new version, a table was added at the end of the guidelines to summarize inherited cancer content across 𝗮𝗹𝗹 NCCN guidelines, including live links to the guidelines and sections referenced (see page 54 on the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post92222/

ICARE Social Media Post September 2022
/span>

Risk of Ovarian Cancer In BRCA1/2 Carriers: Oral Contraceptives and Implants

A new study suggests oral contraceptives and implants lower risk of ovarian cancer in BRCA1/2 carriers.Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35063280/Reference: Xia et al. Gynecol Oncol. 2022;164(3):514-521. doi:10.1016/j.ygyno.2022.01.014. PMID: 35063280.

Permanent link to this article: https://inheritedcancer.net/post92122/

ICARE Social Media Post September 2022

ATM: Breast Cancer Risks

A recent study found that even though ATM has been clearly identified as a breast cancer risk gene with an estimated risk of 13% up to age 80, variant-specific penetrance estimates are needed to guide risk management plans for those with pathogenic mutations.Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35365198/Reference: Renault et al. Breast Cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91922/

ICARE Social Media Post September 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines.Check out the new guidelines at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post91222/

ICARE Featured Video September 2022

TERT Mutations in Myeloid Malignancies

Below you may watch a featured video from the September 2022 Genetics Case Conference, which focused on TERT mutations in myeloid malignancies with guest experts Mary Armanios, MD from Johns Hopkins University School of Medicine.

Permanent link to this article: https://inheritedcancer.net/video90822/

ICARE Social Media Post September 2022

September ICARE Genetics Case Conference

We are excited to announce that our next ICARE genetics case conference, focused on TERT mutations in myeloid malignancies, will be broadly accessible. We are honored to have Mary Armanios, MD as our guest expert for this conference, in which she will provide a featured presentation and case commentary. We encourage you to join us …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post90822/

ICARE Social Media Post August 2022

Nipple sparing mastectomy: BRCA1/2 carriers

According to a recent study, a bilateral prophylactic nipple-sparing mastectomy appears to be at least equally as safe as other types of mastectomy for preventing breast cancer. Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/34342702/Reference: Stanek et al. Aesthetic Plast Surg. 2022 Apr;46(2):706-711. PMID: 34342702.

Permanent link to this article: https://inheritedcancer.net/post82922/

ICARE Social Media Post August 2022

ATM: Breast Cancer Risks

ATM variants are linked to an increased risk of breast cancer, with the ATM V2424G variant causing the highest risks and ATM D1853V, L546V, and S707P variants being the least predictive.Read the full article here: https://pubmed.ncbi.nlm.nih.gov/33402103/Reference: Moslemi, et al. BMC Cancer. 2021 Jan 5;21(1):27. PMID: 33402103.

Permanent link to this article: https://inheritedcancer.net/post81922/

ICARE Social Media Post August 2022

Ovarian Cancer Risks: Aspirin

A new report found that regular aspirin use was associated with a 13% reduction in ovarian cancer risk. Read the full article at the link: https://ascopubs.org/doi/abs/10.1200/JCO.21.01900Reference: Hurwitz et al. J Clin Oncol. 2022. PMID: 35867953.

Permanent link to this article: https://inheritedcancer.net/post81222/

ICARE Featured Video August 2022

Total Body MRI Screening Protocol in Li-Fraumeni Syndrome Patients

Below you may watch a featured video from the August 2022 Genetics Case Conference focused on total body MRI screening protocol in Li-Fraumeni Syndrome patients with guest expert Joanna Shechtel, MD.

Permanent link to this article: https://inheritedcancer.net/video81122/

ICARE Social Media Post August 2022

Pancreatic Cancer Treatment

 

A new study reports that maintenance treatment with Olaparib may benefit BRCA1/2 carriers with pancreatic cancer. These findings demonstrated:⁠long-term survival was more commontime to subsequent therapy was prolongedRead the full article at the link: https://ascopubs.org/doi/pdf/10.1200/JCO.21.01604⁠Reference: Kindler et al. J Clin Oncol. 2022; JCO2101604. PMID: 35834777.

Permanent link to this article: https://inheritedcancer.net/post80522/

ICARE Social Media Post July 2022

Pancreatic Cancer Screening

A recent study found that earlier diagnosis improved survival in people at high risk of pancreatic cancer.High risk was defined based on:family history and/orinherited gene mutation (BRCA1, BRCA2, CDKN2A, Lynch Syndrome genes, PALB2, ATM, and STK11)Read the article at the link: https://ascopost.com/news/june-2022/outcomes-of-pancreas-surveillance-in-the-caps5-study-and-total-caps-cohort/Reference: Dbouk, et al. J Clin Oncol. 2022 Jun 15:JCO2200298. doi: 10.1200/JCO.22.00298. PMID: 35704792.

Permanent link to this article: https://inheritedcancer.net/post72622/

ICARE Social Media Post June 2022

ATM: High and Moderate Risks for Multiple Cancers

A recent study found that pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with multiple cancers. Specifically, moderate-to-high risks for pancreatic, prostate, gastric, and invasive ductal breast cancers, and low-to-moderate risks for ductal carcinoma in situ, male breast cancer, ovarian cancer, colorectal cancer, and melanoma.This provides more data to guide risks and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post62122/

ICARE Social Media Post June 2022

Refractory Pancreatic or Biliary Cancer

A recent small study suggests that immunotherapy may be beneficial for patients with refractory pancreatic or biliary cancer who have inherited homologous recombination deficiency (HRD) genes, BRCA1, BRCA2, and RAD51C.Check out the full article to learn more at 👇https://jamanetwork.com/journals/jamaoncology/article-abstract/2791557Reference: Terrero et al. JAMA Oncol. 2022 Apr:e220611. doi:10.1001/jamaoncol.2022.0611. PMID: 35446342.

Permanent link to this article: https://inheritedcancer.net/post61322/

ICARE Social Media Post June 2022

Maternal Malignancies May Be Identified Through Noninvasive Prenatal Test Results

A new study found that results of noninvasive prenatal testing for fetal aneuploidy screening using cell-free DNA derived from maternal plasma raised suspicion of maternal malignancy in a small proportion of pregnant women. However, among those with suspicious findings, the risk of a confirmed malignancy was quite high.Check out the full article athttps://ascopubs.org/doi/full/10.1200/JCO.21.02260Reference: Heesterbeek et …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60822/

ICARE Featured Video June 2022

Updates on BRCA1 Variants of Uncertain Significance

Below you may watch a featured video from the June 2022 Genetics Case Conference focused on updates on BRCA1 variants of uncertain significance with guest expert Alvaro Monteiro, PhD.

Permanent link to this article: https://inheritedcancer.net/video60222/

ICARE Social Media Post June 2022

New Variants Linked to Hereditary Cancer

A new study evaluated 23 hereditary cancer genes and found 19 new gene associations, including 7 new associations with cancer and 12 new associations with non-neoplastic diseases. Specifically, the below genes were found to have an increased risk of disease:APC: benign liver/bile duct tumors, gastritis, and duodenitisATM: stomach cancer and pancreatic cancerBRCA1/2: ovarian cystsCHEK2: leukemia …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60122/

ICARE Social Media Post May 2022

BRCA Carriers with Risk-Reducing Salpingo-oophorectomy: Risk of Peritoneal Carcinomatosis

A new study found that among BRCA1/2 carriers, the presence of tubal intraepithelial carcinoma during risk-reducing salpingo-oophorectomy (i.e., preventive surgery to remove the ovaries and fallopian tubes) predicts the risk of later peritoneal cancer. These findings demonstrate:the importance of timely risk-reducing removal of the ovaries and fallopian tubesthat it is VERY important to have a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post52422/

ICARE Social Media Post May 2022

Breast Cancer Genes in Women of African Ancestry

A recent study in women of African ancestry confirmed genes previously identified to have associations with breast cancer risk (BRCA1, BRCA2, PALB2, ATM, TP53, NF1, and CHEK2) and provided new evidence of breast cancer risk for RAD51C and RAD51D, which was identified previously in European ancestry populations.Check out the full article at 👇https://pubmed.ncbi.nlm.nih.gov/35396981/Reference: Díaz-Zabala, et …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51722/

ICARE Featured Video May 2022

CanVar: A Robust Variant Curation Tool Developed in the UK

Below you may watch a featured video from the May 2022 Genetics Case Conference focused on CanVar with guest expert Clare Turnbull, MD, PhD.

Permanent link to this article: https://inheritedcancer.net/video51222/

ICARE Social Media Post May 2022

Melanoma Treatment Update

Results from a small study suggest that melanomas in CDKN2A carriers may have better response rates to immunotherapy compared to non-carriers.Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/30291219/Reference: Helgadottir et al. J Med Genet. 2020 May;57(5): 316-321. PMID: 30291219.

Permanent link to this article: https://inheritedcancer.net/post51022/

ICARE Social Media Post May 2022

CDKN2A and Melanoma

Did you know that CDKN2A mutations are found in 35-43% of families with three or more family members with melanoma?Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/33945383/Reference: Pissa et al. Acta Oncol. 2021 Jul;60(7):888-896. PMID: 33945383.

Permanent link to this article: https://inheritedcancer.net/post50622/

Other Cancer Genetics Webinar May 2022

Addressing Global Implementation of Genomic Cancer Risk Assessment

Below you may watch an exciting presentation by Jeffrey Weitzel, MD, in which he discusses global implementation of genomic cancer risk assessment.

Permanent link to this article: https://inheritedcancer.net/video50322/

ICARE Social Media Post April 2022

Spring 2022 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, ICARE Founder, Dr. Tuya Pal, and her oncology colleague, Dr. Sonya Reid, discuss the types of inherited breast cancer and whether having an inherited form of breast cancer affects survival.Check …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42922/

ICARE Social Media Post April 2022

Disparities: PARP Inhibitors & Ovarian Cancer

A recent study found that non-Hispanic Black and Hispanic women are underrepresented in clinical trials evaluating PARP inhibitor use among ovarian cancer patients; therefore, these trials do not accurately represent the ovarian cancer patient population. These findings indicate initiatives to increase diversity in clinical trials are needed. Read the full article for more information 👇https://www.gynecologiconcology-online.net/article/S0090-8258(22)00071-3/fulltext#secst0030Reference: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42222/

ICARE Social Media Post April 2022

BRCA1/2 Carriers with Breast Cancer: Olaparib & Survival

A new study found that adjuvant olaparib significantly extended survival in BRCA1/2 carriers with HER2-negative high-risk early-stage breast cancer. Learn more at the following link: https://www.healio.com/news/hematology-oncology/20220323/adjuvant-olaparib-prolongs-survival-for-certain-patients-with-early-breast-cancer

Permanent link to this article: https://inheritedcancer.net/post41922/

ICARE Featured Video April 2022

Polygenic Risk Scores

Below you may watch a featured video from the April 2022 Genetics Case Conference focused on polygenic risk scores with guest expert Marc Tischkowitz, MD, PhD.

Permanent link to this article: https://inheritedcancer.net/video41422/

ICARE Social Media Post April 2022

Metastatic Prostate Cancer & Olaparib

Read the full article for more information!https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00017-1/fulltextReference: Thiery-Vuillemin, et al. Lancet Oncol. 2022 Mar;23(3):393-405. PMID: 35157830.

Permanent link to this article: https://inheritedcancer.net/post40822/

ICARE Social Media Post April 2022

Detection of Early-Stage Pancreatic Ductal Adenocarcinoma from Blood Samples

Permanent link to this article: https://inheritedcancer.net/post40522/

ICARE Social Media Post April 2022

Breast Cancer Mortality & MRI Screening: ATM, CHEK2, and PALB2

A new study suggests that annual breast MRI screening may reduce deaths from breast cancer by half in women with ATM, CHEK2 and PALB2 gene mutations. The data suggests starting with annual breast MRIs between the ages of 30 to 35, and adding annual mammograms starting at age 40. Read the full article to learn …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post40122/

ICARE Social Media Post March 2022

BRCA1/2: Asian Breast Cancer Patients

A new study highlights the importance of customizing mutation carrier prediction models in order to improve the accuracy of predicting the likelihood of carrying a BRCA mutation in Asian breast cancer patients.Read the article for more info!https://ascopubs.org/doi/abs/10.1200/JCO.21.01647?cid=DM9826&bid=143994923Reference: Hong Ang et al. J Clin Oncol. 2022 Feb 10;JCO2101647. PMID: 35143328.

Permanent link to this article: https://inheritedcancer.net/post32522/

ICARE Social Media Post March 2022

Breast Cancer: Leading Cause Of Cancer-Associated Death Among Black Women

Did you know breast cancer surpassed lung cancer as the leading cause of cancer death among Black women in the United States? Although Black women are at a lower risk for developing breast cancer, they are 41% more likely to die of breast cancer compared with White women.Future research is needed to reverse course, through …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31722/

ICARE Social Media Post March 2022

FDA Approves Olaparib for Adjuvant Treatment of High-risk Early Breast Cancer

On March 11th, the Food and Drug Administration (FDA) approved olaparib (Lynparza) for the adjuvant treatment of BRCA1/2 carriers with human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.Learn more at 👇https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer

Permanent link to this article: https://inheritedcancer.net/post31522/

ICARE Featured Video March 2022

Inherited Colorectal Cancer & Polyposis Syndromes

Below you may watch a featured video from the March 2022 Genetics Case Conference focused on inherited colorectal cancer and polyposis syndromes with guest expert Heather Hampel, MS, LGC.

Permanent link to this article: https://inheritedcancer.net/video31022/

ICARE Social Media Post March 2022

Komen Blog Post: Dr. Pal Interview

Komen Scholar, ICARE Founder and Clinical Geneticist, Dr. Tuya Pal, was recently interviewed for the Komen Blog. In the interview, Dr. Pal discusses the importance of making genetic counseling and testing more accessible in order to help populations who are at high risk for inherited cancer make more informed decisions about their medical care.Read the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post30922/

Other Cancer Genetics Webinar March 2022

Pediatric Inherited Cancer Predisposition

Below you may watch an exciting presentation about inherited pediatric cancer by Daniel Benedetti, MD from Monroe Carell Jr. Children’s Hospital at Vanderbilt.

Permanent link to this article: https://inheritedcancer.net/video30722/

ICARE Social Media Post March 2022

Lynch Syndrome: Uterine Cancer Treatment

 

A new study indicated treatment with pembrolizumab (Ketruda) resulted in benefit in patients with MSI-H advanced uterine cancer. Read the full article to learn more!https://ascopubs.org/doi/10.1200/JCO.21.01874Reference: O’Malley et al. J Clin Oncol. 2022 Jan 6;JCO2101874. PMID: 34990208.

Permanent link to this article: https://inheritedcancer.net/post30122/

ICARE Social Media Post February 2022

Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance

A recent study found that only about 33% of women with ovarian cancer undergo germline BRCA1/2 testing, despite universal recommendations for such patients to have germline genetic testing. Check out the article for more information!https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787937?resultClick=3Reference: Cham et al. JAMA Netw Open. 2022 Jan 4;5(1):e2142703. PMID: 35015069.

Permanent link to this article: https://inheritedcancer.net/post22122/

ICARE Social Media Post Month Year

Genetic Testing & Mortality Among Women with Breast or Ovarian Cancer

A recent study found there were BETTER short-term outcomes among women with:• triple-negative breast cancer and BRCA1 or BRCA2 mutations• ovarian cancer and BRCA2, BRIP1, RAD51C, or ATM mutationsThese findings may be reassuring to individuals with inherited gene mutations related to breast and ovarian cancer. Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/34373918/Reference: Kurian et al. J …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21822/

ICARE Social Media Post February 2022

BRCA1/2 Cancer Risks: Oral Contraceptives

A new study found that among BRCA1/2 carriers oral contraceptive use strongly decreases lifetime cancer risk, despite an 𝗶𝗻𝗶𝘁𝗶𝗮𝗹 increase in breast, ovarian, and endometrial cancer risk. Read the full article to learn more!https://pubmed.ncbi.nlm.nih.gov/35048954/Reference: Schrijver et al. J Natl Cancer Inst. 2022 Jan 20;djac004. PMID: 35048954

Permanent link to this article: https://inheritedcancer.net/post21522/

ICARE Featured Video February 2022

Making an IMPACT Through ICARE

Below you may watch a featured video from the February 2022 Genetics Case Conference, in which Tuya Pal, MD (ICARE Founder) provided an overview of ICARE, highlighting:❶ Research efforts such as clinical trials and genomics studies made possible through ICARE participants and providers❷ How participating in ICARE can benefit both patients and providers

Permanent link to this article: https://inheritedcancer.net/video21022/

ICARE Social Media Post February 2022

Polygenic Risk Scores: BRCA1, BRCA2, PALB2, CHEK2 & ATM

Permanent link to this article: https://inheritedcancer.net/post20822/

ICARE Social Media Post February 2022

Breast Cancer Characteristics Across Genes

 

A new study demonstrated that breast cancer pathology and other clinical features differ by inherited breast cancer gene. Read the full article to learn more!https://jamanetwork.com/journals/jamaoncology/fullarticle/2788577Reference: Breast Cancer Association Consortium. JAMA Oncol. 2022 Jan 27. PMID: 35084436

Permanent link to this article: https://inheritedcancer.net/post20122/

ICARE Social Media Post January 2022

Male Cancer Risks: BRCA1 & BRCA2

A new study found that male BRCA1/2 carriers have a higher risk for breast, pancreatic, and stomach cancer. Additionally, male BRCA2 carriers were found to have higher risks for prostate cancer. Read the full Journal of Clinical Oncology article to learn more!https://ascopubs.org/doi/full/10.1200/JCO.21.02112Reference: Li et al. J Clin Oncol. 2022 Jan 25;JCO2102112. PMID: 35077220.

Permanent link to this article: https://inheritedcancer.net/post12822/

ICARE Social Media Post January 2022

Overview of genetic services delivery for hereditary breast cancer

A recent article by Drs. Sonya Reid, Tuya Pal, and Lucy Spalluto, and Katie Lang, MS, CGC and Anne Weidner, MPH of the ICARE team, has just been published with @SpringerNature in 𝘉𝘳𝘦𝘢𝘴𝘵 𝘊𝘢𝘯𝘤𝘦𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘢𝘯𝘥 𝘛𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵. This article outlines the importance of genetic services and follow-up care for hereditary breast cancer, as well as …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12622/

ICARE Social Media Post January 2022

BRCA Breast Cancer Risks After Age 60

A study that included ICARE participants reported the risk of developing breast cancer remains high after age 60 in both BRCA1 and BRCA2 carriers. Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/33423179/Reference: Stjepanovic et al. Breast Cancer Res Treat. 2021 Jun;187(2):515-523. PMID: 33423179

Permanent link to this article: https://inheritedcancer.net/post12522/

Jan 21

ICARE Social Media Post January 2022

Belzutifan in Von Hippel-Lindau Disease Patients

Belzutifan demonstrated clinical efficacy in patients with renal cell carcinoma who have Von Hippel-Lindau Disease. Learn more by reading the full The New England Journal of Medicine article at 👇https://www.nejm.org/doi/full/10.1056/NEJMoa2103425Reference: Jonasch, et al. N Engl J Med. 2021 Nov 25;385(22):2036-2046. PMID: 34818478.

Permanent link to this article: https://inheritedcancer.net/post12122/

ICARE Social Media Post January 2022

Dr. Pal’s GIM Editorial

 

Estimating Polygenetic Risk Scores in non-Europeans through extrapolating from data in European descent populations is not accurate! Diversity in genomic studies is critically needed for both equity and scientific discovery. For more information, read the Genetics in Medicine editorial by ICARE Founder, Dr. Tuya Pal, here 👇https://www.gimjournal.org/article/S1098-3600(21)05396-X/fulltextReference: Pal. Genet Med. 2021 Nov 20;S1098-3600(21)05396-X. PMID: 34906472.

Permanent link to this article: https://inheritedcancer.net/post11822/

ICARE Featured Video January 2022

JScreen: At-Home Genetic Testing and Education

Below you may watch a featured video from the January 2022 Genetics Case Conference, in which Estie Rose, MS, LCGC presented on JScreen, a non-profit offering genetic testing and education.

Permanent link to this article: https://inheritedcancer.net/video11322/

ICARE Social Media Post January 2022

Gastric Cancer Risks: CDH1

Read the 𝘑𝘈𝘔𝘈 𝘚𝘶𝘳𝘨𝘦𝘳𝘺 article to learn morehttps://jamanetwork.com/journals/jamasurgery/article-abstract/2785097Reference: Gamble et al. JAMA Surg. 2021 Oct 13;e215118. PMID: 34643667.

Permanent link to this article: https://inheritedcancer.net/post11122/

ICARE Social Media Post January 2022

Ovarian Cancer: BRCA1/2 Maintenance Olaparib

Read the full article for more details 👇https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltextReference: Banerjee et al. Lancet Oncol. 2021 Dec;22(12):1721-1731. PMID: 34715071.

Permanent link to this article: https://inheritedcancer.net/post10422/

ICARE Social Media Post December 2021

Fall 2021 Community Spotlight

In every ICARE newsletter we feature a 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 to share their experience with inherited cancer. In the latest edition, Dan Dry Dock Shockley, shares his experience with attenuated familial adenomatous polyposis (AFAP). Check out his full story at 👇https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post123021/

ICARE Social Media Post December 2021

Fall 2021 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Kerry Schaffer discusses the use of PARP inhibitors to treat inherited forms of prostate cancer.Check out Dr. Schaffer’s full response at 👇https://inheritedcancer.net/newsletters/

Permanent link to this article: https://inheritedcancer.net/post122821/

ICARE Social Media Post December 2021

Breast Cancer Risk Prediction Model for Black Women

 

A new breast cancer model has been developed and validated for breast cancer risk prediction, specifically for Black women in the United States. This is in contrast to prior models, which were developed in White women, and used in Black women (which UNDERPREDICTED risks). This is a notable advance as we strive towards health equity …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post122321/

ICARE Social Media Post December 2021

Li-Fraumeni Syndrome Cancer Risks

• Several variants were identified multiple times in those who did and did not meet Li-Fraumeni Syndrome clinical criteria: p.R175, p.G245, p.R248, p.R273, and p.R282• Other variants were exclusively found in those in the Li-Fraumeni Syndrome group: p.M133T, p.P152L, p.C275Y, p.C275, p.R337C, p.R342, and p.R342P• One variant was exclusively found in patients with attenuated Li-Fraumeni …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post122121/

ICARE Social Media Post December 2021

Prostate Cancer Screening: MSH2 & MSH6

A new study suggests men with MSH2 and MSH6 mutations have a higher incidence of prostate cancer, and may be candidates for PSA screening. Read the full article to learn more 👇 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00522-2/fulltext Reference: Bancroft et al. Lancet Oncol. 2021 Nov;22(11):1618-1631. PMID: 34678156.

Permanent link to this article: https://inheritedcancer.net/post121721/

ICARE Social Media Post December 2021

FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease

On August 13th, the FDA approved the use of belzutifan (Welireg) for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors not requiring immediate surgery. For more information, check out The ASCO Post article at 👇https://ascopost.com/news/august-2021/fda-approves-belzutifan-for-cancers-associated-with-von-hippel-lindau-disease/?utm_source=TAP-EN-081321&utm_medium=email&utm_term=49cf1c97d48c2cf8231827e3bcb15769

Permanent link to this article: https://inheritedcancer.net/post121021/

ICARE Social Media Post December 2021

FDA Approves PARP Inhibitor (Olaparib) Treatment for some BRCA carriers with Early Stage Breast Cancer

FDA granted priority review to Olaparib for adjuvant treatment of certain patients with high-risk breast cancer. This designation applies to use of the agent by patients with BRCA-mutated, HER2-negative, high-risk early breast cancer who receive chemotherapy before or after surgery. For additional information, visit: https://tinyurl.com/healioFDAapproval

Permanent link to this article: https://inheritedcancer.net/post120621/

ICARE Social Media Post December 2021

The Impact of Subtype and Race on Breast Cancer Survival

A recent article 𝗹𝗲𝗱 𝗯𝘆 𝗗𝗿𝘀. 𝗦𝗼𝗻𝘆𝗮 𝗥𝗲𝗶𝗱 𝗮𝗻𝗱 𝗧𝘂𝘆𝗮 𝗣𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗜𝗖𝗔𝗥𝗘 𝘁𝗲𝗮𝗺, published in 𝘉𝘳𝘦𝘢𝘴𝘵 𝘊𝘢𝘯𝘤𝘦𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘢𝘯𝘥 𝘛𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵, outlines the impact of race and molecular subtype on HR+, HER2- breast cancer survival. Check out the full article at https://link.springer.com/content/pdf/10.1007/s10549-021-06342-0.pdf Reference: Reid et al. Breast Cancer Res Treat. 2021 Oct;189(3):845-852. PMID: 34331630.

Permanent link to this article: https://inheritedcancer.net/post120321/

ICARE Social Media Post November 2021

Variation in Colorectal Cancer Risk in Families With Lynch Syndrome

For more information, read the Lancet Oncology article led by The International Mismatch Repair Consortium at the below link 👇https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00189-3/fulltext Reference: International Mismatch Repair Consortium. Lancet Oncol. 2021 Jul;22(7):1014-1022. PMID: 34111421.

Permanent link to this article: https://inheritedcancer.net/post113021/

ICARE Featured Video October 2021

Inherited Pediatric Cancers

Below you may watch a featured video from the November 2021 Genetics Case Conference, which focused on inherited pediatric cancer with guest expert Dan Benedetti, MD, MA from Vanderbilt University Medical Center.

Permanent link to this article: https://inheritedcancer.net/video111121/

ICARE Social Media Post November 2021

Changes in Racial and Ethnic Disparities in Access to Care and Health Among US Adults at Age 65 Years

For more information, view the article at 👇https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djab141/6323231 Reference: Johnson et al. PMID: 34291289.

Permanent link to this article: https://inheritedcancer.net/post110921/

ICARE Social Media Post November 2021

Changes in Racial and Ethnic Disparities in Access to Care and Health Among US Adults at Age 65 Years

For more information, read the full article at: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2782345

Permanent link to this article: https://inheritedcancer.net/post110221/

ICARE Social Media Post October 2021

Pancreatic Cancer Risks: ATM

For more information, read the full article at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2783767 Reference: Hsu, et al. JAMA Oncol. 2021 Sep 16:e213701. PMID: 34529012.

Permanent link to this article: https://inheritedcancer.net/post100121/

ICARE Featured Video October 2021

SMARCA4

Below you may watch a featured video from the October 2021 Genetics Case Conference, which focused on SMARCA4 with guest expert William Foulkes, MBBS, PhD from McGill University.

Permanent link to this article: https://inheritedcancer.net/video100721/

ICARE Social Media Post September 2021

USA Today Article: Fighting Cancer with Your Own Family History

Check out the full 𝘜𝘚𝘈 𝘛𝘰𝘥𝘢𝘺 article, featuring commentary from Dr. Tuya Pal (ICARE Founder), highlighting the importance of PALB2 as an inherited breast cancer gene: https://www.futureofpersonalhealth.com/breast-health/fighting-cancer-with-your-own-family-history/# Additional guidance is available through an impactful PALB2 practice resource recently published through ACMG: https://www.acmg.net/PDFLibrary/41436_2021_1151_OnlinePDF.pdf Reference: Tischkowitz, et al. Genet Med. 2021 Aug;23(8):1416-1423. PMID: 33976419

Permanent link to this article: https://inheritedcancer.net/post92221/

ICARE Social Media Post September 2021

New NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Guidelines (Released August 11th)

The National Comprehensive Cancer Network (NCCN) released new guidelines on August 11th for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post91021/

ICARE Featured Video September 2021

Rhabdomyosarcoma and Neuroblastoma

Below you may watch a featured video from the September 2021 Genetics Case Conference, which focused on rhabdomyosarcoma and neuroblastoma with guest expert Douglas Stewart, MD from the National Cancer Institute.

Permanent link to this article: https://inheritedcancer.net/video90921/

Other Cancer Genetics Webinar September 2021

Genetic Counseling in the Context of Paired Germline/Somatic Testing

Below you may watch an exciting presentation about germline and tumor testing for ovarian cancer by Leigha-Senter Jamieson, MS, CGC from The Ohio State University, in which she considers how the role of genetic counselors may expand to support patients in partnership with treating gynecologic oncologists.

Permanent link to this article: https://inheritedcancer.net/video90821/

ICARE Social Media Post August 2021

Genetic Risk Assessment for Hereditary Renal Cell Carcinoma

To view the 30 consensus statements, read the full article at: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33679

Permanent link to this article: https://inheritedcancer.net/post83121/

ICARE Social Media Post August 2021

Breast Cancer Risks: BRCA1/2 & PALB2

For more information, view the article at 👇https://ascopubs.org/doi/full/10.1200/JCO.21.00531

Permanent link to this article: https://inheritedcancer.net/post82421/

ICARE Social Media Post August 2021

Metastatic Breast Cancer Genes

For additional information, read the Journal of Clinical Oncology article at the link below 👇 https://ascopubs.org/doi/10.1200/JCO.20.01200

Permanent link to this article: https://inheritedcancer.net/post82021/

ICARE Social Media Post August 2021

New York Times PALB2 Article

A New York Times article just published focused on the importance of PALB2 as a breast cancer gene (https://www.nytimes.com/…/breast-cancer-palb2-brca.html), which referenced our recent article focused on managing PALB2 carriers sponsored by ACMG – American College of Medical Genetics and Genomics, and developed through a worldwide collaboration (including: Marc Tischkowicz, Judith Balmana, Will Foulkes, Paul James, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post81921/

ICARE Featured Video August 2021

Inherited Prostate Cancer

Below you may watch a featured video from the August 2021 Genetics Case Conference, which focused on inherited prostate cancer with guest expert Kerry Schaffer, MD from Vanderbilt University Medical Center in Nashville, TN.

Permanent link to this article: https://inheritedcancer.net/video81221/

ICARE Social Media Post August 2021

Germline Testing & Advanced Cancers

Check out the article for more information: https://ascopubs.org/doi/pdf/10.1200/JCO.20.03661

Permanent link to this article: https://inheritedcancer.net/post81621/

ICARE Social Media Post August 2021

Breast Cancer Risk Among Breast Cancer Gene Carriers Varies by Polygenic Risk Score

For more information, read the 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘰𝘧 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺 article at the link below:https://ascopubs.org/doi/figure/10.1200/JCO.20.01992

Permanent link to this article: https://inheritedcancer.net/post81321/

ICARE Featured Video August 2021

Updates to National Comprehensive Cancer Network (NCCN) Guidelines

Below you may watch a featured video from the August 2021 ICARE Genetics Case Conferences outlining updates to National Comprehensive Cancer Network (NCCN) guidelines.

Permanent link to this article: https://inheritedcancer.net/video81221_2/

ICARE Social Media Post August 2021

ASCO Guideline Update: Olaparib for Breast Cancer

For additional information, read the updated American Society of Clinical Oncology (ASCO) recommendation (released June 15th, 2021) at the following link: https://www.asco.org/practice-patients/guidelines/breast-cancer?intcmp=ws_ascoorg_gdlns_hereditarybreastcancer_site_pressrelease_061621____#/143725

Permanent link to this article: https://inheritedcancer.net/post81021/

ICARE Social Media Post August 2021

Oral Contraceptive Use & Reduced Ovarian Cancer Risk in BRCA Carriers

For more information, view the AJOG article by Lieske Schrijver and colleagues at the following link: https://www.ajog.org/article/S0002-9378(21)00038-7/fulltext

Permanent link to this article: https://inheritedcancer.net/post80621/

ICARE Social Media Post August 2021

BRCA Mutations in Indian Women with Ovarian Cancer

For more information, view the article at: https://ascopubs.org/doi/full/10.1200/GO.21.00051

Permanent link to this article: https://inheritedcancer.net/post80321/

ICARE Social Media Post July 2021

Inherited Cancer in Colorectal Cancer Patients

For more information, view the article at: https://ascopubs.org/doi/10.1200/PO.20.00525

Permanent link to this article: https://inheritedcancer.net/post72721/

ICARE Social Media Post July 2021

Lifestyle & Colorectal Cancer Risk

For additional information, read the article at the link below: https://academic.oup.com/ajcn/article-abstract/113/4/810/6155851

Permanent link to this article: https://inheritedcancer.net/post72021/

ICARE Social Media Post July 2021

Niraparib Maintenance in BRCA Carriers with Ovarian Cancer

For more information visit: https://www.cancernetwork.com/view/multi-trial-analysis-indicates-niraparib-maintenance-for-brca-ovarian-cancer-leads-to-pfs-benefit-across-settings

Permanent link to this article: https://inheritedcancer.net/post71621/

ICARE Social Media Post July 2021

Disparities in Cancer Survival Among Adolescents and Young Adults

Check out the full article for more information: https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djab006/6117446

Permanent link to this article: https://inheritedcancer.net/post71321/

ICARE Social Media Post July 2021

RAD51C & RAD51D Response to Rucaparib in Ovarian Cancer

Check out the Nature Communications article for more information: https://www.nature.com/articles/s41467-021-22582-6

Permanent link to this article: https://inheritedcancer.net/post70921/

ICARE Social Media Post July 2021

Advances in Pancreatic Cancer Treatment: PALB2 & BRCA1/2

For more information, view the article at the following link below: https://ascopubs.org/doi/abs/10.1200/JCO.21.00003 You may also read the ASCO post article at: https://ascopost.com/news/may-2021/maintenance-rucaparib-in-patients-with-platinum-sensitive-pancreatic-cancer-and-germline-or-somatic-brca1-brca2-or-palb2-variants/?utm_source=TAP%2DEN%2D051221%2DTrending%5FLymphoma&utm_medium=email&utm_term=49cf1c97d48c2cf8231827e3bcb15769

Permanent link to this article: https://inheritedcancer.net/post70621/

ICARE Social Media Post July 2021

PALB2 & Prostate Cancer

For more information, read the article available at: https://www.nature.com/articles/s41416-021-01410-0

Permanent link to this article: https://inheritedcancer.net/post70221/

ICARE Social Media Post June 2021

BRCA: Better Survival with Screening

For more information, please visit: https://www.cancertherapyadvisor.com/home/news/conference-coverage/st-gallen-international-breast-cancer-conference/sg-bcc-2021/breast-cancer-screening-brca-improves-survival-mutation

Permanent link to this article: https://inheritedcancer.net/post62921/

ICARE Social Media Post June 2021

A Population-Based Study of Genes Previously Implicated in Breast Cancer

For additional information, read the article at the following link: https://www.nejm.org/doi/10.1056/NEJMoa2005936

Permanent link to this article: https://inheritedcancer.net/post62521/

ICARE Social Media Post June 2021

BRCA2 Variants of Uncertain Significance

For more information, view the article at: https://pubmed.ncbi.nlm.nih.gov/33609447/

Permanent link to this article: https://inheritedcancer.net/post62221/

ICARE Featured Video June 2021

PALB2

Below you may watch a featured video from the June 2021 Genetics Case Conference, which focused on PALB2 with guest experts Marc Tischkowitz, MD, PhD from the University of Cambridge in Cambridge, England and Steven Narod, MD, FRCPC, FRSC from the Women’s College Research Institute in Toronto, Canada.

Permanent link to this article: https://inheritedcancer.net/video61021/

ICARE Social Media Post June 2021

Actionable Pathogenic Variants Among Caribbean-Born People With Breast or Ovarian Cancer

For more information, view the article at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2776805

Permanent link to this article: https://inheritedcancer.net/post61521/

ICARE Social Media Post June 2021

Olaparib In Patients With Early, High-Risk HER2-Negative Breast Cancer & BRCA Mutations

For more information view the article at: https://www.nejm.org/doi/full/10.1056/NEJMoa2105215

Permanent link to this article: https://inheritedcancer.net/post61121/

ICARE Social Media Post May 2021

Race-Based Oncology

For more information, view the article at the following link: https://ascopubs.org/doi/full/10.1200/PO.20.00418

Permanent link to this article: https://inheritedcancer.net/post52821/

ICARE Social Media Post May 2021

Breast Cancer Awareness Medical Minute

In recognition of 𝗪𝗼𝗺𝗲𝗻’𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 𝗠𝗼𝗻𝘁𝗵, listen to our colleague, Dr. Sonya Reid, talk about the importance of mammography for the early detection of breast cancer! To learn more, check out the American Cancer Society’s Recommendations for the Early Detection of Breast Cancer at: https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html

Permanent link to this article: https://inheritedcancer.net/post52421/

ICARE Social Media Post May 2021

ACMG Gene List

The American College of Medical Genetics and Genomics (ACMG) recently released the highly anticipated recommended minimum gene list for reporting secondary findings (SF) in clinical exome and genome sequencing. ACMG SF v3.0 added 3 new cancer genes (𝘗𝘈𝘓𝘉2, 𝘔𝘈𝘟, and 𝘛𝘔𝘌𝘔127) to bring the total number of inherited cancer genes to 28. For more information …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post52121_2/

ICARE Social Media Post May 2021

USPSTF Earlier Colorectal Cancer Screening At Age 45

The United States Preventive Services Task Force (USPSTF) now recommends routine colorectal cancer screening begin at age 45 (lowered from the previous recommendation to start screening at age 50) due to an increasing number of colorectal cancer cases in younger adults. For more information, check out the full JAMA article at: https://jamanetwork.com/journals/jama/fullarticle/2779985

Permanent link to this article: https://inheritedcancer.net/post52121/

ICARE Social Media Post May 2021

Plexiform Neurofibromas and NF1

For more information, read the article available at: https://ascopubs.org/doi/full/10.1200/JCO.20.02220

Permanent link to this article: https://inheritedcancer.net/post51821/

ICARE Social Media Post May 2021

CDKN2A: Cancer Risks and Risk Management

𝘐𝘯 𝘳𝘦𝘤𝘰𝘨𝘯𝘪𝘵𝘪𝘰𝘯 𝘰𝘧 𝘴𝘬𝘪𝘯 𝘤𝘢𝘯𝘤𝘦𝘳 𝘢𝘸𝘢𝘳𝘦𝘯𝘦𝘴𝘴 𝘮𝘰𝘯𝘵𝘩, we present cancer risks and management for 𝗖𝗗𝗞𝗡𝟮𝗔 per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Version 2.2021 𝗠𝗲𝗻 & 𝗪𝗼𝗺𝗲𝗻:Melanoma risk: Elevated at 28-67% – Recommend annual full-body skin exam, regular self-examinations, and routine sun protective behaviors. Pancreatic cancer risk: >15% – Consider MRI/MRCP and/or endoscopic …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51321/

ICARE Social Media Post May 2021

ACMG Clinical Practice Resource on PALB2

Check out the newly released ACMG Clinical Practice Resource on 𝗣𝗔𝗟𝗕𝟮 developed through a group of worldwide experts!https://www.acmg.net/PDFLibrary/41436_2021_1151_OnlinePDF.pdf Read the ACMG press release at: https://www.acmg.net/PDFLibrary/Global%20Team%20of%20Cancer%20Genetic%20Specialists%20release%20final%20template%205%206.final.pdf

Permanent link to this article: https://inheritedcancer.net/post51121/

ICARE Social Media Post May 2021

Direct-to-Consumer Tests

For additional information, view the BMJ article available at: 👉 https://www.bmj.com/content/372/bmj.n214

Permanent link to this article: https://inheritedcancer.net/post50321/

ICARE Social Media Post April 2021

Reducing Hereditary Cancer Act

The 𝙍𝙚𝙙𝙪𝙘𝙞𝙣𝙜 𝙃𝙚𝙧𝙚𝙙𝙞𝙩𝙖𝙧𝙮 𝘾𝙖𝙣𝙘𝙚𝙧 𝘼𝙘𝙩 is being proposed to ensure Medicare beneficiaries have access to inherited cancer genetic testing, increased screening, and risk-reducing procedures, when medically necessary & appropriate. Under current Medicare guidelines, only those with “signs, symptoms, complaints, or personal histories of disease” meet the criteria for medical services coverage. Genetic testing is only …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post43021/

ICARE Social Media Post April 2021

Effect of Salpingo-Oophorectomy on Breast Cancer Risk in Women With BRCA1 or BRCA2 Pathogenic Variants

For more information, view the JAMA Oncology article available at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2776761

Permanent link to this article: https://inheritedcancer.net/post42821/

ICARE Social Media Post April 2021

Addressing Racial Disparities in Breast Cancer Clinical Trial Enrollment

For more information, read the recently published ASCO Daily News editorial led by 𝗗𝗿. 𝗦𝗼𝗻𝘆𝗮 𝗥𝗲𝗶𝗱 from Vanderbilt University Medical Center, which focused on racial disparities in breast cancer clinical trial enrollment: https://dailynews.ascopubs.org/do/10.1200/ADN.21.200499/full/

Permanent link to this article: https://inheritedcancer.net/post42321/

ICARE Social Media Post April 2021

Komen Disparities Resource

Check out Susan G. Komen’s “𝗞𝗻𝗼𝘄 𝗬𝗼𝘂𝗿 𝗛𝗶𝘀𝘁𝗼𝗿𝘆, 𝗞𝗻𝗼𝘄 𝗬𝗼𝘂𝗿 𝗥𝗶𝘀𝗸” resource, which outlines disparities in breast cancer, how to understand your risk, and recommended screening and management practices. To learn more, please visit: 👉 https://www.komen.org/about-komen/our-impact/breast-cancer/health-equities-initiative/know-your-history/ 👉 https://blog.komen.org/news/black-history-month/

Permanent link to this article: https://inheritedcancer.net/post42021/

ICARE Social Media Post April 2021

Olaparib for Metastatic Breast Cancer

For more information, view the article at: https://ascopubs.org/doi/abs/10.1200/JCO.20.02151

Permanent link to this article: https://inheritedcancer.net/post41321/

ICARE Social Media Post April 2021

Winter 2021 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Rebecca Smith explains how a genetic change (or mutation) is classified as pathogenic or benign. Check out Dr. Smith’s full response in our Winter 2021 newsletter at: https://inheritedcancer.net/newsletters/

Permanent link to this article: https://inheritedcancer.net/post40921/

ICARE Featured Video April 2021

Multiple Primary Tumors

Below you may watch a featured video from the April 2021 Genetics Case Conference, which focused on multiple primary tumors with guest expert James Whitworth, MD, PhD from the University of Cambridge.

Permanent link to this article: https://inheritedcancer.net/video40921/

ICARE Social Media Post April 2021

Fruits and Vegetables Lower Mortality

For further information, view the article available at:https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.048996

Permanent link to this article: https://inheritedcancer.net/post40621/

ICARE Social Media Post April 2021

Family Communication of Genetic Test Results Among Women with Inherited Breast Cancer Genes

Check out a recent article led by the ICARE team, published in the Journal of Genetic Counseling, outlining family communication of genetic test results among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Check out the full article at: https://onlinelibrary.wiley.com/doi/full/10.1002/jgc4.1356

Permanent link to this article: https://inheritedcancer.net/post40221/

ICARE Social Media Post March 2021

STK11: Cancer Risks and Risk Management

Gene: STK11 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 Women:Breast cancer risk: Elevated at 40-60% – Recommend annual mammogram and breast MRI starting at around age 30. Ovarian tumor risk (typically benign sex cord/Sertoli cell tumors): Elevated at 18-21% – Recommend annual pelvic exam starting at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post33021/

ICARE Social Media Post March 2021

MUTYH: Cancer Risks and Risk Management

Gene: MUTYH Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 Men & women with two mutations in MUTYH:Colon cancer risk: High risk – Recommend colonoscopy every 1-2 years beginning at age 25-30; colectomy considered based on polyp burden and age. Duodenal cancer risk: Elevated – Consider baseline …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32321/

ICARE Social Media Post March 2021

Winter 2021 Community Spotlight

In every ICARE newsletter we feature a 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 to share their experience with inherited cancer. In the latest edition, Dave Dubin, co-founder of AliveAndKickn, shares his experience with Lynch Syndrome. Check out his full story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post31921/

ICARE Social Media Post March 2021

APC: Cancer Risks and Risk Management

𝗚𝗲𝗻𝗲: 𝗔𝗣𝗖 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 𝗠𝗲𝗻 & 𝗪𝗼𝗺𝗲𝗻:𝘈𝘗𝘊 mutation leading to classic form of Familial Adenomatous Polyposis (FAP):Colorectal cancer risk: >99% if untreated – Treatment is based on polyp burden and includes proctocolectomy (with subsequent endoscopic screening of the ileal pouch) or …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31621/

ICARE Social Media Post March 2021

Colorectal Cancer Risk Assessment Tool

In honor of 𝗖𝗼𝗹𝗼𝗿𝗲𝗰𝘁𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗠𝗼𝗻𝘁𝗵, we wanted to highlight the National Cancer Institute’s Colorectal Cancer Risk Assessment Tool (CCRAT) designed for healthcare providers to use with select patients to estimate the risk of colorectal cancer. You may access the tool at https://ccrisktool.cancer.gov

Permanent link to this article: https://inheritedcancer.net/post31221/

ICARE Featured Video March 2021

Inherited Colorectal Cancer

Below you may watch a featured video from the March 2021 Genetics Case Conference, which focused on inherited colorectal cancer with guest expert Georgia Wiesner, MD from Vanderbilt University Medical Center.

Permanent link to this article: https://inheritedcancer.net/video31121/

ICARE Social Media Post March 2021

Three Articles: Breast Cancer Risks

For additional information about the: 》US-based study, visit: https://www.nejm.org/doi/full/10.1056/nejmoa2005936 》International study, visit: https://www.nejm.org/doi/full/10.1056/nejmoa1913948 》Accompanying editorial: https://www.nejm.org/doi/full/10.1056/NEJMe2035083

Permanent link to this article: https://inheritedcancer.net/post30921/

ICARE Social Media Post March 2021

Breastfeeding and the Risk of Epithelial Ovarian Cancer Among Women with A BRCA1 or BRCA2 Mutation

For further information, view the article available at: https://www.gynecologiconcology-online.net/action/showPdf?pii=S0090-8258%2820%2933947-0

Permanent link to this article: https://inheritedcancer.net/post30221/

ICARE Social Media Post February 2021

Olaparib and Invasive Disease-Free Survival in Patients with BRCA, High-Risk, Early Breast Cancer

For additional information visit: https://www.onclive.com/view/adjuvant-olaparib-showcases-idfs-improvement-in-brca-high-risk-early-breast-cancer

Permanent link to this article: https://inheritedcancer.net/post22321/

ICARE Featured Video February 2021

DICER1

Below you may watch a featured video from the February 2021 Genetics Case Conference, which focused on DICER1 with guest expert Douglas Stewart, MD from the National Cancer Institute.

Permanent link to this article: https://inheritedcancer.net/video21121/

ICARE Newsletter Winter 2021

Inherited Breast Cancer Genes: Two New Important Articles Just Released

Results of a United States (U.S.)-based study1 and an international study2 were released in January in the New England Journal of Medicine and provide a much clearer picture about the role of inherited breast cancer genes in women without a family history of cancer, and how common these genes may be in the general population. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2021/

ICARE Newsletter Winter 2021

Updates to National Comprehensive Cancer Network (NCCN) Guidelines Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

Released September 8th, 2020: Genetic testing criteria by cancer type: Breast Cancer: Broadened to include relatives with ALL grades of prostate cancer (not just high-grade) Having multiple breast cancer diagnoses no longer depends on whether the diagnoses were on two different breasts Prostate Cancer: Now includes cribriform histology and ANY risk group (not just high-grade …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2021/

ICARE Newsletter Winter 2021

Exploring Disparities Among Those with Inherited Cancers

It has never been more urgent to ensure that advances in genomic technologies do not further widen existing cancer health disparities. In the fall of 2020, the American Association for Cancer Research (AACR) put forth a report focused on cancer health disparities, in which they highlighted several issues.1 Notably, disparities in inherited cancer care were …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nlw2021/

ICARE Newsletter Winter 2021

Study Suggests Low Yield of MRI Surveillance After Bilateral Mastectomy

A study of 159 women, including BRCA1/2 carriers, who had a bilateral mastectomy with reconstruction and underwent breast MRI screening, showed few women had detection of breast cancer through MRI after their bilateral mastectomy. These results support the recommendation that BRCA1/2 carriers with or without breast cancer who have a bilateral mastectomy with reconstruction do …

Continue reading

Permanent link to this article: https://inheritedcancer.net/8nlw2021/

ICARE Newsletter Winter 2021

Community Spotlight

My genes don’t define me. I am AliveAndKickn. Pretty bold statement. AliveAndKickn is more than just a name. It’s a way of life. I joke that Lynch Syndrome is the genetic predisposition to colon cancer, endometrial cancer, other cancers…and soccer. But that’s just me. Besides half a dozen surgeries since 1997, I have and still play and coach the game I love. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnlw2021/

ICARE Newsletter Winter 2021

Learning You Have a Mutation in an Inherited Cancer Gene: What’s Next?

The benefits achieved through genetic testing for inherited cancer only happen by acting upon the results. This can be through guiding cancer treatment, receiving appropriate cancer risk management strategies, and sharing results with at-risk family members so they too can benefit from this information. We recently reported on results of our study, made possible through …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nlw2021/

ICARE Newsletter Winter 2021

CHEK2 is NOT a Li-Fraumeni Syndrome Gene

An old study back in 1999 suggested that CHEK2 may be a Li-Fraumeni Syndrome gene.1 However, a subsequent report in 2002 clearly refuted this original assertion, and based on additional data and analysis concluded that “… it is very unlikely that CHEK2 is an alternative Li-Fraumeni Syndrome susceptibility gene.”2 Another subsequent report in 2008 based …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nlw2021/

ICARE Newsletter Winter 2021

Assessing How Pregnancy and Breastfeeding May Affect Cancer Risks in BRCA Carriers

Results of a recently published study suggested that pregnancy after breast cancer in BRCA carriers does not lead to a worse outcome in women or their fetuses.1 This information is reassuring for BRCA carriers who have had a prior diagnosis of breast cancer and are considering having children. In another study among female BRCA carriers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2021/

ICARE Newsletter Winter 2021

Ask the Expert

In each newsletter, we give participants the opportunity to have their questions addressed by experts in the field. This question was addressed by Rebecca Smith, PhD, Laboratory Director at Genetics Associates, Inc. with over 20 years of experience in biomedical research and 7 years of experience in clinical laboratory diagnostics. If you have a question …

Continue reading

Permanent link to this article: https://inheritedcancer.net/9nlw2021/

ICARE Newsletter Winter 2021

Inherited Cancer Treatment: Updates and Relevant Policies

Over the last several months, the American Society of Clinical Oncology published a number of guidelines related to the use of PARP inhibitors among those with BRCA-associated cancers, including guidelines focused on ovarian cancer,1 metastatic pancreatic cancer,2 and breast cancer.3 Additionally, costs of drugs also have great potential to influence policy, highlighting the importance of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nlw2021/

ICARE Social Media Post February 2021

ICARE Winter 2021 Newsletter

The ICARE Winter 2021 Newsletter is now available! Check out this latest edition for recent research and clinical updates, a Q&A with a genomics expert, and an inspiring community spotlight piece. You can read the newsletter by visiting: https://inheritedcancer.net/wp-content/uploads/ICARE-2021-Winter-Newsletter.pdf. Please feel free to share with family members, friends, and/or your healthcare providers.

Permanent link to this article: https://inheritedcancer.net/post20921/

ICARE Social Media Post February 2021

Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM Carriers

Our team recently published “Sharing Genetic Test Results with Family Members of 𝘉𝘙𝘊𝘈, 𝘗𝘈𝘓𝘉2, 𝘊𝘏𝘌𝘒2, and 𝘈𝘛𝘔 Carriers” in 𝘗𝘢𝘵𝘪𝘦𝘯𝘵 𝘌𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘊𝘰𝘶𝘯𝘴𝘦𝘭𝘪𝘯𝘨 Special Issue on Genetics. View the article available at:https://www.sciencedirect.com/science/article/pii/S0738399120306832 Challenges and barriers to family sharing included concern for family members’ reactions, complexities of information, lack of closeness, perceived relevance, & emotional impact. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post20821/

ICARE Social Media Post February 2021

Strategies to Enhance the Identification of Hereditary Breast Cancer Gene Carriers

Check out a recent review article led by the ICARE team, published in 𝘌𝘹𝘱𝘦𝘳𝘵 𝘙𝘦𝘷𝘪𝘦𝘸 𝘰𝘧 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘋𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤𝘴, outlining strategies to improve the identification of inherited breast cancer gene carriers. Check out the full article at: https://www.tandfonline.com/doi/pdf/10.1080/14737159.2020.1816829?needAccess=true

Permanent link to this article: https://inheritedcancer.net/post20221/

ICARE Social Media Post January 2021

Male Breast Cancer Global Alliance

The Male Breast Cancer Global Alliance shares stories from male breast cancer survivors all over the world. To learn more and find resources for affected men and their families, please visit www.mbcglobalalliance.org. The Male Breast Cancer Global Alliance also developed printable and shareable cards in over 20 languages outlining the proper way to do self-breast …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12621/

ICARE Social Media Post January 2021

COVID-19 Vaccine Myths

                                              Although we don’t typically post on vaccines, given the public health importance of the COVID-19 vaccine and the questions we have received related to whether the vaccine could change one’s DNA, we …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12221/

ICARE Social Media Post January 2021

Sharing Genetic Test Results with Family Members of BRCA, PALB2, CHEK2, and ATM

Check out a new article by the ICARE team, published in Patient Education and Counseling, evaluating the motivators and barriers to sharing personal genetic test results with family members. The article is 𝗳𝗿𝗲𝗲 to access and download 𝘂𝗻𝘁𝗶𝗹 𝗠𝗮𝗿𝗰𝗵 𝟱𝘁𝗵 at: https://www.sciencedirect.com/science/article/pii/S0738399120306832

Permanent link to this article: https://inheritedcancer.net/post11521/

ICARE Featured Video January 2021

Tumor Testing/Germline Significance

Below you may watch a featured video from the January 2021 Genetics Case Conference, which focused on tumor testing/germline significance with guest expert Ben Ho Park, MD, PhD from Vanderbilt University Medical Center.    

Permanent link to this article: https://inheritedcancer.net/video11421/

ICARE Social Media Post January 2021

Qualitative Methods for Refining a Web-Based Educational Tool for Patients Focused on Inherited Cancer Predisposition

Check out a study led by the ICARE team, published with @SpringerNature in the Journal of Cancer Education, outlining the evaluation and refinement strategies of an interactive web-based tool developed to provide education about inherited cancer risk. Check out a full-text view-only version of the paper at https://rdcu.be/cc8sR or read the abstract at https://pubmed.ncbi.nlm.nih.gov/33400205/ (PMID: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11221/

ICARE Social Media Post January 2021

Family Sharing Resources: GeneSHARE

With the tremendous advances in gene-based care among those at risk for inherited cancer, we are trying to develop and improve tools and strategies to make it easier for more people to benefit from genetic testing. We are excited to share with you a free online toolkit called 𝗚𝗲𝗻𝗲𝗦𝗛𝗔𝗥𝗘, which is aimed at helping patients …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post10821/

ICARE Publication January 2021

Qualitative Methods for Refining a Web-Based Educational Tool for Patients Focused on Inherited Cancer Predisposition

Abstract To address the increasing demand for inherited cancer genetic testing, we developed and evaluated a web-based educational tool to streamline genetic counseling (GC). Consented patients viewed the initial prototype containing core content (Version 1-Core) and provided feedback through three open-ended survey questions. Additional data were collected through individual interviews from a subgroup who viewed …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub10521_2/

ICARE Publication January 2021

Sharing genetic test results with family members of BRCA, PALB2, CHEK2, and ATM carriers

Abstract Objective: This study explored motivators and challenges/barriers to sharing personal genetic test results (GTR) with family members (FM). Methods: Semi-structured, in-depth interviews were conducted with 62 women who had a pathogenic or likely pathogenic (P/LP) variant in a BRCA, PALB2, CHEK2, or ATM gene. Selective qualitative data analysis focused on eliciting motivators and challenges/barriers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub10521/

ICARE Social Media Post January 2021

National Cancer Institute (NCI) Cancer Genetics PDQ

For further information, check out the National Cancer Institute’s PDQ® Cancer Genetics Summary available at: https://www.cancer.gov/publications/pdq/information-summaries/genetics

Permanent link to this article: https://inheritedcancer.net/post10521/

ICARE Social Media Post December 2020

Genetic Testing in Women with Breast Cancer

Approximately 4,000 women with breast cancer were tested for mutations in nine breast cancer genes – 6.2% had mutations in at least one of the nine genes, and 2.7% had mutations in either 𝘽𝙍𝘾𝘼1 or 𝘽𝙍𝘾𝘼2. Comparisons between women who did versus did not meet National Comprehensive Cancer Network (NCCN) guidelines for testing showed that: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post122920/

ICARE Social Media Post December 2020

Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

For further information, read the article available at: https://jnccn.org/…/journals/jnccn/18/11/article-p1528.xml

Permanent link to this article: https://inheritedcancer.net/post122220/

ICARE Social Media Post December 2020

CHEK2 is NOT a Li-Fraumeni Syndrome Gene

For additional details, read the articles at the links below: 𝟭𝟵𝟵𝟵: https://pubmed.ncbi.nlm.nih.gov/10617473/ 𝟮𝟬𝟬𝟮: https://pubmed.ncbi.nlm.nih.gov/12442270/ 𝟮𝟬𝟬𝟴: https://pubmed.ncbi.nlm.nih.gov/18178638/

Permanent link to this article: https://inheritedcancer.net/post121820/

ICARE Social Media Post December 2020

CDH1 Cancer Risks

When a 𝘾𝘿𝙃1 mutation is identified, several factors should be considered to figure out what the cancer risks might be and what medical management should be advised. Specifically, differences in cancer risks among those with a 𝘾𝘿𝙃1 mutation are not well understood.   Identifying a 𝘾𝘿𝙃1 mutation in families with hereditary diffuse gastric cancer (HDGC) …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post121520/

ICARE Publication December 2020

Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women

Abstract Background: The risks of breast cancer in African American (AA) women associated with inherited mutations in breast cancer predisposition genes are not well defined. Thus, whether multigene germline hereditary cancer testing panels are applicable to this population is unknown. We assessed associations between mutations in panel-based genes and breast cancer risk in 5054 AA women …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub121420/

ICARE Social Media Post December 2020

PALB2-associated Metastatic Breast Cancer

For further information, view the article at: https://ascopubs.org/doi/abs/10.1200/JCO.20.02151

Permanent link to this article: https://inheritedcancer.net/post121120/

ICARE Featured Video December 2020

NCCN Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines

Below you may watch a featured video from the December 2020 Genetics Case Conference, which outlined updates to the National Comprehensive Cancer Network (NCCN) guidelines. Check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf  

Permanent link to this article: https://inheritedcancer.net/video121020/

ICARE Social Media Post December 2020

New NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Guidelines

The National Comprehensive Cancer Network (NCCN) released new guidelines on November 20th for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/…/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post120820/

ICARE Social Media Post December 2020

Broader Germline Testing for Urothelial Cancer

The most common inherited form of urothelial cancers is Lynch Syndrome. However, a study showed that of 586 individuals with urothelial cancer, 80 had a mutation in an inherited cancer gene (14%). Mutations in several genes were observed; however, 𝙈𝙎𝙃2 and 𝘽𝙍𝘾𝘼2 were both significantly associated with urothelial cancer (odds ratio of 3.7).   Confirmatory …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post120420/

ICARE Social Media Post December 2020

Breast Cancer Polygenic Risk Score May Help Predict Risk of Contralateral Disease

For further information, view the article available at: https://www.sciencedirect.com/…/pii/S0002929720303219

Permanent link to this article: https://inheritedcancer.net/post120120/

ICARE Social Media Post November 2020

Olaparib May Be Cost-Effective Maintenance Treatment For Women With Newly Diagnosed Ovarian Cancer and BRCA Mutation

For further information, view the article available at: https://www.gynecologiconcology-online.net/…/fulltext

Permanent link to this article: https://inheritedcancer.net/post112720/

ICARE Social Media Post November 2020

Impact of Pregnancy After Breast Cancer in Women With Deleterious Germline BRCA Mutations

Check out the original article by visiting: https://pubmed.ncbi.nlm.nih.gov/32673153/

Permanent link to this article: https://inheritedcancer.net/post112420/

ICARE Social Media Post November 2020

ASCO Guideline Updates: Breast Cancer

The American Society of Clinical Oncology (ASCO) published updated guidelines for the management of hereditary breast cancer for the following gene carriers:   𝘽𝙍𝘾𝘼1/2 • Consider breast-conserving therapy • Consider nipple-sparing mastectomy, if medically appropriate • Advanced breast cancer: ⫸ PARP inhibitors (olaparib, talazoparib) preferred over non-platinum single agent chemotherapy ⫸ Platinum agents are recommended …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post112020/

ICARE Social Media Post November 2020

ASCO Guidelines for Patients with Metastatic Pancreatic Cancer

For additional details, refer to the article available at: https://ascopubs.org/doi/full/10.1200/JCO.20.01364

Permanent link to this article: https://inheritedcancer.net/post111720/

ICARE Social Media Post November 2020

Polygenic Risk Scores in Predicting Breast Cancer Risk

For further information, view the article available at: https://ascopubs.org/doi/full/10.1200/PO.19.00360

Permanent link to this article: https://inheritedcancer.net/post111320/

ICARE Featured Video November 2020

CHEK2 is NOT a Li-Fraumeni Syndrome Gene

Below you may watch a featured video from the November 2020 Genetics Case Conference, which outlined how CHEK2 is NOT a Li-Fraumeni Syndrome gene. For additional details, read the articles at the links below: 𝟭𝟵𝟵𝟵: https://pubmed.ncbi.nlm.nih.gov/10617473​ 𝟮𝟬𝟬𝟮: https://pubmed.ncbi.nlm.nih.gov/12442270​ 𝟮𝟬𝟬𝟴: https://pubmed.ncbi.nlm.nih.gov/18178638

Permanent link to this article: https://inheritedcancer.net/video111220/

ICARE Social Media Post November 2020

B-GREAT 2020 Newsletter

The B-GREAT 2020 Newsletter is now available! Check out this latest edition for research updates and information about racial inequalities in healthcare. You can read the newsletter by visiting: https://bgreatinitiative.inheritedcancer.net/wp-content/uploads/BGREAT-Newsletter-2020.pdf. Please feel free to share with family members, friends, and/or your healthcare providers.  We will be publishing these newsletters twice a year starting in 2021. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111020/

ICARE Publication November 2020

Family communication of genetic test results among women with inherited breast cancer genes

Abstract Identification of inherited breast cancer may guide care. These benefits can be amplified through communication of genetic test results with at-risk family members and subsequent family testing (FT). Females with a pathogenic/likely pathogenic (P/LP) variant in BRCA1/2, PALB2, CHEK2, and/or ATM were surveyed about family communication (FC) of genetic test results and FT. Comparisons …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub111020/

ICARE Social Media Post November 2020

Clinical Trial Participation Powers Patient’s Positive Attitude

Brooke Thomas has leaned on 12 years of experience as a medical social worker and found ways to stay positive and upbeat through it all – and she has a lot to be positive about these days, thanks to an amazing response to her treatment as part of a clinical trial at Vanderbilt-Ingram Cancer Center. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110620/

ICARE Social Media Post November 2020

Identifying Individuals At-Risk for Inherited Cancer: Disparities Among Ovarian Cancer Patients

This study highlights disparities among ovarian cancer patients. For further information, view the article at: https://pubmed.ncbi.nlm.nih.gov/30964716/

Permanent link to this article: https://inheritedcancer.net/post110320/

ICARE Social Media Post October 2020

CDH1: Cancer Risks and Risk Management

Gene: 𝘾𝘿𝙃𝟭 Cancer Risks and Management per NCCN Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021 and Gastric Version 3.2020: 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 55% – Recommend annual mammogram starting at age 30; consider breast MRI with contrast starting at age 30. 𝗠𝗲𝗻 𝗮𝗻𝗱 𝗪𝗼𝗺𝗲𝗻: Stomach cancer risk: Elevated at 83% for women, and 67% …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post103020/

ICARE Social Media Post October 2020

Polygenic Risk Scores in Refining Breast Cancer Risks

For further information, view the article available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767768

Permanent link to this article: https://inheritedcancer.net/post102720/

ICARE Social Media Post October 2020

PTEN: Cancer Risks and Risk Management

Gene: 𝙋𝙏𝙀𝙉 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021: 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 85% – Recommend annual mammogram starting at age 30-35 (or 5-10 years before the earliest known breast cancer in the family); consider breast MRI with contrast starting at age 30-35; consider …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102320/

ICARE Social Media Post October 2020

Three Genetic Variants Identified That May Raise Breast Cancer Risks in Men

For more information, view the article available at: https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaa101/5885091

Permanent link to this article: https://inheritedcancer.net/post102020/

ICARE Social Media Post October 2020

TP53: Cancer Risks and Risk Management

Gene: 𝙏𝙋𝟱𝟯 Syndrome: Li-Fraumeni Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast/Ovarian/Pancreatic Version 1.2021: 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 54% – Recommend clinical breast exam every 6-12 months starting at age 20, annual breast MRI with contrast starting at age 20, and annual mammogram starting at age 30; …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101620/

ICARE Social Media Post October 2020

New ASCO Guidelines On Use Of PARP Inhibitors To Manage Ovarian Cancer

New guidelines for the use of PARP inhibitors to treat ovarian cancer among those with BRCA1 or BRCA2 mutations were published through the American Society of Clinical Oncology (ASCO) to guide providers about the role of this class of drugs in the management of this type of cancer. Link to the guidelines are available at: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101320/

ICARE Social Media Post October 2020

CHEK2: Cancer Risks and Risk Management

Gene: 𝘾𝙃𝙀𝙆2 Cancer Risks and Management per National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Version 1.2020 & Breast/Ovarian/Pancreatic Version 1.2021: 𝗪𝗼𝗺𝗲𝗻: Breast Cancer Risk: Elevated at 28-44% – Recommend annual mammogram starting at age 40 and consider annual breast MRIs with contrast starting at age 40. 𝗠𝗲𝗻 𝗮𝗻𝗱 𝗪𝗼𝗺𝗲𝗻: Colorectal Cancer Risk: Elevated …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100920/

ICARE Featured Video September & October 2020

NCCN Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines

Below you may watch a featured video from the September 2020 and October 2020 Genetics Case Conference, which outlined updates to the National Comprehensive Cancer Network (NCCN) guidelines. Check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/video100820/

ICARE Social Media Post October 2020

Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer

Among BRCA carriers with metastatic breast cancer, the combination of veliparib AND chemotherapy with platinum-based agents (carboplatin) and taxanes (paclitaxel) led to a longer duration of progression free survival (disease that did not progress), compared to those treated with ONLY chemotherapy. To read the full article visit: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30447-2/fulltext [This finding was previously outlined last year …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100620/

ICARE Social Media Post October 2020

ATM: Cancer Risks and Risk Management

Gene: 𝘼𝙏𝙈 Cancer Risks and Management (per NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2021) 𝗪𝗼𝗺𝗲𝗻: Breast cancer risk: Elevated at 30% – Recommend annual mammogram starting at age 40 and consider annual breast MRIs starting at age 40. Ovarian cancer risk: Possibly increased, not well established – Manage based on family history. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100220/

ICARE Publication September 2020

Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation

Abstract Objective: BRCA mutation carriers face a high lifetime risk of developing ovarian cancer. The strong inverse association between breastfeeding and the risk of ovarian cancer is established in the general population but is less well studied among women with a germline BRCA1 or BRCA2 mutation. Method: Thus, we conducted a matched case-control analysis to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub93020/

ICARE Social Media Post September 2020

Living with Lynch 2020 Virtual Patient Workshop

SJoin the Colon Cancer Coalition and AliveAndKickn for the Living with Lynch 2020 Virtual Patient Workshop on𝗙𝗿𝗶𝗱𝗮𝘆, 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟵𝘁𝗵 𝗳𝗿𝗼𝗺 𝟭𝗽𝗺-𝟱𝗽𝗺 𝗘𝗧 to hear unique patient perspectives and the latest information from experts on Lynch syndrome.  Visit https://www.livingwithlynch.org/2020-living-with-lynch to register for this free workshop today! 

Permanent link to this article: https://inheritedcancer.net/post92920/

ICARE Social Media Post September 2020

AACR Cancer Disparities Progress Report 2020

The American Association for Cancer Research (AACR) published a Cancer Disparities Progress Report. “… our limited knowledge of cancer biology in racial and ethnic minorities, including their inherited cancer predisposition and the genomic underpinnings of cancer initiation and progression, diminishes the potential of precision medicine in these populations.” This report discusses relevant information about inherited …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post92520/

ICARE Social Media Post September 2020

FDA Grants Breakthrough Therapy Status to MK-6482 for Treatment of Patients With VHL Disease-Associated Renal Cell Carcinoma

For additional information, please visit: https://www.onclive.com/view/fda-grants-breakthrough-status-to-mk-6482-for-select-vhl-disease-associated-rcc   Also check out the abstract presented at the 2020 ASCO meeting: https://meetinglibrary.asco.org/record/185945/abstract

Permanent link to this article: https://inheritedcancer.net/post92220/

ICARE Social Media Post September 2020

Rucaparib May Have Antitumor Activity in Male BRCA Carriers with Metastatic Prostate Cancer

For further information, view the article available at: https://ascopubs.org/doi/full/10.1200/JCO.20.01035

Permanent link to this article: https://inheritedcancer.net/post91820/

ICARE Social Media Post September 2020

ICARE Summer 2020 Newsletter

The ICARE Summer 2020 Newsletter is now available! Check out this latest edition for recent research and clinical updates as well as a Q&A with a nationally renowned clinical geneticist from Vanderbilt-Ingram Cancer Center.    You can read the newsletter by visiting: https://inheritedcancer.net/wp-content/uploads/ICARE-2020-Summer-Newsletter.pdf    Please feel free to share with family members, friends, and/or your …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91620/

ICARE Social Media Post September 2020

NCCN Genetic Testing Criteria Updates by Cancer

The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to genetic testing criteria by cancer type as follows:   Breast Cancer:  Broadened to include relatives with ALL grades of prostate cancer (not just high-grade) Now having multiple breast cancer diagnoses is NOT dependent on whether the diagnoses were …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91520/

ICARE Social Media Post September 2020

NCCN Breast Cancer Pathology Updates

The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020. Check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post91420/

ICARE Publication September 2020

Strategies to enhance identification of hereditary breast cancer gene carriers

No abstract available Reid S, et al. Strategies to enhance identification of hereditary breast cancer gene carriers. Expert Rev Mol Diagn. 2020 Sep; 20(9):861-865. Epub 2020 Sep 11. PMID: 32856489. 

Permanent link to this article: https://inheritedcancer.net/pub91120/

ICARE Social Media Post September 2020

NCCN Genetic Testing Choice Updates

The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to genetic testing choices and considerations as follows: Choice of multi-gene panel may be guided by genes included, analyses offered, and financial assistance programs available for family testing Significant limitations in interpretations of polygenic risk scores:  NOT recommended for …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91120/

ICARE Social Media Post September 2020

NCCN Breast Cancer Risk Management Updates by Gene

The National Comprehensive Cancer Network (NCCN) released new guidelines on September 8th, 2020, which included updates to breast cancer risk management recommendations by gene as follows:  NBN – high-risk breast screening was removed as there is insufficient evidence to support high cancer risks BARD1 – added consideration for high-risk breast screening starting at age 40  …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91020/

ICARE Featured Video September 2020

Inherited Blood Cancers

Below you may watch a featured video from the September 2020 Genetics Case Conference, which focused on inherited blood cancers with guest expert Sarah Bannon, MS, CGC from the University of Texas MD Anderson Cancer Center.    

Permanent link to this article: https://inheritedcancer.net/video91020/

ICARE Social Media Post September 2020

ACMG Guidelines for Genetic Testing for All Breast Cancer

Check out Vanderbilt’s article about genetic testing considerations at: https://discover.vumc.org/2020/02/genetic-testing-considerations-for-breast-cancer-patients/     Check out the original document from the American College of Medical Genetics and Genomics at: https://www.nature.com/articles/s41436-019-0712-x

Permanent link to this article: https://inheritedcancer.net/post90820/

ICARE Social Media Post September 2020

GREM1 Duplication

The GREM1 gene leads to hereditary mixed polyposis syndrome, characterized by multiple polyps of mixed pathology and high risks for colorectal cancer.   A specific duplication in the 5′ regulatory region of the GREM1 gene has been found in a subset of Ashkenazi Jewish individuals with hereditary mixed polyposis syndrome; therefore, GREM1 genetic testing is …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post90420/

ICARE Social Media Post September 2020

Biallelic Mutations in BRCA1 Cause Fanconi Anemia

BRCA1 is not typically thought to be one of the genes which cause Fanconi anemia. However, rare cases of individuals with biallelic BRCA1 mutations (mutations in both copies of the gene) have been reported. One case involved a woman who had breast cancer at age 23, and was born with multiple birth defects consistent with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post90120/

ICARE Social Media Post August 2020

Older Women with Breast Cancer Have Higher Risks of Ovarian and Other Cancers

Among 4,500 post-menopausal women with breast cancer, 3.55% had a mutation in a gene associated with inherited breast cancer (3-fold higher than what was seen among women who were cancer-free). BRCA1/2 mutations were seen more frequently in women diagnosed with breast cancer at or below age 65 (2.21%) compared to those diagnosed after age 65 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82820/

ICARE Social Media Post August 2020

Pheochromocytoma and Paraganglioma Genetic Testing

More than 40% of patients with pheochromocytoma or paraganglioma, regardless of age and family history, carry an inherited gene mutation. Given that gene mutation carriers may benefit from gene-specific cancer screening, all individuals diagnosed with one of these tumors should seek genetic counseling to discuss genetic testing options. Genes that predispose to pheochromocytoma and paraganglioma …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82520/

ICARE Social Media Post August 2020

Optimal Timing of Prophylactic Gastrectomy for CDH1 Carriers

Individuals with a CDH1 mutation and classic personal and family history of diffuse gastric (stomach) cancer have a very high risk of developing and dying from stomach cancer, if they do not have preventive surgery to remove their stomach. A simulation study to assess prophylactic total gastrectomy (PTG; the removal of the stomach to prevent …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82120/

ICARE Social Media Post August 2020

MRI Surveillance Has Very Low Yield After Bilateral Mastectomy and Reconstruction

A study of 159 women, including BRCA carriers, who had bilateral mastectomy with reconstruction, underwent breast MRI screening. The results showed few women had detection of breast cancer through MRI, after their bilateral mastectomy. These results support the recommendation against screening MRI in women who have had bilateral mastectomy with reconstruction due to a diagnosis …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post81820/

ICARE Newsletter Summer 2020

Treatment Advances Among Those with Neurofibromatosis Type 1

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Neurofibromatosis Type 1 (NF1):  The FDA granted selumetinib (a MEK inhibitor) breakthrough therapy designation for treatment of inoperable plexiform neurofibromas.

Permanent link to this article: https://inheritedcancer.net/8nls2020/

ICARE Newsletter Summer 2020

Treatment Advances Among Those with Lynch Syndrome

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Lynch Syndrome:  Colorectal Cancer: Among patients with MSI-H or MMR-deficient colorectal cancers (frequently seen among those with Lynch syndrome), pembrolizumab …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nls2020/

ICARE Newsletter Summer 2020

Ask the Expert

In each newsletter, we give participants the opportunity to have their questions addressed by experts in the field. This question was addressed by Georgia Wiesner, MD, MS, a nationally renowned clinical cancer geneticist, who is an Ingram Professor of Cancer Research, Professor of Medicine in the Division of Genetic Medicine, and the Director of the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nls2020/

ICARE Newsletter Summer 2020

Identifying Individuals At-Risk for Inherited Cancer

We have known for a while that many people who have mutations in BRCA1/2 and other inherited cancer risk genes are unaware of their mutation as they have not yet had genetic testing. A recent study among women aged 20 or older living in California and Georgia, which included almost 80,000 breast cancer patients and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nls2020/

ICARE Newsletter Summer 2020

Community Spotlight

PTEN is one of the body’s tumor suppressor genes, which controls cell growth. When a PTEN mutation is present, cells may grow uncontrollably, causing tumors to develop that may become cancerous. A patient born with a PTEN mutation is at high risk for developing breast, thyroid, kidney, colon, and endometrial cancer. My PTEN journey began …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnls2020/

ICARE Newsletter Summer 2020

Treatment Advances Among Those with Von-Hippel Lindau (VHL) Disease

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Von-Hippel Lindau (VHL) Disease:  Among patients with VHL-associated clear cell renal cell carcinoma (RCC), a recent study suggested potential benefit …

Continue reading

Permanent link to this article: https://inheritedcancer.net/9nls2020/

ICARE Newsletter Summer 2020

Treatment Advances Among BRCA1/2 Carriers

There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: BRCA1/2 Carriers:  Breast Cancer: For those with later stage or metastatic breast cancer, the FDA currently has approvals for the use …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2020/

ICARE Newsletter Summer 2020

Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines

Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines (Version 1.2020, posted July 21, 2020) For individuals with Lynch Syndrome: Cancer risks were updated based on information from recent studies: Main updates included cancer risks in PMS2 (endometrial, ovarian, and prostate cancer), MSH2 and EPCAM (prostate and brain cancer), and MSH6 (prostate …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2020/

ICARE Newsletter Summer 2020

Guideline-Concordant Care Among Women with Inherited Cancer Gene Mutations

Testing for inherited cancer among breast cancer patients has tremendous potential to guide appropriate care following testing. Yet, a number of efforts suggest that women are not consistently receiving care according to current national guidelines based on their genetic test result. In fact, results from studies suggest many women for whom risk-reducing mastectomy would not …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2020/

ICARE Newsletter Summer 2020

Polygenic Risk Scores and Colon Cancer

A recent study focused on how polygenic risk scores (PRS) may be related to colorectal cancers. Of note, PRS are calculated using genetic differences throughout someone’s DNA, in combination with their clinical and family history of cancer. PRS, alongside environmental and lifestyle risk factors, may help to identify people who may benefit from screening at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2020/

ICARE Social Media Post August 2020

Inherited Prostate Cancer Risk

Over 600,000 men age 40 and older who were part of a family with at least three consecutive generations affected with prostate cancer were studied from the Utah Population Database. Findings from this study showed that: 36,000 had prostate cancer (5.9%) 2,500 had early-onset disease (7%) 4,000 had lethal disease (11.1%) 15,000 had clinically significant …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post81420/

ICARE Social Media Post August 2020

CDC Resource for Free Breast Cancer Screening

We are here to help! Our followers asked us to provide information about screening resources for women with hereditary breast cancer. We would like to make folks aware about a CDC program that provides free breast cancer screening for women who are uninsured and underinsured. ⁣⁣ ⁣⁣ Check out more information at: https://www.cdc.gov/cancer/nbccedp/ ⁣⁣

Permanent link to this article: https://inheritedcancer.net/post81120/

ICARE Social Media Post August 2020

Presymptomatic BRCA1/2 Carriers May Have Better Outcomes

Check out the article at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2768011

Permanent link to this article: https://inheritedcancer.net/post80720/

ICARE Social Media Post August 2020

Disparities in BRCA Counseling Across Diverse Populations

A recently published study based on data from our participants showed that few young Black women with breast cancer see a genetic counselor AND those with insurance are LESS likely to see a genetic counselor. ⁣⁣ ⁣⁣ For more information, check out the full study at: https://www.nature.com/articles/s41436-020-0762-0 

Permanent link to this article: https://inheritedcancer.net/post80420/

ICARE Social Media Post August 2020

Genes That Predispose African American Women to Breast Cancer

A recently published study based on data including our participants identified genes that predispose African American patients to breast cancer.  For more information, check out the full study at: https://academic.oup.com/jnci/article/doi/10.1093/jnci/djaa040/5838706.

Permanent link to this article: https://inheritedcancer.net/post80320/

ICARE Social Media Post July 2020

Cancer Risks in Men with BRCA1 and BRCA2 Pathogenic Variants

Check out the article at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2767423

Permanent link to this article: https://inheritedcancer.net/post73120/

ICARE Social Media Post July 2020

Updates to 2020 NCCN Genetic/Familial Colorectal Guidelines

The National Comprehensive Cancer Network (NCCN) released new guidelines for 2020 on July 21, 2020. The big changes included refining some of the risks for genes involved in Lynch Syndrome, and providing specific guidance about cancer screening that may slightly differ by gene. You can check out the full guidelines by creating a FREE account …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72420/

ICARE Social Media Post July 2020

Racial Inequalities in Genetics

[ngg src=”galleries” ids=”1″ display=”basic_slideshow” arrows=”1″ show_thumbnail_link=”0″]It is important to talk about racial inequalities in healthcare as it affects the care received among Black patients. Through our research efforts, we not only want to address the issue of racism but also think about ways to make healthcare more equitable. A recently published study including our research …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72120/

ICARE Social Media Post July 2020

Breast Cancer Risks May be Higher in Women with Two CHEK2 Mutations Versus One CHEK2 Mutation

A study comparing women with two CHEK2 mutations to one CHEK2 mutation showed that those with two mutations were: -more likely to get breast cancer (80.6% versus 41.2%) -more likely to be diagnosed at or below age 50 (61.3% versus 23.9%) -more likely to have a second breast cancer diagnosis (22.6% versus 8.1%) These findings …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post71720/

ICARE Social Media Post July 2020

Individuals with a First-Degree Relative with Blood Cancer Are at Increased Risk for Blood-Related Cancer

Individuals with a first-degree relative (for example, parent, sibling, or child) with blood cancer, such as lymphoma, have a higher chance of being diagnosed with blood-related cancer (i.e., hematologic malignancy), according to a recent study. The risk to develop certain blood cancers depends on how closely related the relative is (e.g., higher risks for first-degree …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post71420/

ICARE Social Media Post July 2020

BRCA1/2 and Other Gene Carriers with Breast Cancer Don’t Always Receive Recommended Treatment

BRCA1/2 and other gene mutation carriers with early stage breast cancer are not always receiving cancer treatment as recommended by national guidelines. Even though more and more people have been tested for hereditary cancer over the years, using this information accurately to guide treatment has not been as successful. These findings highlight the need for …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post71020/

ICARE Featured Video July 2020

BAP1

Below you may watch a featured video from the July 2020 Genetics Case Conference, which focused on BAP1 with guest expert Dr. Mohamed Abdel-Rahman from The Ohio State University.     To learn more about the BAP1 study, please click here. To refer your patients to the BAP1 study, please contact The Ohio State University BAP1 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/video70920/

ICARE Publication July 2020

Update on multi-gene panel testing and communication of genetic test results

Abstract With technological advances, multi-gene panel testing has become increasingly used to identify patients at risk for hereditary breast cancer (HBC). There are currently evidence-based interventions and breast cancer screening strategies that exist for cancer prevention and early detection among patients with HBC. Moreover, in addition to the personal impact of identifying HBC, this information …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub70820/

ICARE Social Media Post July 2020

Pancreatic Cancer Can Run in Families

Individuals with a family history of pancreatic cancer have a higher risk to develop pancreatic cancer. A recent study reported the following pancreatic cancer risks compared to the general population, based on relationship to an individual with pancreatic cancer: First-degree relative (e.g., parent, sibling, child) – 1.76 fold higher Second-degree relative (e.g., aunts, uncles, grandparents) …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post70720/

ICARE Social Media Post July 2020

Community Spotlight: Mari-Lynn Slayton

In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Winter 2016 ICARE Newsletter is Mari-Lynn Slayton, who was found to have a PALB2 mutation after two breast cancer diagnoses. Check out her story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post70220/

ICARE Publication July 2020

A Web-Based Tool to Automate Portions of Pretest Genetic Counseling for Inherited Cancer

Abstract Background: Increasing demand for genetic testing for inherited cancer risk coupled with a shortage of providers trained in genetics highlight the potential for automated tools embedded in the clinic process to meet this demand. We developed and tested a scalable, easy-to-use, 12-minute web-based educational tool that included standard pretest genetic counseling elements related to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub70120/

ICARE Social Media Post June 2020

Advances in Treatment for Colorectal Cancer

On June 29, 2020, the FDA approved the use of Keytruda (pembrolizumab), as first-line treatment in unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer. Among people with Lynch syndrome, the risk for colorectal cancer (which often has microsatellite instability and/or mismatch-repair deficiency) is raised. Keytruda (pembrolizumab) showed to double the progression-free …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post63020/

ICARE Social Media Post June 2020

Higher Chance of VUS Results in Minorities

Asian, Hispanic, and Black women with breast cancer had higher rates of variants of uncertain significance (VUS) on genetic test results for hereditary cancer genes compared to White women with breast cancer according to a recent study. Check out the full article at https://link.springer.com/article/10.1007%2Fs13187-019-01646-8

Permanent link to this article: https://inheritedcancer.net/post62620/

ICARE Social Media Post June 2020

Community Spotlight: Kelly Frank

June is cancer survivor month! In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Winter 2019 ICARE Newsletter is Kelly Frank, who was found to have a BRIP1 mutation after an ovarian cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post62320/

ICARE Social Media Post June 2020

Advances in Treatment for BRCA-Mutated Triple Negative Breast Cancer

In a study of 914 women with different breast cancer subtypes, overall pathologic complete response rates were: Higher in those with BRCA1/2 mutations (60.4% versus 46.7%) No differences were seen in those with mutations in other inherited cancer genes Among patients with triple-negative breast cancer, BRCA1/2 mutations had highest response rates to treatment in both …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post61920/

ICARE Social Media Post June 2020

Community Spotlight: Patricia Blumenthal

In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our community spotlight in our Summer 2018 ICARE Newsletter is Patricia Blumenthal, who was found to have a BRCA2 mutation. Check out her story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post61620/

ICARE Social Media Post June 2020

Advances in BRCA1/2 Breast Cancer Treatment

Through a randomized phase 2 study (called the INFORM trial) among BRCA1/2 carriers with breast cancer, cisplatin was no better in inducing pathologic complete remission compared to AC. The pathologic complete remission rate was 18% for cisplatin and 26% for AC. Cisplatin is not better than other chemotherapy for induction therapy for breast cancers in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post61220/

ICARE Social Media Post June 2020

Community Spotlight: Christy Mattey

In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our latest community spotlight in our Winter 2017 ICARE Newsletter is Christy Mattey, who was found to have a CHEK2 mutation after a breast cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post60920/

ICARE Social Media Post June 2020

Advances in Treatment for Pancreatic Cancer: Cisplatin + Gemcitabine

In BRCA1/2 or PALB2 carriers with stage 3 or 4 pancreatic cancer, the combination of cisplatin + gemtricitabine with veliparib (a PARP inhibitor), did NOT seem to provide additional benefit over cisplatin + gemtricitabine alone. Through this phase 2 randomized control trial, response rates in both treatment arms were high with similar overall survival rates. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60520/

ICARE Social Media Post June 2020

Community Spotlight: Terry Arnold

June is Cancer Survivor Month! In every ICARE Newsletter we feature an ICARE participant as a community spotlight. Our latest community spotlight in our Summer 2017 ICARE Newsletter is Terry Arnold, who was found to have a BRCA1 mutation after a breast cancer diagnosis. Check out her story at: https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post60220/

ICARE Social Media Post May 2020

Platinum Based Chemotherapy for Metastatic Pancreatic Cancer

A recent study found that patients with metastatic pancreatic cancer who had mutations in the DNA repair genes (either inherited or just in the tumor) had better clinical outcomes after platinum-based chemotherapy compared to patients without these mutations. Check out the link to full article: https://clincancerres.aacrjournals.org/content/early/2020/05/20/1078-0432.CCR-20-0418

Permanent link to this article: https://inheritedcancer.net/post52920/

ICARE Social Media Post May 2020

Cancer Risk Management Among Female BRCA1/2, PALB2, CHEK2, and ATM Carriers in ICARE

A new article was recently published based on data from BRCA1/2, PALB2, CHEK2, and ATM carriers in ICARE. Findings suggest potential overtreatment through risk-reducing surgery among women with pathogenic/likely pathogenic variants in breast cancer genes. This highlights the importance of promoting guideline-adherent, risk-appropriate care. Check out the full article at https://rdcu.be/b4mbg

Permanent link to this article: https://inheritedcancer.net/post52620/

ICARE Social Media Post May 2020

Advances in Treatment for Metastatic Prostate Cancer: Olaparib

On May 19, 2020 the FDA approved the use of olaparib (Lynparza) as treatment in BRCA and other gene carriers (homologous recombination repair genes) with metastatic castration-resistant prostate cancer who have been treated with enzalutamide or abiraterone. Link to full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer

Permanent link to this article: https://inheritedcancer.net/post52220/

ICARE Publication May 2020

Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers

Abstract Purpose: Identification of inherited breast cancer may guide cancer risk management. We sought to compare risk management practices across women with inherited breast cancer genes. Methods: Females with a pathogenic/likely pathogenic (P/LP) variant in BRCA1/2, PALB2, CHEK2, and/or ATM were surveyed about cancer risk management. Comparisons were made across genes. Results: The 235 participants with P/LP variants …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub52220/

ICARE Social Media Post May 2020

Advances in Treatment for Metastatic Prostate Cancer: Rucaparib

On May 15, 2020 the FDA approved the use of rucaparib (Rubraca) as treatment in BRCA carriers with metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Link to full article: https://www.fda.gov/drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate

Permanent link to this article: https://inheritedcancer.net/post51920/

ICARE Social Media Post May 2020

MRI May Detect Breast Cancer Earlier than Mammograms

The National Comprehensive Cancer Network (NCCN) currently recommends an annual breast MRI and an annual mammography for high-risk women (lifetime breast cancer risk at or above 20%). Among women at high risk for breast cancer, MRI detected breast cancer at an earlier stage than mammograms. Women with BRCA1/2 and TP53 were NOT included in this …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51520/

ICARE Featured Video May 2020

Variant Classification

Below you may watch a featured video from the May 2020 Genetics Case Conference, which focused on deciphering variant reports and classification with guest expert Dr. Rebecca Smith from Vanderbilt University Medical Center.    

Permanent link to this article: https://inheritedcancer.net/video51420/

ICARE Social Media Post May 2020

Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib & bevacizumab

On May 8, 2020 the FDA approved the use of olaparib (Lynparza) as first-line maintenance treatment in BRCA1/2 carriers (deleterious or suspected deleterious mutations) and/or a genomic instability, with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Link to full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary

Permanent link to this article: https://inheritedcancer.net/post51220/

ICARE Publication May 2020

Patterns and covariates of benefit finding in young Black breast cancer survivors: A longitudinal, observational study

Abstract Objective: To examine the patterns and covariates of benefit finding over time among young Black breast cancer (BC) survivors. Methods: Black women (N = 305) with invasive BC diagnosed ≤50 years were recruited an average of 1.9 years post-BC diagnosis. Participants completed self-report questionnaires of benefit finding, social support, and illness intrusions at three …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub51120/

ICARE Social Media Post May 2020

Advances in Ovarian Cancer Treatment for BRCA1/2 Carriers: Olaparib

In recognition of World Ovarian Cancer Day, we’d like to share some exciting results from a study of women with ovarian cancer and a BRCA mutation: In a recent phase III trial, olaparib (PARP inhibitor) showed improved response and progression-free survival compared with chemotherapy (without platinum) in BRCA carriers with platinum-sensitive relapsed ovarian cancer who …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post50820/

ICARE Social Media Post May 2020

Advances in Treatment for Metastatic Prostate Cancer: Olaparib

Findings from a recent study showed that olaparib (PARP inhibitor) significantly improved progression-free survival in patients with BRCA1, BRCA2, or ATM genetic alterations. Benefits were also more broadly seen among patients with homologous recombination repair gene defects. Link to full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1911440 Check out the ASCO post article at: https://www.ascopost.com/news/may-2020/olaparib-for-patients-with-mcrpc-and-homologous-recombination-repair-gene-alterations/

Permanent link to this article: https://inheritedcancer.net/post50620/

ICARE Social Media Post May 2020

CDH1: Gastric and Breast Cancer Risks

CDH1 mutation carriers are at higher risk for diffuse gastric cancer (men and women) and lobular breast cancer (women). Current strategies to manage high risks of gastric cancer include prophylactic gastrectomy (i.e., removal of the stomach), which can have severe physical and psychological implications. A recent study found that men have a higher risk of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post50520/

ICARE Social Media Post May 2020

New Blood Test May Find Ovarian Cancer Early

A study of 80 women identified 4 proteins in blood that may help to detect ovarian cancer early. Further research is still needed with larger groups of women to determine if this new blood test would be a reliable test to find ovarian cancer early. Check out the full article at https://www.nature.com/articles/s41416-019-0544-0

Permanent link to this article: https://inheritedcancer.net/post50120/

ICARE Social Media Post April 2020

Advances in Treatment for Ovarian Cancer in BRCA1/2 Carriers: Niraparib

On April 29, 2020 the FDA approved the use of niraparib (Zeluja) as first-line maintenance treatment in BRCA1/2 carriers with advanced ovarian cancer! More details available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer

Permanent link to this article: https://inheritedcancer.net/post42920/

ICARE Social Media Post April 2020

PALB2: Cancer Risks and Risk Management

Gene: PALB2 Cancer Risks and Management (per NCCN version 1.2020): Women: Breast cancer risk: Elevated at 53% – Recommend annual breast MRI with contrast starting at age 30, and annual mammogram with consideration of tomosynthesis starting at age 30; Consider risk-reducing mastectomy. Ovarian cancer risk: Elevated at 5% – Manage based on family history. Men …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42820/

ICARE Publication April 2020

Acceptability and outcomes of multigene panel testing among young Black breast cancer survivors

No abstract available Conley C, et al. Acceptability and outcomes of multigene panel testing among young Black breast cancer survivors. Breast J. 2020 Oct;26(10):2112-2114. Epub 2020 Apr 22. PMID: 32319712.

Permanent link to this article: https://inheritedcancer.net/pub42220/

ICARE Social Media Post April 2020

BRCA2: Cancer Risks and Risk Management

Gene: BRCA2 Cancer Risks and Management (per NCCN version 3.2019): Women: Breast cancer risk: Elevated at 60%-70% – Recommend clinical breast exam every 6-12 months starting at age 25, annual breast MRI with contrast starting at age 25, and annual mammogram with consideration of tomosynthesis starting at age 30; consider risk-reducing mastectomy. Ovarian cancer risk: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42120/

ICARE Social Media Post April 2020

ASCO Guideline: Genetic Testing for Ovarian Cancer

The American Society of Clinical Oncology (ASCO) recently published a guideline reinforcing the longstanding recommendation that all women diagnosed with epithelial ovarian cancer (EOC) be offered genetic testing for hereditary ovarian cancer genes. Many of these women (>15%) have an inherited mutation, most commonly BRCA1 or BRCA2. Identifying BRCA1/2 mutations may help guide cancer treatment. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post41720/

ICARE Social Media Post April 2020

BRCA1: Cancer Risks and Risk Management

Gene: BRCA1 Cancer Risks and Management (per NCCN version 3.2019): Women: Breast cancer risk: Elevated at 60%-70% – Recommend clinical breast exam every 6-12 months starting at age 25, annual breast MRI with contrast starting at age 25, and annual mammogram with consideration of tomosynthesis starting at age 30; consider risk-reducing mastectomy. Ovarian cancer risk: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post41420/

ICARE Social Media Post April 2020

Treatment Patterns in Women with Inherited Breast Cancer

Results from a population-based study of over 20,000 women from SEER registries of Georgia and California diagnosed with stage 0 to stage III breast cancer between 2014 and 2016 tested for inherited breast cancer were recently published. Findings suggest that women who test positive for certain mutations receive certain patterns of treatment. These patterns of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post41020/

ICARE Social Media Post April 2020

EPCAM: Cancer Risks and Risk Management

Gene: EPCAM Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 21%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 10%-38% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Men and Women: Colorectal cancer risk: Elevated at 43%-52% – Recommend colonoscopy every 1-2 years starting at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post4120/

ICARE Social Media Post March 2020

Cancer Treatment in Childhood and Treatment-Associated Polyposis

Treatment-associated polyposis (TAP) should be considered in patients who develop many colon polyps after treatment for a childhood or young adulthood cancer but do not have an identified mutation in a hereditary cancer gene. A recent study reported that 35% of patients with TAP developed over 50 colorectal polyps, and 94% had multiple types of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32720/

ICARE Social Media Post March 2020

PMS2: Cancer Risks and Risk Management

Gene: PMS2 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 0%-15% – Consider risk-reducing hysterectomy. Men and Women: Colorectal cancer risk: Elevated at 12%-20% – Recommend colonoscopy every 1-2 years starting at age 20-25 Gastric cancer risk: Not well established – Consider upper endoscopy every 3-5 years beginning at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32420/

ICARE Social Media Post March 2020

Study Based on ICARE Participants with ATM and CHEK2 Mutations

Women with ATM and CHEK2 mutations have a lifetime breast cancer risk greater than 20%, which is the threshold at which screening through a breast MRI is recommended. A recently published study based on ICARE participants with ATM and CHEK2 mutations suggested that most female family members of ATM and CHEK2 mutation carriers do not …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32020/

ICARE Social Media Post March 2020

MSH6: Cancer Risks and Risk Management

Gene: MSH6 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: 17%-46% – Consider risk-reducing hysterectomy. Ovarian cancer risk: 1%-11% – Evidence is insufficient to make specific recommendations. Men and Women: Colorectal cancer risk: 15%-44% – Recommend colonoscopy every 1-2 years starting at age 20-25. Gastric cancer risk: 0%-5% – Consider upper …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31720/

ICARE Social Media Post March 2020

Polygenic Risk Score and Colon Cancer Risk

A Polygenic Risk Score (PRS) is calculated using genetic differences throughout someone’s DNA, in combination with clinical and family history of cancer. This score, alongside environmental and lifestyle risk factors, may help to identify people who might benefit from screening at an earlier age. Important facts about PRS: – It does NOT look for changes …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31320/

ICARE Social Media Post March 2020

MSH2: Cancer Risks and Risk Management

Gene: MSH2 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 21%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 10%-38% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Men and Women: Colorectal cancer risk: Elevated at 43%-52% – Recommend colonoscopy every 1-2 years starting at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31020/

ICARE Social Media Post March 2020

Colon Cancer and Polyp Risks

New colon cancer and polyposis genes recently identified include NTHL1, POLE, POLD1, MSH3, and RNF43. Previous studies suggest these genes raise the risk for colon cancer and polyposis; however, recent data suggest that environmental factors may also play an important role in risk. Ultimately, these genes account for a very small fraction of polyposis cases. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post3620/

ICARE Social Media Post March 2020

MLH1: Cancer Risks and Risk Management

Gene: MLH1 Cancer Risks and Management (per NCCN version 3.2019): Women: Endometrial cancer risk: Elevated at 43%-57% – Consider risk-reducing hysterectomy. Ovarian cancer risk: Elevated at 5%-20% – Recommend risk-reducing bilateral salpingo-oophorectomy (removal of ovaries and fallopian tubes). Breast cancer risk: Elevated at 12%-17% – Manage same as general population. Men and Women: Colorectal cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post3320/

ICARE Social Media Post February 2020

Advances in Treatment: Plexiform Neurofibromas in NF1

The FDA has granted a breakthrough therapy designation to selumetinib, a MEK inhibitor, for treatment of inoperable plexiform neurofibromas. These types of neurofibromas are almost exclusively seen in individuals with neurofibromatosis type 1 (NF1). These plexiform neurofibromas are benign tumors on the nerve sheaths and can develop anywhere in the body. These tumors typically cause …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post22820/

ICARE Social Media Post February 2020

Genetic Testing in Tumors versus Genetic Testing for Cancer Risk

There are different types of genetic/DNA tests offered to patients with cancer: 1) Tumor tests, mainly done to guide cancer treatment. 2) Blood or saliva tests (on normal DNA that individual was born with) to identify inherited cancer predisposition, which may also guide cancer treatment in some instances. Genetic testing of the tumor detects mutations …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post22620/

ICARE Newsletter Winter 2020

Community Spotlight

I was diagnosed with breast cancer in December 2018 and was found to be PALB2+. The PALB2 gene had not been tested for when my older sister was diagnosed with breast cancer and had genetic testing done four years earlier. This was new! My cancer was very similar to my sister’s, but being PALB2+ changed …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnlw2020/

ICARE Newsletter Winter 2020

Treatment Advances Among Those with Inherited Prostate Cancer Predisposition

A recent study reported a high complete response rate among men with a BRCA1/2 mutation with metastatic, castration-resistant prostate cancer who were treated with niraparib (a PARP inhibitor) of 63% compared to 17% in the non-BRCA1/2 group.1 Based on this data, the Federal Drug Administration (FDA) granted breakthrough therapy designation to niraparib on October 3, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2020/

ICARE Newsletter Winter 2020

New Study Based on ICARE Participants with ATM & CHEK2 Mutations

We are excited to tell you about our recently published results based solely on data from ICARE participants with ATM and CHEK2 mutations. Our findings suggest most female family members of ATM and CHEK2 mutation carriers do not qualify for breast MRI screening based on family cancer history alone. This emphasizes the need to share …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-winter-2020new-study-based-on-icare-participants-with-atm-chek2-mutations/

ICARE Newsletter Winter 2020

Treatment Advances Among Those with Inherited Pancreatic Cancer Predisposition

Results from a recent study showed olaparib (a PARP inhibitor) nearly doubled the progression-free survival in BRCA1/2 carriers with metastatic pancreatic cancer.1 Based on this data, the FDA approved the use of olaparib as a first-line maintenance treatment in BRCA1/2 carriers with metastatic, platinum-sensitive pancreatic cancer. This represents another treatment advance in pancreatic cancer and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2020/

ICARE Newsletter Winter 2020

PALB2 Mutations & Cancer Risk

A newly published study of 524 families with pathogenic PALB2 mutations from around the world, including almost 50 ICARE participants, represents the largest, most comprehensive effort to evaluate cancer risks.1 Results showed increased risks for female breast cancer (53%), ovarian cancer (5%), pancreatic cancer (2-3%), and male breast cancer (1%). Findings did not suggest higher …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nlw2020/

ICARE Newsletter Winter 2020

Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

There were significant updates and restructuring of the guidelines, with some highlights included below: Substantial reorganization of the guidelines as follows: Now organized by organ site, rather than primarily by certain high penetrance genes Focused efforts to simplify genetic testing criteria Only one flow diagram included, to outline the ‘genetic testing process’ Following scenarios now …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2020/

ICARE Newsletter Winter 2020

Updated Pancreatic Cancer Screening Guidelines through CAPS Consortium

The International Cancer of the Pancreas Screening (CAPS) Consortium recently published updated recommendations about pancreatic cancer screening through MRI/magnetic retrograde cholangiopancreatography (MRCP) and/or an endoscopic ultrasound (EUS).1 Specifically, these guidelines now recommend that individuals with a CDKN2A or STK11 mutation begin screening at age 40. Screening for individuals with a BRCA1/2, ATM, PALB2, MLH1, or …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nlw2020/

ICARE Newsletter Winter 2020

Ask the Expert

Through each newsletter, we give our participants an opportunity to have their questions answered by experts. If you have a question you would like addressed, please email the study team at ICARE@InheritedCancer.net for consideration in future newsletters. The following question was addressed by Ben Ho Park, MD, PhD, who is the Donna S. Hall Chair …

Continue reading

Permanent link to this article: https://inheritedcancer.net/8nlw2020/

ICARE Newsletter Winter 2020

Lynch Syndrome Cancer Risks Across Genes

A worldwide study reporting on cancer risks among individuals with mutations in Lynch syndrome genes showed that there are substantial differences in cancer risks across the various genes.1 Specifically, the risk for colorectal cancer in those with  MLH1, MSH2, and MSH6 mutations was substantially higher than what was seen for those with PMS2 mutations. Additionally, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nlw2020/

ICARE Social Media Post February 2020

PMS2 and MSH6 Colorectal Cancer Risks

Individuals with Lynch syndrome have an increased risk of colorectal cancer (CRC) and other cancers. The level of CRC risk is different based on which gene they have a mutation in. Of note, MLH1 and MSH2 carriers have the highest risk of colorectal cancer, generally in the range of 43%-52% by age 70. A recent …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post22020/

ICARE Social Media Post February 2020

Ovarian Cancer Risks in BRCA1/2

The risk of ovarian cancer is raised in women with BRCA1/2 mutations. Recent findings suggest that higher body mass index (BMI) may further raise the risk of ovarian cancer in premenopausal BRCA1/2 carriers. Note that all women with BRCA1/2 mutations are at high risk for ovarian cancer, and should follow current National Comprehensive Cancer Network …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21820/

ICARE Publication February 2020

Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors

Abstract Purpose: All women diagnosed with breast cancer (BC) ≤age 50 should be referred for genetic counseling (GC) and testing. We sought to compare differences in provider practices and access across a racially and ethnically diverse population of young BC survivors. Methods: A registry-based sample of women diagnosed with invasive BC ≤age 50 from 2009 to 2012 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub21820/

ICARE Social Media Post February 2020

Characteristics and Patterns of Spread for BRCA-associated Breast Cancers

BRCA1/2 have distinct characteristics and patterns of spread. A recent study evaluated the characteristics of BRCA1/2 carriers and found that 73% ofBRCA1-associated breast cancers were triple negative; and 72% of BRCA2-associated breast cancers were hormone receptor positive. There were also distinct pattern of spread of breast cancer, with BRCA1 carriers more likely to experience lung …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21320/

ICARE Social Media Post February 2020

Medication Use for Risk Reduction

Based on studies that show benefits of estrogen and androgen blockers in reducing breast cancer risk in high-risk women, the United States Preventative Service Task Force (USPSTF) recommends that clinicians offer risk-reducing medications to women at increased risk for breast cancer; however, they recommend against routine use of these medications in average-risk women. Hormone receptor …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21120/

ICARE Social Media Post February 2020

Lynch Syndrome Cancer Risks Across Genes

A worldwide study suggests that risks for cancers for the various Lynch syndrome genes have some differences. The risk of colorectal cancer for those with a mutation in the MLH1, MSH2 and MSH6 genes is higher than what is seen for carriers of a PMS2 mutation. Additionally, men with MSH2 gene mutations have a higher …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post2720/

ICARE Social Media Post February 2020

Differences in Pancreatic Cancer Screening Recommendations from the National Comprehensive Cancer Network (NCCN) and the International Cancer of the Pancreas Screening (CAPS) Consortium

The National Comprehensive Cancer Network (NCCN) and the International Cancer of the Pancreas Screening (CAPS) Consortium recently updated pancreatic cancer screening recommendations. However, there are some differences between these recommendations. Specifically, screening with annual MRI/magnetic retrograde cholangiopancreatography (MRCP) and/or endoscopic ultrasound (EUS) is recommended as follows for NCCN versus CAPS: STK11 regardless of family history: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post2620/

ICARE Social Media Post February 2020

Updated Pancreatic Cancer Screening Guidelines through the International Cancer of the Pancreas Screening (CAPS) Consortium

The International Cancer of the Pancreas Screening (CAPS) Consortium recently published updated pancreatic cancer screening recommendations. The recommendations include: Screening with MRI/magnetic retrograde cholangiopancreaography (MRCP) and/or endoscopic ultrasound (EUS) The screening was recommended for the following individuals: CDKN2A and STK11 mutation carriers starting at age 40 BRCA1/2, ATM, PALB2, MLH1, and MSH2 mutation carriers (if …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post2420/

ICARE Social Media Post January 2020

Advances in Treatment for Lynch Syndrome-Related Endometrial Cancer

A recent phase II study showed increased response to an immunotherapy drug (avelumab), in women with endometrial cancer with mismatch repair deficiency. Among women with Lynch Syndrome, the risk for endometrial cancer (which often has mismatch repair deficiency) is raised. This new study shows promising treatment options for women with endometrial cancer and Lynch syndrome …

Continue reading

Permanent link to this article: https://inheritedcancer.net/13020/

ICARE Social Media Post January 2020

New Gene: DUOX2

DUOX2 represents a newly identified gene that might predispose patients to thyroid cancer (specifically, ‘non-medullary’ thyroid cancer). The specific gene change (or ‘mutation’) that leads to thyroid cancer predisposition is known as Y1203H Additional studies are needed to confirm this association. Check it out at ASCO Post: https://tinyurl.com/sw3ew63 𝐨𝐫 you can access the article at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12420/

ICARE Publication January 2020

Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers

Abstract Background: With the increasing use of multigene panel tests, pathogenic and likely pathogenic (P/LP) variants are identified more frequently in the moderate-penetrance breast cancer genes ATM and CHEK2. Lifetime breast cancer risk among women with P/LP variants in these genes generally exceeds 20%, meeting the threshold at which high-risk breast cancer screening through breast magnetic …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub12220/

ICARE Social Media Post January 2020

New Gene: RABL3

About 10% of pancreatic cancers are thought to be the result of an inherited mutation. All of the genes that predispose patients to pancreatic cancers have not yet been discovered. Recently, a new gene known as RABL3 was linked to pancreatic cancer. This gene may increase the risk of hereditary pancreatic cancer. Additional studies are …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12120/

ICARE Social Media Post January 2020

Ovarian Cancer Screening in BRCA1 Carriers

A new study of Polish BRCA1 carriers showed that screening through transvaginal ultrasound was not effective or  reliable in detecting ovarian cancer early. Consequently, preventive oophorectomy remains the only proven method to lower ovarian cancer risks and increase survival. Check out the article at: https://www.ncbi.nlm.nih.gov/pubmed/31500890. Check out the NCCN ovarian cancer screening recommendations for BRCA1 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11720/

ICARE Social Media Post January 2020

Racial Disparities in Genetic Testing for Women with Ovarian Cancer

Women of non-European ancestry diagnosed with ovarian cancer have lower rates of referral for genetic testing despite current national guidelines stating ALL women with ovarian cancer and/or a close-blood relative with ovarian cancer should be offered genetic counseling and testing. One study reported that only 1/3 of Black, Latina, and Asian women were referred for …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11620/

ICARE Social Media Post January 2020

Polygenic Risk Scores

A Polygenic Risk Score (PRS) is calculated using genetic differences throughout someone’s DNA, in combination with clinical and family history of cancer. This unique type of score may be utilized to calculate the lifetime risk of breast cancer. Important facts about PRS’s: Different from BRCA1/2 testing, which look for changes in these specific genes Should …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11420/

ICARE Social Media Post January 2020

Women with BRCA1/2: Risk-reducing Mastectomy versus Screening

In a study of 5000 healthy female BRCA1/2 carriers (without a breast cancer diagnosis): BRCA1 carriers: after an average of over 10 years follow-up, survival was higher in those who had bilateral mastectomy (99.7%) compared to those who had breast screening through mammograms and breast MRIs (93%). BRCA2 carriers: no significant differences were seen between …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11020/

ICARE Featured Video January 2020

PALB2

Below you may watch a featured video from the January 2020 Genetics Case Conference, which focused on PALB2 gene mutations with guest expert Dr. Marc Tischkowitz from the University of Cambridge.    

Permanent link to this article: https://inheritedcancer.net/video10920/

ICARE Social Media Post January 2020

Celebrating 10 Years of ICARE

  Happy New Year! 2020 represents a decade for ICARE We are celebrating 10 years of research, education, and engagement, through which we have enrolled nearly 3500 participants, including over 2000 gene mutation carriers, disseminated 15 newsletters, led and collaborated on multiple research projects, and impacted individuals affected by inherited cancer predisposition all over the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post1920/

ICARE Publication January 2020

The big reveal: Family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer

Abstract Despite higher incidence and mortality of breast cancer among younger Black women, genetic testing outcomes remain severely understudied among Blacks. Past research on disclosure of genetic testing results to family members has disproportionately focused on White, educated, high socioeconomic status women. This study addresses this gap in knowledge by assessing (a) to whom Black …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub10720/

ICARE Social Media Post January 2020

Advances in Treatment for Pancreatic Cancer in BRCA Carriers

The FDA approved the use of olaparib, a PARP inhibitor, as first-line maintenance treatment in BRCA1/2 carriers with metastatic, platinum-sensitive, pancreatic cancer. Platinum-sensitive cancer is a cancer that responds to treatment with drugs that contain the metal platinum, such as carboplatin or cisplatin. Olaparib showed to nearly double the progression-free survival in BRCA1/2 carriers with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post1320/

ICARE Social Media Post December 2019

Evaluation of PARP Inhibitors in BRCA-Associated Prostate Cancer

The FDA granted breakthrough therapy designation to niraparib (a PARP inhibitor) for the treatment of men with BRCA1/2 positive, metastatic castration-resistant, and heavily pre-treated prostate cancer. Results from a recent study show a 63% complete response rate in men with BRCA1/2 positive, metastatic castration-resistant prostate cancer treated with niraparib compared to 17% in the non- …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post122019/

ICARE Social Media Post December 2019

PALB2 Mutations and Cancer Risk

A new published study of 524 families with PALB2 mutations, including our very own ICARE participants, from around the world showed increased risks of female breast, ovarian, pancreatic, and male breast cancer. The level of risk for female breast cancer is enough to recommend cancer risk management. Cancer risk management includes screening or risk-reducing surgery. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post121619/

ICARE Publication December 2019

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

Abstract Purpose: To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized. Methods: We analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub121619/

ICARE Social Media Post December 2019

American College of Medical Genetics and Genomics: Points-to-Consider Document: “Is there Evidence to Support BRCA1/2 and Other Inherited Breast Cancer Genetic Testing for all Breast Cancer Patients?”

                    The American College of Medical Genetics and Genomics (ACMG) put forth a Points-to-Consider document: “Is there Evidence to Support BRCA1/2 and Other Inherited Breast Cancer Genetic Testing for all Breast Cancer Patients?” The document discusses: 1) Current data to support testing in breast cancer patients …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post121319/

ICARE Publication December 2019

Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG)

No abstract available Pal T, et al. Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020 Apr;22(4):681-685. Epub 2019 Dec 13. PMID: 33455826.

Permanent link to this article: https://inheritedcancer.net/pub121319/

ICARE Featured Video December 2019

NCCN Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines

Below you may watch a featured video from the December 2019 Genetics Case Conference, which outlined updates to the National Comprehensive Cancer Network (NCCN) guidelines.  

Permanent link to this article: https://inheritedcancer.net/video121219/

ICARE Social Media Post December 2019

Patient Reported Outcomes In A Study of PARP Inhibitors in BRCA Carriers with Metastatic Breast Cancer

Did you know? PROs are impacting treatment advances in metastatic breast cancer. Olaparib increased progression-free survival among BRCA carriers with metastatic HER2- breast cancer. Thanks to patient reported outcomes, a new study now suggests it also improved patients’ quality of life! Check it out the new article published in October 2019 directly at https://www.ncbi.nlm.nih.gov/pubmed/31446213!

Permanent link to this article: https://inheritedcancer.net/post12819/

ICARE Social Media Post December 2019

Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial Breast, Ovarian, and Pancreatic Guidelines (V1.2020)

We are excited to share the latest version of the NCCN Genetic/Familial Breast, Ovarian and Pancreatic Guidelines (V1.2020), which were just updated. Some of the changes made include: PALB2 was added as a high penetrance gene (similar to BRCA1, BRCA2, CDH1, PTEN and TP53) It is appropriate to consider risk reducing mastectomy for cancer risk management …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12419/

ICARE Social Media Post December 2019

Explaining Patient Reported Outcomes

The National Quality Forum defines patient reported outcomes (PROs) as “any report of the status of a patient’s health condition that comes directly from the patient.” PROs have the potential to increase overall outcomes and care process and enhance patient and family centered care.

Permanent link to this article: https://inheritedcancer.net/post12319/

ICARE Publication November 2019

Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer

Abstract Purpose: Prognostic value of Oncotype DX Breast Recurrence Score (RS) in male patients with breast cancer is understudied. We evaluated associations of RS with overall mortality in male patients with breast cancer and compared it with female counterparts. Experimental design: With a cohort of 848 male and 110,898 female patients with breast cancer identified from the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub112019/

ICARE Featured Video November 2019

Polygenic Risk Scores

Below you may watch a featured video from the November 2019 Genetics Case Conference, which focused on Polygenic Risk Scores with guest expert Dr. Amanda Toland from The Ohio State University.    

Permanent link to this article: https://inheritedcancer.net/video111419/

ICARE Social Media Post November 2019

Educational Resources: The Family Link Between Breast and Ovarian Cancer in Black Women

The differences seen in access to healthcare across different racial groups are known as health disparities. To address the gap in awareness, we have pursued efforts to raise awareness about inherited breast cancer among African Americans. We are excited to introduce you to another invaluable resource, the Breast Cancer Genetics Research and Education for African American …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11119/

ICARE Social Media Post November 2019

High Frequency of BRCA in Unselected Women with Metastatic Breast Cancer

Did you know? National practice guidelines currently recommend ALL women with metastatic (HER2-) breast cancer to get genetic testing for inherited cancer (including BRCA1/2 testing), because it can guide eligibility for treatment with PARP inhibitors. A new study led by our colleague at the Vanderbilt-Ingram Cancer Center, Dr. Ben Park, suggests that more women with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110719/

ICARE Publication November 2019

Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study

Abstract Background: Black women are overrepresented among premenopausal breast cancer (BC) survivors. These patients warrant genetic testing (GT) followed by risk-reducing behaviors. This study documented patterns and predictors of cancer risk-management behaviors among young black BC survivors after GT. Methods: Black women (n = 143) with a diagnosis of BC at the age of 50 years or …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub110119/

ICARE Social Media Post October 2019

Lifestyle Factors Associated with Familial and Inherited Breast Cancer Risks

Body mass index (BMI) is an indicator of fat content in the body. A lower body mass index may reduce breast cancer risk in women, including those with a family history of breast cancer. However, a new study reported that higher BMI also increases breast cancer risk in the general population and those with a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102919/

ICARE Social Media Post October 2019

Physical Activity Associated with Familial and Inherited Breast Cancer Risks

BRCA1/2 carriers may benefit from physical activity to reduce breast cancer risks, just like women in the general population! We know that women in the general population benefit from physical activity to reduce their breast cancer risk, but a recent study showed that this benefit also extends to those with a BRCA1/2 mutation and those with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102819/

ICARE Social Media Post October 2019

BRCA Testing In Black Women

Did you know? Although BRCA testing has been around for over TWO decades, not all populations have benefitted equally from testing. In fact, our previous research has shown that black patients are less aware of BUT interested in genetic testing…when they know about it. In addition, healthcare providers are less likely to identify and suggest …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102419/

ICARE Social Media Post October 2019

Inherited Breast Cancer Among Latina Women

Latina women are at risk for inherited breast cancer: Breast cancer mortality rates are higher among Latina women compared to non-Hispanic White women. Latina women also have a higher prevalence of triple-negative breast cancer when compared to with non-Hispanic White women. Latina women are diagnosed with breast cancer at earlier ages, 56 years versus 63 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102319/

ICARE Social Media Post October 2019

Advances in Treatment for Advanced Breast Cancer in BRCA Carriers

Monotherapy with PARP inhibitors is FDA-approved for patients with metastatic breast cancer with BRCA mutations. BUT, does adding additional drugs (called ‘combination therapy’) help? In BRCA carriers with metastatic breast cancer, the combination of veliparib AND chemotherapy with platinum-based agents (carboplatin) and taxanes (paclitaxel) led to a longer duration of progression free survival (disease that …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101819/

ICARE Social Media Post October 2019

Advances in Early Stage Breast Cancer Treatment for BRCA Carriers

New benefits from a PARP inhibitor, talazoparib, among BRCA carriers with early stage breast cancer. The current FDA approvals for the use of PARP inhibitors is limited to women with metastatic (stage IV) breast cancer. These drugs are being tested in early stage breast cancer to shrink down the tumor (called neoadjuvant treatment) before surgery …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101519/

ICARE Social Media Post October 2019

Male Breast Cancer Risk

Did you know? Beyonce’s father, Matthew Knowles, was diagnosed with breast cancer. He states, “we used to think this was only an issue for women, but this is male or female.” According to CBS news, “he is hoping that sharing his story as man with breast cancer will shine a light on the risk men …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post10619/

ICARE Publication September 2019

Overall Mortality After Diagnosis of Breast Cancer in Men vs Women

Abstract Importance: Survival differences between male and female patients with breast cancer have been reported, but the underlying factors associated with the disparity have not been fully studied. This understanding is fundamental to developing strategies for cancer treatment and survivorship care. Objective: To compare mortality between male and female patients with breast cancer and quantitatively evaluate the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub91919/

ICARE Social Media Post September 2019

Family Sharing Resources: GeneSHARE

With the tremendous advances in gene-based care among those with inherited cancer risk, we are trying to develop tools and strategies to make it easier for more people to benefit from genetic education and testing. We are proud to introduce you to GeneSHARE, a free online toolkit for YOU, to help share positive test results …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91319/

ICARE Newsletter Summer 2019

Ask the Expert

The following question was addressed by Gillian Hooker, PhD, ScM, LCGC, who is the president-elect for the National Society of Genetic Counselors, Adjunct Associate Professor in the Division of Genetic Medicine at the Vanderbilt University Medical Center, and the Vice President of Clinical Development for Concert Genetics in Nashville, TN. Q. Why was the BRCA1/2 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/10nls2019/

ICARE Newsletter Summer 2019

Ovarian Cancer Treatment Advances for BRCA1/2 Carriers

A recently reported study of women with ovarian cancer and homologous recombination deficiency (HRD) who received a PARP inhibitor (niraparib) as fourth line or later treatment showed potential clinical benefit. Specifically, median overall survival after treatment was 19 months in the HRD-positive group (including those with BRCA1/2 mutations) compared to 15.5 months in the HRD-negative …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nls2019/

ICARE Newsletter Summer 2019

Updates to National Comprehensive Cancer Network (NCCN) Genetic/Familial High-Risk Assessment: Colorectal Guidelines

(Version 1.2019, posted July 3, 2019) For Individuals with Lynch Syndrome: The cancer risk table was updated: Addition of new cancer risks by specific genes: breast and bladder cancers Updates of cancer risks by specific genes: ovarian, prostate, gastric, pancreatic, urothelial, small bowel, and brain/CNS cancers Removal of reference to sebaceous neoplasms Recommendations for cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2019/

ICARE Newsletter Summer 2019

New Information About Cancer Risks for Inherited Cancer Genes: BRCA1/2

Looking at pregnancy history and breast cancer risk, a recent study of almost 8,000 women with BRCA1/2 mutations evaluated breast cancer risks related to pregnancy.1 Findings suggested the overall number of pregnancies was not associated with breast cancer risk in BRCA1 carriers; however, BRCA1 carriers with one pregnancy were at higher risk for breast cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nls2019/

ICARE Newsletter Summer 2019

Community Spotlight

Life was great at 45. I had nothing more than a few headaches and was a tad overweight. After a friend was diagnosed with breast cancer, I realized I had not had a mammogram in a couple of years, so I scheduled an appointment. One mass was found, but it was benign and nothing to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnls2019/

ICARE Newsletter Summer 2019

Pancreatic Cancer Treatment Advances for BRCA1/2 Carriers

Results from a clinical trial of individuals with a BRCA1/2 mutation and pancreatic cancer showed that patients who received a PARP inhibitor (olaparib) for maintenance treatment had almost half the risk of their disease progressing when compared to receiving a placebo.1 In fact, after 2 years, 22.1% of patients who received olaparib had no disease …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2019/

ICARE Newsletter Summer 2019

New Information About Cancer Risks for Inherited Cancer Genes: CHEK2

In a study of inherited mutations in the CHEK2 gene, findings suggest there were two specific mutations that could predispose men to testicular germ cell tumors (TGCT). Specifically, 205 men with these tumors were tested for 48 DNA repair genes, and findings were then tested in other patient populations. These findings suggest that CHEK2 mutations …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nls2019/

ICARE Newsletter Summer 2019

New Information About Cancer Risks for Inherited Cancer Genes: DICER1

In a study of over 100 individuals with a DICER1 mutation, findings suggest that 5.3% of individuals had developed cancer by age 10, and 19.3% by age 50. After age 10, cancer risks for women were higher compared to men. Specific cancers for which risks were high included gynecologic and thyroid cancers. These findings are …

Continue reading

Permanent link to this article: https://inheritedcancer.net/8nls2019/

ICARE Newsletter Summer 2019

Expansion of Criteria for BRCA1/2 Testing through the USPSTF

The U.S. Preventive Services Task Force (USPSTF) came out with new genetic testing guidelines for the BRCA1/2 genes, which has garnered substantial media attention. This task force consists of a team of primary care and preventive medicine healthcare experts to lower the chance of a conflict of interest  (which is also the reason that subspecialty …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2019/

ICARE Newsletter Summer 2019

Prostate Cancer Treatment Advances for BRCA1/2 Carriers

There is now information to suggest that identifying inherited mutations in DNA repair genes, such as BRCA1/2 and other genes, in men with metastatic prostate cancer may open doors for other treatment options. Results of a phase 2 clinical trial among men with metastatic and heavily pre-treated prostate cancer were presented at the American Society …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2019/

ICARE Newsletter Summer 2019

Expanding Our Thinking About Cancer Risks in TP53 Mutations and Li-Fraumeni Syndrome

Since expanded genetic testing has become available through multigene panel tests, studies have suggested that many people identified to have TP53 mutations do not have a typical personal or family history, which is usually seen with Li-Fraumeni syndrome (LFS). A recent study looking at over 300 individuals with TP53 mutations (identified through multi-gene panel testing) …

Continue reading

Permanent link to this article: https://inheritedcancer.net/11nls2019/

ICARE Newsletter Summer 2019

New Information About Cancer Risks for Inherited Cancer Genes: HAUS6, KANLS1, PCR1

Through a study of over 13,000 patients with serous ovarian cancers and almost 41,000 controls, 34 genes that raise the risk for ovarian cancer were identified. Additional laboratory studies were conducted to further characterize some of these genes, suggesting that three of these new genes may be essential (HAUS6, KANLS1, and PRC1). This study has …

Continue reading

Permanent link to this article: https://inheritedcancer.net/9nls2019/

ICARE Publication April 2019

A Framework for Pilot Testing Health Risk Video Narratives

Abstract Narrative messages may be superior to didactic messages when providing educational information due to their natural format for information sharing, ability to engage audiences, and engender positive thoughts about the message. Although narrative messages are gaining popularity in health promotion, little guidance exists regarding the development phase. Our team created a psychosocial narrative video …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub41819/

ICARE Publication April 2019

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

Abstract Background: Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian cancer. In the current study, we report on uptake of cancer screening and risk-reduction options in a cohort of BRCA mutation carriers from ten countries over two time periods (1995 to 2008 and 2009 to 2017). Methods: Eligible subjects were identified …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub41119/

ICARE Publication April 2019

A randomized controlled intervention to promote readiness to genetic counseling for breast cancer survivors

Abstract Objective: Breast cancer (BC) survivors with a genetic mutation are at higher risk for subsequent cancer; knowing genetic risk status could help survivors make decisions about follow-up screening. Uptake of genetic counseling and testing (GC/GT) to determine BRCA status is low among high risk BC survivors. This study assessed feasibility, acceptability, and preliminary efficacy of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub41119-2/

ICARE Newsletter Winter 2019

Other Advances in Cancer Treatment Among Cancer Patients with Inherited Disease: Familial Adenomatous Polyposis (FAP)

A new drug (sorafenib) showed promising results among patients with desmoid tumors, which are a type of tumor for which patients with Familial Adenomatous Polyposis (FAP) due to APC gene mutations are at risk. These tumors frequently grow and encompass internal organs and can be hard to remove surgically. The newly published research showed that …

Continue reading

Permanent link to this article: https://inheritedcancer.net/9nlw2019/

ICARE Newsletter Winter 2019

Advances in Biomarkers to Detect Pancreatic Cancer Early

Early detection of pancreatic cancer is tremendously important, given that most patients who develop the disease are diagnosed at a later stage of the disease when it is usually incurable. Although screening through imaging studies has been proposed (i.e., magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound),1 data to support this type of screening as an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/12nlw2019/

ICARE Newsletter Winter 2019

Community Spotlight

When I was 50 years old I was in pretty good physical shape and I thought I was finally getting six pack abs. I was wrong – those abs were a large football sized tumor, along with a variety of smaller tumors. I was diagnosed with Stage 4 ovarian cancer. I had a hysterectomy and fibroid removal …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnlw2019/

ICARE Newsletter Winter 2019

Other Advances in Cancer Treatment Among Cancer Patients with Inherited Disease: Lynch Syndrome

Pertaining to metastatic prostate cancer, recently published data reported 8.1% of men with advanced prostate cancer had evidence of mismatch repair (MMR) mutations in their tumors. These types of mutations are frequently seen in tumors among Lynch syndrome patients. In addition, men with this type of tumor had much poorer survival. Tumors with MMR defects …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nlw2019/

ICARE Newsletter Winter 2019

New Genes: GALNT12

A gene called GALNT12 may be yet another inherited colorectal cancer gene,1 as originally suggested by prior studies.2 The current study screened almost 500 colorectal cancer patients and identified 8 rare variants that may be disease causing. The frequency of variants among colorectal cancer patients was much higher than that observed among population-matched healthy controls, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/13nlw2019/

ICARE Newsletter Winter 2019

Other Advances in Cancer Treatment Among Cancer Patients with Inherited Disease: von Hippel-Lindau (VHL) Disease

Additional exciting advances include the results of a new drug (pazopanib) to treat an inherited cancer condition called von Hippel-Lindau Disease (VHL), in which patients are predisposed to kidney cancers, pancreatic tumors, and hemangioblastomas (i.e., tumors involving the blood vessels). Study results showed that among 31 patients with VHL, overall response rate with the drug …

Continue reading

Permanent link to this article: https://inheritedcancer.net/8nlw2019/

ICARE Newsletter Winter 2019

Basal Cell Cancers May Be a Risk Factor to Predict Inherited Cancer Predisposition

An interesting area of progress to identify individuals with inherited risks included a study of over 13,000 individuals with six or more basal cell cancers (BCC) evaluated through a claims database. Results indicated ~20% of these individuals had a germline mutation in a DNA repair gene, including BRCA1/2, PALB2, and the Lynch syndrome genes, among …

Continue reading

Permanent link to this article: https://inheritedcancer.net/10nlw2019/

ICARE Newsletter Winter 2019

Ask the Expert

The following question was addressed by Georgia Wiesner, MD, MS, a nationally renowned clinical cancer geneticist, who is an Ingram Professor of Cancer Research, Professor of Medicine in the Division of Genetic Medicine, and the Director of the Clinical and Translational Hereditary Cancer Program for the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. Q. What are …

Continue reading

Permanent link to this article: https://inheritedcancer.net/14nlw2019/

ICARE Newsletter Winter 2019

New Research and Approvals of PARP Inhibitor Drugs to Treat Prostate Cancer in BRCA Carriers

Treatment among patients with metastatic castration-resistant prostate cancer: A PARP inhibitor (rucaparib) was granted a breakthrough therapy designation in October 2018 for monotherapy (i.e., sole treatment) among men with metastatic castration-resistant prostate cancer (with a BRCA1/2 mutation) who have received at least one prior androgen receptor-directed treatment and taxane-based chemotherapy. This designation was granted based …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2019/

ICARE Newsletter Winter 2019

New Research and Approvals of PARP Inhibitor Drugs to Treat Breast Cancer in BRCA Carriers

Treatment among patients with advanced or metastatic breast cancer: A PARP inhibitor (talazoparib) was approved by the FDA on October 16, 2018 for BRCA carriers with HER2-negative locally advanced or metastatic breast cancer, based on results of the EMBRACA trial outlined in the last ICARE newsletter. Litton JK, et al. N Engl J Med. 2018 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2019/

ICARE Newsletter Winter 2019

Expansion of Lynch Syndrome Tumor Spectrum Which May Have Treatment Implications

Although the Lynch syndrome tumor spectrum is thought to be limited to cancers of the colorectum, endometrium, ovaries, stomach, and a few other cancer types, a recent article suggested there might be a broader tumor spectrum than previously considered. Furthermore, colorectal and endometrial cancers which develop among Lynch syndrome patients frequently are determined on tumor …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nlw2019/

ICARE Newsletter Winter 2019

Refining Treatment for Aggressive Prostate Cancer in Men with BRCA2

A recent study reported that a large proportion of men with aggressive prostate cancer have inherited cancer gene mutations. Specifically, among 400 patients with castration-resistant prostate cancer, 16.2% had a germline mutation in a DNA damage repair gene, including 3% with a BRCA2 mutation. Among BRCA2 carriers, survival was 17.4 months, which was much lower …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nlw2019/

ICARE Newsletter Winter 2019

New Research and Approvals of PARP Inhibitor Drugs to Treat Ovarian Cancer in BRCA Carriers

First line maintenance treatment among patients newly diagnosed with advanced ovarian cancer: The results of a trial using a PARP inhibitor (olaparib) as maintenance treatment among ovarian cancer patients with advanced disease, a BRCA mutation, and complete or partial response to platinum-based chemotherapy showed that survival at 3 years was 60% among those who got …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2019/

ICARE Newsletter Winter 2019

High Proportion of Inherited Genes Detected Among Patients with Advanced Renal Cancer

In a study of advanced renal cell cancer patients, inherited cancer gene mutations were identified in 16%, of which 5.5% had mutations in genes related to renal cell cancer. Among the subgroup with non-clear cell renal cancer, about a fifth had an inherited cancer gene mutation, half of which had a gene mutation that could …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nlw2019/

ICARE Newsletter Winter 2019

Testing Interpretation and Variant Reclassification

Results of germline genetic testing generally yield three types of test results: Deleterious (positive), Negative (no mutation detected), and Variant of Uncertain Significance (VUS). As more genes are tested, the chance for a positive result goes up, as does the chance of receiving a VUS result.1 VUS results tell us that it remains uncertain whether …

Continue reading

Permanent link to this article: https://inheritedcancer.net/15nlw2019/

ICARE Newsletter Winter 2019

New Online Risk Calculator to More Accurately Predict Breast Cancer Risk

Prediction of breast cancer risk is important to identify those at highest and lowest risks, to help guide screening. A previously developed risk algorithm called Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) was recently extended to include truncating mutations in the BRCA genes, PALB2, CHEK2, and ATM. This online risk …

Continue reading

Permanent link to this article: https://inheritedcancer.net/11nlw2019/

ICARE Publication January 2019

Genetic Testing Across Young Hispanic and Non-Hispanic White Breast Cancer Survivors: Facilitators, Barriers, and Awareness of the Genetic Information Nondiscrimination Act

Abstract Aims: This study compared facilitators and barriers to genetic testing and determined awareness about the Genetic Information Nondiscrimination Act (GINA) across young Hispanic and non-Hispanic white (NHW) breast cancer (BC) survivors. Materials and methods: Women diagnosed with BC of age ≤50 years in 2009-2012 were recruited through the Florida State Cancer Registry to complete a questionnaire. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub12419/

ICARE Publication November 2018

Health beliefs associated with readiness for genetic counseling among high risk breast cancer survivors

Abstract We used the Health Belief Model (HBM) to explore factors associated with readiness for genetic counseling among breast cancer survivors. Breast cancer survivors meeting NCCN genetic counseling referral criteria completed questionnaires capturing demographic and clinical information and factors guided by the HBM, including health beliefs, psychosocial variables, and cues to action. Using logistic regression, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub112818/

ICARE Newsletter Summer 2018

The Role of Inherited Genes Increasingly Recognized in Pancreatic Cancer

A number of recent studies have suggested that a substantial number of individuals with pancreatic cancer have a mutation in an inherited cancer gene.  In a study of over 300 patients with pancreatic cancer (and with one or two family members with pancreatic cancer), 12% were found to have a mutation in 1 of 11 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nls2018/

ICARE Newsletter Summer 2018

Community Spotlight

I was aware from a very young age that breast cancer was part of our family. I knew that my great-grandmother (whom I never met) had breast cancer and my grandmother was diagnosed in her 50’s. While I didn’t grow up being afraid of the disease, I was far more aware of it than were …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnls2018/

ICARE Newsletter Summer 2018

Updates to NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines

(Version 1.2019, posted July 11, 2018) Regardless of family history, some individuals with a hereditary breast- and ovarian-related cancer may benefit from genetic testing to determine eligibility for targeted treatment The multi-gene testing section table was updated with: A potential association of ATM with ovarian cancer risk Potential increased risk of BARD1 with breast cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2018/

ICARE Newsletter Summer 2018

Prevention of Colorectal Cancer Among Individuals with Familial Adenomatous Polyposis (FAP)

Through a randomized trial, patients with FAP were treated with sulindac and erlotinib versus placebo for 6 months. Results of the study showed that those treated with sulindac and erlotinib had 70% fewer polyps than those in the placebo group. The lower number of polyps was seen in both those with an intact colorectum and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/9nls2018/

ICARE Newsletter Summer 2018

NTHL1: A New Gene for Inherited Colorectal Cancers

In a study of 51 individuals with multiple colon polyps drawn from 48 families, genetic testing through whole-exome sequencing identified 7 individuals (from 3 unrelated families) to have a mutation in both copies of their NTHL1 gene, and pedigree structure was consistent with autosomal recessive inheritance.1 All these individuals had colorectal cancer and a large …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nls2018/

ICARE Newsletter Summer 2018

Updates to NCCN Genetic/Familial High-Risk Assessment: Colorectal Guidelines

For Individuals with Lynch Syndrome: Surveillance for gastric and small bowel cancer now indicates there is no clear data to support this, but surveillance can be performed every 3-5 years starting at age 40 Lack of evidence to make a recommendation for pancreatic or prostate cancer screening, beyond those already recommended through other NCCN Guideline …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2018/

ICARE Newsletter Summer 2018

Inherited Leukemias: The Importance of TP53/Li-Fraumeni Syndrome and Other Genes

It has long been established that the risk for developing leukemia in childhood is high among individuals with Li-Fraumeni Syndrome; however, better understanding the characteristics of leukemia among these individuals is important to guide treatment approaches. In a study of children with Acute Lymphocytic Leukemia (ALL), those with a germline TP53 mutation (compared to those …

Continue reading

Permanent link to this article: https://inheritedcancer.net/11nls2018/

ICARE Newsletter Summer 2018

Another PARP-Inhibitor Trial Among BRCA Carriers with Advanced Breast Cancer

In a Phase 3 clinical trial among BRCA carriers with advanced breast cancer, an oral PARP Inhibitor (talazoparib) was compared to standard chemotherapy.  Among those who received the PARP inhibitor, risk of disease progression or death was 46% lower, and the response rate was double. Furthermore, the side effect profile, quality-of-life measures, and breast cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/8nls2018/

ICARE Newsletter Summer 2018

Differences in Breast Cancer Risks Among Women with Lynch Syndrome

Breast cancer risks were recently reported among a sample of 423 women with mutations in one of the Lynch syndrome genes (MLH1, MSH2, MSH6, or PMS2).1 Results indicated that breast cancer risks were substantially higher among those with MSH6 and PMS2 mutations, compared to MLH1 and MSH2 mutations. In fact, breast cancer risk to age …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2018/

ICARE Newsletter Summer 2018

New Data to Suggest Additional Genes Associated with Breast and Ovarian Cancer

A recent study reported on cancer risks among over 10,000 cancer patients across the United States who had genetic testing. Findings suggest breast cancer risks were associated with ATM, CHEK2, and PALB2, as expected; but an association was also found with MSH6 (in line with other recently published data, as outlined in another article in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nls2018/

ICARE Newsletter Summer 2018

Refining Cancer Risks Among Individuals with Lynch Syndrome

Over the past year, multiple studies have refined risks and types of cancer among individuals with Lynch syndrome. Through a Scandinavian study, risks for 13 types of cancer (with colorectal cancers being excluded), were reported to be elevated with differences related to gender, age, and the gene in which mutation was present. Incidence rates of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2018/

ICARE Newsletter Summer 2018

Ask the Expert

The following question was addressed by Ronald D. Alvarez, MD, MBA who is Professor, Chairman, and Clinical Service Chief of the Department of Obstetrics and Gynecology at Vanderbilt University Medical Center in Nashville, Tennessee. Dr. Alvarez has been the recipient of several National Cancer Institute (NCI) and other industry funded grants in support of his …

Continue reading

Permanent link to this article: https://inheritedcancer.net/10nls2018/

ICARE Newsletter Winter 2018

Community Spotlight

A cancer diagnosis is a life-changing event for every patient and their extended family. However, how we respond to this diagnosis are as individual as our very existence as evidenced by our looks and personalities. Following my diagnosis of stage 4 prostate cancer in 2014 at age 54 which had spread to my bones, I …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnlw2018/

ICARE Newsletter Winter 2018

Advances in the Understanding of Inherited Prostate Cancer

Findings through a recent study reported that inherited cancer gene mutations were present in 8.2% of those with advanced or metastatic prostate cancer, which provides additional support to include this group of men in broader testing, particularly as targeted treatments based on inherited gene mutations becomes increasingly available.1 Another recent study suggested that those with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/10nlw2018/

ICARE Newsletter Winter 2018

The Role of “Non-Truncating” Mutations in RAD51D on Ovarian Cancer Risk

As testing has broadened to include newer inherited cancer genes, studies have suggested that mutations which shorten the protein (“truncating mutations”) in the RAD51D gene are associated with ovarian cancer.  However, a recent study examined ovarian cancer risks for a “non-truncating” change (a single base pair within the gene is changed which is called a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2018/

ICARE Newsletter Winter 2018

Updates to NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines

(Version 1.2018, posted Oct. 3, 2017) Metastatic prostate cancer was added as an indication for evaluation and testing for the BRCA1 and BRCA2 genes Among BRCA1, BRCA2, TP53 and PTEN carriers, women between ages 25-29 may consider having an annual mammogram with consideration of tomosynthesis if a breast MRI is not available. Among female BRCA2 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2018/

ICARE Newsletter Winter 2018

Getting Closer to Detecting Cancers Early Through a Blood Test?

A recent study reported on a single blood test, named “CancerSEEK”, which can screen for 8 common types of cancer (ovarian, liver, stomach, pancreas, esophagus, colorectal, lung, and breast) and may help to identify the location at which the cancer started. This test evaluated the blood from over 1000 patients with Stage 1 to 3 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2018/

ICARE Newsletter Winter 2018

Advances in New Treatments for Individuals with Lynch Syndrome

A recently published phase II clinical trial investigated the use of a new class of drugs (called PD-1 Inhibitors) in DNA mismatch repair-deficient/ microsatellite instability-high colorectal tumors (which are features seen in the majority of colorectal tumors from individuals with Lynch Syndrome) among patients with metastatic disease.1 Investigators found patients who received two PD-1 Inhibitors …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nlw2018/

ICARE Newsletter Winter 2018

Refining Risks and Outcomes of Breast Cancer in BRCA Carriers

In an effort to further study breast cancer risks among BRCA carriers, a recently published study compared breast cancer risks among those with and without a close family member (first-degree relative) with breast cancer.1 Findings showed that risk for breast cancer by age 80 was 60.8% in BRCA1 carriers and 63.1% among BRCA2 carriers, with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nlw2018/

ICARE Newsletter Winter 2018

FDA Approval of PARP Inhibitor (Lynparza) for Treatment of Advanced Breast Cancer

On January 12, 2018, the FDA approved the first PARP Inhibitor (Lynparza) for treatment in patients with advanced breast cancer due to inherited BRCA mutations.1 This drug is already approved for certain BRCA carriers for advanced ovarian cancer. PARP inhibitors were originally developed to target the specific pathway through which cancer develops among those with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nlw2018/

ICARE Newsletter Winter 2018

Ask the Expert

The following question was addressed by Dr. Ingrid Meszoely is a breast surgeon and Clinical Director of the Vanderbilt Breast Center at One Hundred Oaks. She leads a high-risk clinic, through which she and her team of nurse practitioners manage patients with inherited breast cancer predisposition. Her research interests include both clinical and translational breast …

Continue reading

Permanent link to this article: https://inheritedcancer.net/8nlw2018/

ICARE Newsletter Winter 2018

Study Suggests Inherited Cancer Genes Are Important in Pancreatic Cancer

In a recent study which included over 800 patients with pancreatic ductal cancer, inherited cancer gene mutations were found in a much higher proportion than expected. Almost 5% of these patients had mutations identified in inherited cancer genes, the majority of which were in genes thought to be associated with pancreatic cancer (including BRCA2, ATM, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/9nlw2018/

ICARE Newsletter Winter 2018

Advances in Cancer Screening Among Li-Fraumeni Syndrome Patients

Several research groups from around the world that have conducted cancer screening among patients with Li-Fraumeni syndrome and a germline TP53 mutation have recently reported on their observations. Specifically, the National Cancer Institute group demonstrated that screening inclusive of rapid total body MRI detected cancers at an early stage,1 similar to findings published through other …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nlw2018/

ICARE Newsletter Summer 2017

Ask the Expert

The following question was addressed by Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at the Women’s College Research Institute in Toronto, Canada. Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Q. In women with a BRCA mutation and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nls2017/

ICARE Newsletter Summer 2017

Emerging FDA Approvals of Immunotherapy Among Patients With Metastatic MSI-H Cancers

Over the last few years, immunotherapy has emerged as an exciting new class of drugs. As early as 2015, immunotherapy through PD-1 Inhibitors among patients with MSI-H colorectal cancers was shown to be of potential benefit.1 As many individuals with Lynch Syndrome have cancers that are MSI-H and mismatch repair deficient, this class of drugs …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2017/

ICARE Newsletter Summer 2017

Breast and Ovarian Cancer Risks Among BRCA Carriers Followed Over Time

Findings from an international study of over 6000 women with a BRCA1 mutation and almost 4000 women with a BRCA2 mutation followed for an average of 5 years were recently published.1 Results showed the risk of breast cancer by age 80 was ~70% for both BRCA1 and BRCA2 carriers. Rates of breast cancer increased until …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2017/

ICARE Newsletter Summer 2017

Community Spotlight

After a long rainy summer filled with doctor visits, I was finally diagnosed with triple-negative inflammatory breast cancer (TN IBC) at the age of 49. I completed treatment in June 2008 and was grateful to have a new phase to my vocabulary – NED, ‘no evidence of disease’. Since there was no cancer history in my …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnls2017/

ICARE Newsletter Summer 2017

New Results of a PARP Inhibitor Study Among BRCA Carriers with Metastatic Breast Cancer

Over the last decade, a new class of drugs called “PARP Inhibitors” has been evaluated as a form of targeted treatment among BRCA carriers. Results were recently reported from a Phase 3 clinical trial among BRCA carriers with HER2-negative metastatic breast cancer who received two or less prior chemotherapy regimens for their metastatic disease. Study …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nls2017/

ICARE Newsletter Summer 2017

What Are the Benefits of Adding a Mammogram to MRI for Breast Cancer Screening Among Women with BRCA Mutations?

Recently, researchers evaluated the benefit of adding a mammogram to MRI for breast cancer screening among ~2000 women with a BRCA1 or BRCA2 mutation. Results indicated that the addition of mammography to MRI did not substantially raise the chance of detecting breast cancer in the overall group. However, one-third of breast cancer cases diagnosed among …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nls2017/

ICARE Newsletter Summer 2017

What Are New and Subsequent Cancer Risks Among Patients with Li-Fraumeni Syndrome?

Although individuals with Li-Fraumeni Syndrome (LFS), due to mutations in the TP53 gene, have a very high lifetime risk of cancer, risks of initial and subsequent cancers are not well defined. Through a group of patients with the classic form of LFS, researchers at the National Cancer Institute estimated their cancer risks. They evaluated a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2017/

ICARE Newsletter Summer 2017

Breast and Ovarian Cancer Associations for Genes Tested Through Multi-Gene Panels

As testing for multiple genes at the same time (“multi-gene panel testing”) has become increasingly available with tremendous advances in genetic testing technology, it has become critical to evaluate and refine cancer associations and levels of risk for many of these genes now tested. Through a commercial laboratory database of almost 100,000 results of multi-gene …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2017/

ICARE Publication August 2017

A community-academic partnership to explore informational needs of African American women as a primer for cancer clinical trial recruitment

Abstract Background: African Americans (AAs) are less likely to participate in cancer clinical trials (CCTs) despite experiencing disproportionately higher rates of cancer mortality. As a way to address these ongoing disparities, this study sought to qualitatively explore informational needs regarding CCTs among AA women and identify message considerations for educational information targeting AA women and their …

Continue reading

Permanent link to this article: https://inheritedcancer.net/pub82217/

ICARE Newsletter Winter 2017

Community Spotlight

On my 43rd birthday I was diagnosed with an advanced stage breast cancer. Although my BRCA1 and BRCA2 results were surprisingly negative, I was certain there must be a genetic component to my breast cancer since I was diagnosed at a fairly young age. I remained in contact with my geneticist, Dr. Georgia Wiesner, and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnlw2017/

ICARE Newsletter Winter 2017

Newly Approved PARP-Inhibitor (Rucaparib) to Treat BRCA Carriers with Ovarian Cancer

The FDA just approved another PARP inhibitor, rucaparib, for BRCA carriers with ovarian cancer who have already been treated with two or more chemotherapies. Among those with BRCA-mutant ovarian cancers, 54% had a partial or complete response to the drug with a median duration response of 9.2 months. The agency also approved a companion diagnostic …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nlw2017/

ICARE Newsletter Winter 2017

Characterizing Breast Cancers That Develop Among Women with a CHEK2 Mutation

With increasing use of multi-gene panel tests, one of the genes in which mutations are frequently detected among breast cancer patients and others is the CHEK2 gene. This gene has been shown to have a 2-3 fold excess risk for breast cancer. There are many CHEK2 mutations that have been identified that generally fall into …

Continue reading

Permanent link to this article: https://inheritedcancer.net/8nlw2017/

ICARE Newsletter Winter 2017

New Study Suggesting BRCA1/2 and ATM Are Associated with Aggressive Prostate Cancer

Among 799 patients with prostate cancer, the rate of BRCA1/2 mutations was much higher among those who passed away of prostate cancer (6.07%) compared to those with low risk disease (1.44%).1 Among the group that died of prostate cancer, those with BRCA1/2 or ATM mutations passed away at an earlier age and had a shorter …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2017/

ICARE Newsletter Winter 2017

NCCN Guidelines Version 1.2017: Genetic/Familial High-Risk Assessment: Breast and Ovarian

Additional guidance pertaining to cancer risk management was provided in the most recent version of the NCCN Guidelines for inherited breast and ovarian cancer. These guidelines now include an expanded table outlining cancer risks and management for each gene, taking into account the age at initiation of each risk management modality as well as footnotes …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2017/

ICARE Newsletter Winter 2017

A Newly Identified Inherited Colon Cancer Gene: FAN1

There continues to be rapid advances in identifying new genes involved in inherited cancer risk.  An example of yet another recently identified gene is FAN1, in which a nonsense variant (i.e. the premature change or loss of a protein) was identified following exome sequencing in 3 individuals from a family who met clinical criteria for …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nlw2017/

ICARE Newsletter Winter 2017

Ask the Expert

The following question was addressed by Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at the Women’s College Research Institute in Toronto, Canada. Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Q. Does salpingo-oophorectomy reduce the risk of breast …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nlw2017/

ICARE Newsletter Winter 2017

The Potential Promise of Immunotherapy Targeted to Those with Bi-Allelic Mutations in Lynch Syndrome Genes

People with Lynch Syndrome have a non-working Lynch gene (“mutation”), while the other copy of that gene is normal (recognizing that all of these genes come in pairs, with one member of the pair coming from each parent). Over the last few years, there has been an increased realization that some individuals have a mutation …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2017/

ICARE Newsletter Winter 2017

How Does Having a Mother with Breast Cancer and a BRCA Mutation Affect Adolescent Girls?

A recent study compared psychosocial adjustment and risk perception among 11 to 19 year old daughters of women with breast cancer, comparing those with a BRCA mutation versus those without.1 The overall findings from the study were reassuring, suggesting that adolescent girls from BRCA-positive families had higher self-esteem and similar psychosocial adjustment compared to their …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nlw2017/

ICARE Newsletter Summer 2016

Cancer Chemoprevention in Individuals with Familial Adenomatous Polyposis (FAP)

Prior research has demonstrated that NSAIDs significantly reduce colonic and rectal polyp burden among individuals with FAP although their impact on outcomes remains to be determined.1,2 Recent data extended these results to the small intestine through completion of a randomized clinical trial among patients with FAP which demonstrated that use of sulindac and erlotinib compared …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nls2016/

ICARE Newsletter Summer 2016

Practice Guideline Updates for NCCN Genetic/Familial High-Risk Assessment

The National Comprehensive Cancer Network (NCCN) is a network of oncology healthcare providers who work together to develop best practice guidelines for the delivery of cancer care. Given the increasing use of testing for mutations in several inherited cancer genes at one time (called “multi-gene panel testing”), the Breast/Ovarian and Colorectal Panels sought to provide …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2016/

ICARE Newsletter Summer 2016

What Are the Endometrial Cancer Risks Among BRCA Carriers?

Although BRCA mutations confer increased risk for ovarian, fallopian tube, and primary peritoneal cancer, there have been limited and conflicting risks reported for endometrial cancer. Consequently, current practice guidelines only recommend the removal of the fallopian tubes and ovaries as a risk-reducing option for BRCA carriers.1 Specifically, through a prospective study of 4500 women with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/9nls2016/

ICARE Newsletter Summer 2016

CHEK2 *1100delC Mutation Carriers: Breast Cancer Risk by Age and Tumor Type and Other Associated Cancer Risks

The CHEK2 *1100delC mutation is the most common “truncating” mutation (causing a shortened protein) in the CHEK2 gene among Europeans, with lifetime breast cancer risk in the range of 20-30% among female carriers. Results of data pooled from over 30 studies which included 40,000 breast cancer cases and 40,000 controls, showed that estrogen receptor (ER) …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nls2016/

ICARE Newsletter Summer 2016

Practice Guideline Updates for NCCN Genetic/Familial High-Risk Assessment

The National Comprehensive Cancer Network (NCCN) is a network of oncology healthcare providers who work together to develop best practice guidelines for the delivery of cancer care. Given the increasing use of testing for mutations in several inherited cancer genes at one time (called “multi-gene panel testing”), the Breast/Ovarian and Colorectal Panels sought to provide …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2016/

ICARE Newsletter Summer 2016

Ask the Expert

The following question was addressed by Dr. Christine Laronga at the Moffitt Cancer Center: Q. How should bone health be monitored in women with a BRCA mutation after removal of the ovaries (i.e., risk-reducing salpingo-oophorectomy (RRSO))? A. Women with a BRCA mutation have a substantially high risk to develop ovarian cancer in their lifetime, yet …

Continue reading

Permanent link to this article: https://inheritedcancer.net/10nls2016/

ICARE Newsletter Summer 2016

Risk of Second Cancers Among Those with PTEN Mutations

A recently published study to evaluate the risk of second cancers among PTEN mutation carriers showed that women with breast cancer had a 10-year second breast cancer cumulative risk of almost 30%. Overall, the risk of second primary cancers was almost 8-fold that of the general population, primarily due to the higher risks of cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/8nls2016/

ICARE Newsletter Summer 2016

Surveillance Among Individuals with Li-Fraumeni Syndrome (LFS): An 11 Year Follow-Up Study

Results from the original screening protocol for LFS1 were recently updated following collection of 11 years of follow-up data.2 Through this study, 89 patients with LFS were given the option of a clinical surveillance protocol consisting of a physical examination as well as frequent biochemical and imaging studies. Forty asymptomatic tumors were detected in 32% …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nls2016/

ICARE Newsletter Summer 2016

Inherited Cancer Genes and Metastatic Prostate Cancer

Several prior studies have suggested that men with a BRCA mutation (primarily BRCA2) tend to develop an aggressive form of prostate cancer that is more likely to metastasize. These findings were recently extended through a new study published in the New England Journal of Medicine.1 In this study, almost 700 men with metastatic prostate cancer, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2016/

ICARE Newsletter Summer 2016

Community Spotlight

When I was diagnosed with cancer the first time at age 38, my sister (a breast cancer survivor since the age of 29) was positive we had a BRCA gene mutation. However, after we both had genetic testing done in 2006 the results showed we didn’t. Doctors said they were surprised we did not have a mutation in one of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnls2016/

ICARE Newsletter Summer 2016

An Approach to Making Risk Management Recommendations for Newer Inherited Cancer Genes

A recent article sought to develop an approach to cancer risk management among individuals with mutations in newer inherited cancer genes, many of which result in a moderate (rather than ‘high’) cancer risk. Overall, the investigators suggest a framework that takes the age-specific, lifetime, and absolute cancer risks into account for inherited cancer genes where …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2016/

ICARE Newsletter Winter 2016

Improving Our Understanding of Cancer Risks Among Individuals with Li-Fraumeni Syndrome

A recent study from France included over 400 patients with Li-Fraumeni Syndrome (all of whom had an inherited TP53 gene mutation). Cancer types among children and adults differed, with the main cancer types among children being osteosarcomas, adrenocortical carcinomas, central nervous system (CNS) tumors and soft tissue sarcomas; whereas among adults, the main cancer types …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nlw2016/

ICARE Newsletter Winter 2016

How Much Does Age at First Breast Cancer Affect the Risk of Contralateral Breast Cancer Risk in BRCA Carriers?

A recently published study of Dutch patients (including 200 BRCA1 carriers, 71 BRCA2 carriers, and 6023 non-carriers) showed that the contralateral breast cancer (breast cancer in the opposite breast) risks at 10 years was 21.1% for BRCA1, 10.8% for BRCA2, and 5.1% for non-carriers. Among BRCA mutation carriers, it was important to take age at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2016/

ICARE Newsletter Winter 2016

Ask the Expert

The following question was addressed by Dr. Christine Laronga at the Moffitt Cancer Center: Q. As a BRCA carrier, is it reasonable for me to consider nipple-sparing mastectomy (compared to total mastectomy) to reduce my future risks of breast cancer? A. One  strategy to manage the high (60-70%) lifetime breast cancer risk among women with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nlw2016/

ICARE Newsletter Winter 2016

Community Spotlight

I was first diagnosed with breast cancer when I was 56 years old.  Because of my strong family history of breast cancer, I was referred for genetic counseling and had BRCA testing at that time. Recently, I was diagnosed with breast cancer again. When I went to see my surgeon, she advised me to have more genetic …

Continue reading

Permanent link to this article: https://inheritedcancer.net/spotlightnlw2016/

ICARE Newsletter Winter 2016

Potential Use of PARP-Inhibitors Among Men with Prostate Cancer Who Carry a Mutation in BRCA or Other DNA-Repair Gene

A recent study published in the New England Journal of Medicine suggests that PARP-Inhibitors may be of potential use in men who are no longer responding to standard treatments and carry either somatic (i.e., tumor) and/or germline (inherited) mutations in DNA-repair genes (i.e., BRCA1/2, ATM, Fanconi Anemia genes and CHEK2).1 Of 49 men with prostate …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nlw2016/

ICARE Newsletter Winter 2016

The Importance of Sharing Genetic Test Results with Family Members

Once an individual has had genetic testing for inherited cancer predisposition this information could help their close family members.  For example, when a BRCA mutation or a mutation in another inherited cancer gene is found, it is important for close family members (with or without a diagnosis of cancer) to know so they too can …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2016/

ICARE Newsletter Winter 2016

What Is the Risk for Ovarian Cancer Among Women with Mutations in Newer Ovarian Cancer Genes?

The most common form of inherited ovarian cancer is due to mutations in the BRCA1 and BRCA2 genes, which are present in 10-15% of women with ovarian cancer and lead to an ovarian cancer risk of up to 44% and 27%, respectively.  Another set of genes known to raise ovarian cancer risks are the mismatch …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2016/

ICARE Newsletter Winter 2016

More Information About the Inherited Component of Pancreatic Cancer

Although pancreatic cancer is one of the cancer types seen among individuals with mutations in inherited cancer genes (including BRCA2 and BRCA1), the proportion of individuals with pancreatic cancer who have an inherited cause has remained uncertain.  To further clarify the role of BRCA1 and BRCA2 (BRCA), over 300 patients with pancreatic cancer were tested …

Continue reading

Permanent link to this article: https://inheritedcancer.net/7nlw2016/

ICARE Newsletter Summer 2015

The Rapid Pace of Discovering More Inherited Cancer Genes Continues

Over the last few months, a number of additional genes associated with inherited cancer predisposition have been identified. A few of these genes include: 1) the RECQL gene which appears to be another rare gene involved in inherited breast cancer1; 2) the SMAD9 gene associated with hamartomatous polyposis and ganglioneuromas of the intestinal tract2; 3) …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2015/

ICARE Newsletter Summer 2015

Location and Type of BRCA1/2 Mutation May Impact Breast and Ovarian Cancer Risks

A study of almost 20,000 BRCA1 carriers and 12,000 BRCA2 carriers demonstrated differences in breast and ovarian cancer risks depending on the location and type of mutation. Although all regions are associated with increased risk for breast and ovarian cancers among BRCA1/2 carriers, there were specific regions that were associated with even higher cancer risks. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nls2015/

ICARE Newsletter Summer 2015

Advances in Preventive and Treatment Approaches for Individuals with Lynch Syndrome

A study of over 1800 individuals with a mutation in one of the Lynch Syndrome genes was recently completed to assess whether aspirin and ibuprofen use may reduce colon cancer risk. Results showed that in those who took aspirin or ibuprofen for between 1 month and 4.9 years, the colon cancer risks were lower than …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nls2015/

ICARE Newsletter Summer 2015

Breast Cancer Risks and Outcomes Among Women with a PALB2 Mutation

Through a recent study of over 12,000 Polish women with breast cancer, PALB2 mutations were detected in almost 1%.  In this study, about one third of those with a PALB2 mutation had triple negative (lacking estrogen, progesterone and HER2 receptors) breast cancer and the average age at breast cancer diagnosis was 53.3 years.  Breast tumors …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2015/

ICARE Newsletter Summer 2015

2015 NCCN Clinical Practice Guideline Update

Breast and Ovarian Management Based on Genetic Test Resultsa   Recommend Breast MRIc (>20% lifetime risk of breast cancerd) Recommend Risk-reducing salpingo-oophorectomy Discuss Option of Risk-reducing mastectomy Intervention warranted based on gene and/or risk level ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, TP53 BRCA1, BRCA2, Lynch syndromee BRCA1, BRCA2, CDH1, PTEN, TP53 Insufficient evidence …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2015/

ICARE Newsletter Summer 2015

Ask the Expert

The following question was addressed to Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at Women’s College Research Institute in Toronto, Canada. Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Over the course of his career, he has profoundly shaped …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2015/

ICARE Newsletter Winter 2015

Highlights of the 2014 National Comprehensive Cancer Network (NCCN) Update

Genetic/Familial High-Risk Assessment: Breast and Ovarian Guidelines For breast cancer screening in BRCA carriers, yearly MRI is recommended starting at age 25; mammograms may be considered in instances where MRI is unavailable or individualized based on earliest age of onset in the family. From age 30-75, annual mammogram and breast MRI is recommended.  Above age …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nlw2015/

ICARE Newsletter Winter 2015

Highlights of the 2014 National Comprehensive Cancer Network (NCCN) Update

Genetic/Familial High-Risk Assessment: Colorectal Guidelines Recommendation that tumors from newly diagnosed colorectal cancer patients be screened for Lynch syndrome (called “Universal Tumor Screening”). A new algorithm was created for Routine Tumor Testing Criteria for Lynch Syndrome Surveillance/Management recommendations were refined by gene for the various Lynch Syndrome genes. Management recommendations were refined for other inherited …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nlw2015/

ICARE Newsletter Winter 2015

PALB2: A Third Important Gene for Inherited Breast Cancer

Following the publication of an important article in the New England Journal of Medicine (NEJM) in August 2014, germline PALB2 gene mutations were confirmed as the third most important gene for inherited breast cancer, following BRCA1 and BRCA2.1 PALB2 stands for “partner and localizer of BRCA2” and is located on chromosome 16. Studies suggest that PALB2 mutations …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2015/

ICARE Newsletter Winter 2015

The First PARP-Inhibitor to Be Approved for Clinical Use in BRCA Carriers

More frequently, cancer drugs are being developed to treat tumors based on their molecular make-up. PARP inhibitors are the first class of drugs specifically developed to treat BRCA-related tumors through targeting the DNA repair pathway. The PARP Inhibitors target this pathway and cause cancer cells to die while healthy cells are spared. Although PARP inhibitors …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2015/

ICARE Newsletter Winter 2015

Discovery of New Colorectal Cancer Genes

New inherited cancer genes continue to be discovered with the exciting advances made possible through next-generation sequencing technologies. Recent studies identified that the POL genes predispose to inherited colorectal cancer.1,2,3 In one study, Niemenen and colleagues studied a four-generation family with Lynch Syndrome with no evidence of mismatch repair deficiency.2 Through various means (including genetic …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nlw2015/

ICARE Newsletter Winter 2015

Ask the Expert

The following question was addressed to Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at Women’s College Research Institute in Toronto, Canada. Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Over the course of his career, he has profoundly shaped …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2015/

ICARE Newsletter Summer 2014

Is Breast Cancer Risk Affected by Timing of Oral Contraceptives in BRCA1 Carriers?

Although oral contraceptives (OC) reduce the risk of ovarian cancer in BRCA carriers,1 it is possible that they may raise breast cancer risk. Thus it is important to understand whether age at OC use is a factor when determining impact on breast cancer risk. To address this question, a recent study (which included data from …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2014/

ICARE Newsletter Summer 2014

What Are Factors That Modify Cancer Risk in BRCA Carriers?

Since the discovery of the BRCA genes about two decades ago, a number of studies have reported on factors that may modify cancer risks in those who carry gene mutations. Recently, results of previously published studies were collected through a comprehensive literature review to estimate the overall effects of various risk modifiers in BRCA carriers. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2014/

ICARE Newsletter Summer 2014

Is There a Higher Risk of Prostate Cancer in Individuals with Lynch Syndrome?

Over the last few years, there have been studies to suggest that men with Lynch Syndrome may have a higher risk for developing prostate cancer.1,2,3,4,5 The results of these studies have differed as to whether there is an association with an aggressive form of disease. For example, some studies report the risk of developing prostate …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nls2014/

ICARE Newsletter Summer 2014

Early Results to Suggest That PSA Screening May Help to Detect Prostate Cancer Early in Men with BRCA Mutations

Over the last few years, there have been a number of studies to suggest that men with BRCA mutations, particularly BRCA2, have a higher risk of developing aggressive prostate cancer. It remains uncertain whether these men might benefit from screening through the prostate-specific antigen (PSA) test. Within the last few years, PSA screening guidelines in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2014/

ICARE Newsletter Summer 2014

Ask the Expert

The following question was addressed by Dr. Steven Narod who is a Tier I Canada Research Chair in Breast Cancer and a senior scientist at Women’s College Research Institute in Toronto, Canada.  Dr. Narod is a world-leader in the field of breast and ovarian cancer genetics. Over the course of his career, he has profoundly shaped …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2014/

ICARE Newsletter Summer 2014

New Study to Suggest Benefits of Oophorectomy in BRCA Mutation Carriers

A recent study published in the Journal of Clinical Oncology reported that prophylactic oophorectomy resulted in reducing the risk of ovarian cancer by 80%, and reduced all-cause mortality by 77%.1 The authors reported results on almost 5800 women, of whom 186 developed either ovarian, fallopian tube or peritoneal cancer. Women who had bilateral oophorectomy had …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nls2014/

ICARE Newsletter Winter 2014

Recent Evidence to Suggest That Individuals with Germline Mutations in the PTEN gene (Which Leads to Cowden Syndrome) May Have Higher Renal Cancer Risks

Cowden Syndrome is an inherited condition that leads to higher risks for breast and thyroid cancer, and possibly other cancers.1 There have been a few recent studies that suggest that this condition also puts individuals at a higher risk for kidney cancer. Specifically, Tan et al2 reported a lifetime risk of 30.6% (95% CI: 17.8-49.4) …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2014/

ICARE Newsletter Winter 2014

Tamoxifen May Reduce Contralateral Breast Cancer Risk in BRCA Carriers

There have been suggestions that Tamoxifen may reduce risks for contralateral breast cancer (i.e., breast cancer in the other breast) in BRCA carriers if taken after the initial breast cancer diagnosis, based mainly on retrospective studies. Only one prospective study has looked at this question, and showed that Tamoxifen may be useful in BRCA2, but …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2014/

ICARE Newsletter Winter 2014

Ask the Expert

The following question was addressed by Dr. Laronga who is a breast surgeon based at the Moffitt Cancer Center: Q. What are the risks of breast cancer after ovarian cancer in BRCA carriers? What risk management options are recommended? A. BRCA carriers remain at a higher risk of breast cancer, even after having ovarian cancer; …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nlw2014/

ICARE Newsletter Winter 2014

Contralateral Mastectomy May Improve Survival in BRCA Mutation Carriers

It has been established that women who carry a germline BRCA mutation face breast cancer risks of 60-70% in their lifetime. After an initial breast cancer diagnosis, these women face a high risk for contralateral breast cancer. Some women with BRCA mutations move forward with contralateral mastectomy when they develop their first breast cancer diagnosis (as …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2014/

ICARE Newsletter Summer 2013

Sharing BRCA Test Results with Adolescent and Young Adult Children—What Does the Latest Research Show?

While there are specific recommendations against BRCA testing for minors,1 guidelines are less clear about whether parents should share their own test results with their children. Because there are no recommended surveillance or risk reduction options prior to age 25 for known BRCA mutation carriers, there has been debate about balancing the benefits of sharing …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2013/

ICARE Newsletter Summer 2013

US Preventive Services Task Force (USPSTF) Guidelines for Inherited Breast and Ovarian Cancer and Implications to the Affordable Care Act (ACA)

Recently, the USPSTF released updated draft guidelines in April 2013 (from those previously published in 2005) for inherited breast and ovarian cancer due to germline BRCA1 and BRCA2 gene mutations.1 USPSTF is comprised of primary care providers who review the available literature and issue guidelines about risk assessment, testing and management based on available evidence. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nls2013/

ICARE Newsletter Summer 2013

Male BRCA Carriers Have Poorer Outcomes from Prostate Cancer

Over the last few years, a number of studies have suggested that men with germline BRCA mutations (especially BRCA2) have poorer outcomes when they develop prostate cancer. In fact, a recent study of 2019 patients with prostate cancer, including 18 BRCA1 carriers, 61 BRCA2 carriers, and 1940 noncarriers indicated that germline mutations were more frequently …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2013/

ICARE Newsletter Summer 2013

Oophorectomy Following Menopause

Prior studies have indicated that removal of the ovaries and fallopian tubes reduces the ovarian cancer risk by ~80% and breast cancer risk by ~50%, particularly when performed pre-menopausally. However a recent case control study of 2854 pairs of women with a BRCA1 or BRCA2 mutation with or without breast cancer showed that the risk …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2013/

ICARE Newsletter Summer 2013

BRCA Testing: Supreme Court Update

In a landmark decision regarding the patenting of human genes on Thursday June 13, 2013, the Supreme Court of the United States unanimously ruled that human genes may not be patented. The case specifically concerned the BRCA1 and BRCA2 gene patents, held by the Utah-based company, Myriad Genetics. In the ruling, Justice Clarence Thomas wrote for the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2013/

ICARE Newsletter Summer 2013

Ask the Expert

The following question was addressed by Dr. Pal, who is a Clinical Geneticist based at the Moffitt Cancer Center: Q. Does exposure to radiation increase breast cancer risk in BRCA mutation carriers? A. A number of studies have been conducted to evaluate whether BRCA mutation carriers may be more prone to radiation-induced breast cancer than …

Continue reading

Permanent link to this article: https://inheritedcancer.net/6nls2013/

ICARE Newsletter Winter 2013

Ask the Expert

The following question was addressed by Dr. Lora Thompson, a Clinical Psychologist at the Moffitt Cancer Center:                                                             Q. How do I talk to family members about my genetic test results? A. The ability to share risk information with family members is a common reason why many individuals undergo genetic testing. Family members may feel appreciative …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nlw2013/

ICARE Newsletter Winter 2013

Points to Consider Regarding Bilateral Salpingectomy as a Risk Reduction Procedure for Ovarian Cancer

Over the last few years, there has been evidence to suggest that a substantial proportion of ovarian cancer may start in the fallopian tubes, although some cancer clearly arises in the ovary.  As a result, removal of both fallopian tubes (called ‘bilateral salpingectomy’) has been suggested as an interim procedure to reduce risk in BRCA …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nlw2013/

ICARE Newsletter Winter 2013

The Selection of Chemotherapy in BRCA Patients with Pancreatic Cancer

Some evidence suggests that individuals with BRCA mutations who develop pancreatic cancer may benefit from specific chemotherapy regimens. In a recent review of this topic, Kim et al reported on a study of 5 patients with BRCA mutations (4 BRCA2 and 1 BRCA1) who were treated with a platinum-based chemotherapy regimen.1 Of these patients, 3 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nlw2013/

ICARE Newsletter Winter 2013

Is Lynch Syndrome Associated with Breast Cancer?

The cancer spectrum typically seen in individuals with Lynch Syndrome includes cancers of the colon, endometrium, ovary, stomach, and other cancers (including cancer of the renal pelvis, ureter, small bowel and pancreas).  The issue of whether breast cancer risk is elevated in those with Lynch syndrome has been controversial, with conflicting results between various studies.  …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nlw2013/

ICARE Newsletter Summer 2012

Ask the Expert: What are the risks of hormone replacement therapy (HRT) on breast cancer risk in women with BRCA mutations?

The following questions were addressed by Drs. Pal and Lancaster at the Moffitt Cancer Center: Q. What are the risks of hormone replacement therapy (HRT) on breast cancer risk in women with BRCA mutations? A. Concern about HRT in BRCA carriers is its potential to raise the risk of breast cancer, as seen in the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/4nls2012/

ICARE Newsletter Summer 2012

New Study Suggests Breast Cancer Risk for Non-Carriers of Family-Specific BRCA Mutations Is Not Increased

Data from a population-based study was recently reported to estimate breast cancer risk among family members who tested negative for a known BRCA1/2 family mutation (i.e., non-carriers). The study included 3047 women diagnosed with breast cancer. Results from the study indicated there was no increased risk for breast cancer in non-carriers as compared to family …

Continue reading

Permanent link to this article: https://inheritedcancer.net/3nls2012/

ICARE Newsletter Summer 2012

Emerging Cancer Panels for Testing Patients for Inherited Cancer Predisposition

Genetic testing for inherited cancer predisposition is typically performed by testing for one condition at a time. However, with the tremendous advances in genetic testing technologies over the last few years, the cost of testing has plummeted. To put this into perspective, the first human genome cost 2-3 billion dollars to sequence and took over …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2012/

ICARE Newsletter Summer 2012

Ask the Expert: What are the recommendations for screening following prophylactic surgeries?

The following questions were addressed by Drs. Pal and Lancaster at the Moffitt Cancer Center: Q. What are the recommendations for screening following prophylactic surgeries? A. In BRCA mutation carriers, bilateral prophylactic mastectomy reduces the risk of breast cancer by over 90%. It essentially lowers the risk of breast cancer to below that of the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/5nls2012/

ICARE Newsletter Summer 2012

Prostate Cancer Screening Recommendations for Men with BRCA Mutations

Over the last few years, there have been several studies that suggest that men with BRCA mutations are at a higher risk for developing and dying from aggressive prostate cancer. It is possible that PSA testing may be of benefit in men with BRCA mutations. However, until the utility of PSA is determined in these …

Continue reading

Permanent link to this article: https://inheritedcancer.net/2nls2012/

ICARE Newsletter Summer 2011

Ask the Expert

We are fortunate to have Dr.  Alvaro Monteiro, who is a molecular geneticist and expert on the BRCA1 and BRCA2 genes, as a member of our team. For our first ICARE newsletter, Dr. Monteiro teaches us about Variants of Uncertain Significance. Q. What is a Variant of Uncertain Significance (VUS) test result? How do researchers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/1nls2011/